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Abstract 
HIV-1 is the etiological agent behind acquired immune deficiency syndrome (AIDS) – a chronic, 
life-threatening condition that compromises host immune function. After nearly four decades 
and despite ongoing global efforts, HIV-1 persists in nearly 38 million individuals worldwide. Of 
this population, only 60% have access to life-saving combination antiretroviral therapy (cART), 
clearly emphasizing the need to realize a cure. Unfortunately, the establishment of replication-
competent provirus in resting CD4+ T lymphocytes represents a significant barrier to HIV-1 
curative research. The viral reservoir is highly stable and has a half-life of ~44 months. 
Therefore, it is unlikely that infection will naturally exhaust over the course of a human lifetime. 
Furthermore, infected cells are phenotypically indistinguishable from uninfected CD4+ T cells – 
thus making it difficult to selectively target these cells for eradication. Evidence suggests that 
HIV preferentially infects and establishes latency within HIV-specific CD4+ T cells and that HIV 
latency reversal can be achieved using HIV derived proteins. Therefore, a therapeutic vaccine 
that represents the entire proteome of HIV within a given individual, immediately prior to 
antiretroviral therapy, might activate the entire cellular reservoir and initiate proviral gene 
transcription. Herein, we investigate the ability of a highly diverse virus-like particle formulation 
to ‘shock’ HIV-infected cells into transcriptional activity, thus leading to their eradication via 
immune-mediated or viral cytopathic effects. This activation vector (ACT-VEC) represents the 
first targeted approach to HIV-1 latency reversal. Based on the detection of viral RNA in culture 
supernatants, we show that ACT-VEC significantly outperforms other clinically relevant latency 
reversing agents at both the acute and chronic stages of infection. Using a quantitative 
outgrowth assay, we determined that ACT-VEC was also capable of inducing replication 
competent provirus from HIV-infected CD4+ T cells. Furthermore, we provide preliminary 
evidence that a virus-like particle formulation can provide an immune-mediated ‘kill’ after 
transcriptional reactivation occurs. Our VLP construct is also minimally antigenic, suggesting 
that it will be well tolerated in vivo. All together, our research suggests that ACT-VEC is a highly 
efficacious transcriptional reactivator that merits further investigation in the context of curative 
therapeutic strategies.   
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Summary for Lay Audience  
Human immunodeficiency virus 1 (HIV-1) is a virus that, in the absence of treatment, leads to 
acquired immunodeficiency syndrome (AIDS). AIDS is typically described as a period during 
which a subclass of immune cells, called T cells, die. In the absence of T cells, an HIV-infected 
individual is unable to mount a proper immune response and can be at an increased risk of 
infection by other pathogens (ie. bacteria, viruses, etc.). These infections, which are often 
uncommon in humans with properly functioning immune systems, lead to AIDS-related death. 
Despite efforts to stop HIV-1, the virus continues to persist in approximately 38 million 
individuals worldwide. Of this, approximately 60% have access to lifesaving medications which 
function to inhibit the virus’ life cycle. Unfortunately, several factors ultimately prevent these 
medications from being a long-term feasible solution, including i) high therapy-associated cost, 
ii) the requirement to take medication daily, for life, iii) logistical barriers, and iv) economic 
barriers. Furthermore, the currently available medications are non-curative due to the ability 
for HIV-1 to persist within host immune cells. There remains a need for new strategies capable 
of removing cells harboring HIV-1. The literature suggests that the reservoir can be targeted 
using small, HIV-1 proteins. These proteins are presented to cells that have a high likelihood of 
harboring latent HIV-1 and, subsequently, can stimulate the target cell. After reactivation, cells 
can be targeted by the immune system for destruction. Herein, we present an activator vector 
(ACT-VEC) that contains proteins encompassing the entirety of HIV-1. This activator vector 
currently outperforms all clinically-relevant drugs designed to remove latent HIV-1. ACT-VEC 
causes minimal immune activation, which suggests that it will be well tolerated in further 
stages of testing. Overall, we present a novel vaccine formulation capable of removing latent 
virus from host CD4 T cells. The activator vector represents a novel strategy for achieving HIV-1 
cure and merits further investigation. 
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 - Introduction 
1.1 A Landscape of HIV-1 Infection 
1.1.1 A Timeline of HIV-1 Discovery 
On June 5, 1981, a report was released by the United Stated Centers for Disease Control and 
Prevention (CDC) describing an unusual case of Pneumocystis carinii in five previously healthy 
men, all of whom had sex with men (MSM), in the Los Angeles area.1 The occurrence of these 
cases was particularly notable as Pneumocystic pneumonia is usually only prevalent in highly 
immunocompromised individuals, leading medical experts to wonder what etiological agent had 
led to the disease’s onset.2 In the ensuing days and weeks, numerous reports were filed with 
similar cases, all of which occurred within the MSM community. This finding, in conjunction with 
the occurrence of Kaposi’s Sarcoma, an aggressive cancer caused by various Herpesviruses, in 41 
homosexual men, led to many individuals referring to the condition as ‘Gay-Related immune 
deficiency’ or GRID. By the end of the year, 121 individuals had succumbed to the illness. The 
cause of these deaths remained elusive and engrained a public stigma towards the MSM 
community – already, what is now known as HIV-1, was causing panic and devastation. 
It was not until 1983 that the CDC began reporting cases in female sexual partners of individuals 
with Acquired Immune Deficiency Syndrome (AIDS).3 To add to this observation, a subsequent 
report further noted cases in intravenous drug users, Haitians, and hemophiliacs.4 This revelation 
changed the AIDS paradigm. Suddenly, a disease of the homosexual community had become one 
more likely associated with a sexual or blood-associated pathogen. That year, Dr. Luc Montagnier 
and Dr. Barré-Sinoussi, researchers at the French Pasteur Institute, along with colleagues, were 
the first to identify a T cell tropic retrovirus within a lymph node biopsy of an individual preceding 
AIDS.5 At the time, this retrovirus was called Lymphadenopathy Associated Virus (LAV). In April 
of 1984, Dr. Robert Gallo confirmed that a retrovirus, which he termed HTLV-III, was indeed the 
etiological agent responsible for AIDS and was identical to the virus isolated in France.6 The 
ambiguous nature of the viruses name, HTLV-III/LAV, was addressed in 1986, when the 
International Committee on the Taxonomy of Viruses agreed upon a unifying name, Human 
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Immunodeficiency Virus (HIV).7  Montagnier and  Barré-Sinoussi, went on to receive the Nobel 
Prize for the discovery of HIV-1 in 2008.8  
Despite the 1980s being a seminal period regarding HIV identification and characterization, the 
first transmission event likely occurred several decades prior. In fact, HIV-1 viral sequences were 
detected as early as 1959 in plasma samples collected from an African individual.9 The finding 
suggests that an early transmission event, one that pre-dated the Los Angeles cases, likely 
occurred in the geographical area. A supporting study of the V3-V5 Env region of HIV implicated 
Central Africa and, specifically, the Democratic Republic of Congo, as a ‘hotspot’ for HIV-1 group 
M genetic diversity.10 The high level of cocirculating subtypes and recombinant viral forms 
implicate this region as a pivotal area for HIV-1 dispersal. Interestingly, researchers observed that 
HIV shares many commonalities with Simian Immunodeficiency Virus (SIV), and both 
preferentially target and infect lymphocytes in a mechanistically similar way. With evidence of 
zoonotic transmission between various non-human primates (NHPs), it was realistic to conclude 
that such a transmission event could occur between NHPs and humans, as well. The ‘hunter’ 
theory hypothesized that transmission occurred when a human hunter became exposed to the 
SIV-infected blood of his/her NHP prey.11 Although there have likely been multiple cross-species 
transmission events throughout time, most events likely failed to disperse throughout the 
general population due to host defense mechanisms. However, a single well-adapted viral 
transmission event from chimpanzees (SIVcpz) is thought to be responsible for the zoonotic 
transmission of the AIDS-associated, HIV-1 group M viruses.12–14  
1.1.2 The Global Burden of HIV-1 – From Past to Present 
Since the beginning of the epidemic, HIV-1 has infected approximately 75 million individuals 
worldwide.15 Today, an estimated 37.9 million individuals live with HIV-1 infection, wherein 1/5th, 
or 8 million people, are unaware of their HIV-1 status despite increasing global efforts. 
Notwithstanding, the advent of combination anti-retroviral therapy (cART) has transformed the 
HIV-1 death sentence into a chronic lifelong illness for approximately 23 million people with 
access to these life-saving drugs. As a greater proportion of individuals begin accessing cART, 
year-to-year mortality from AIDS-related death is also declining. From the period of 2016 to 2019, 
mortality has declined by approximately 25%, from 1.1 million reported deaths to 770 000 
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deaths, respectively.15,16 Though the impact of these multi-national efforts are noticeable, there 
is still much that needs to be done, and UNAIDS still strives to achieve their ’90-90-90’ goal, 
despite failing to do so by their original 2020 deadline. This goal pushes for 90% of HIV-infected 
individuals to i) know their HIV status, ii) have access to cART and, iii) retain prolonged viral 
suppression. Such efforts come at a significant cost, however, with US$ 19.0 billion in AIDS relief 
in 2018.  Clearly, HIV-1 has established itself amongst the most devastating infectious diseases 
to date, and great effort has been invested into the identification of novel strategies for 
prevention and cure. Such efforts hope to address the HIV-1 epidemic in both a more sustainable 
and accessible manner.  
1.2 Characterization of the HIV-1 Virus 
1.2.1 The Structural and Genomic Makeup of HIV-1 
Human Immunodeficiency Virus (HIV) is taxonomically classified as a member of the genus 
Lentivirus and the family, Retroviridae. The HIV genome is comprised of two positive-sense, 
single-stranded RNAs (ssRNAs) within a conical capsid composed of virally-derived p24 protein.17 
The 9.7 kb genome encodes for sixteen (16) viral proteins, which can be stratified into structural, 
regulatory, or accessory proteins.18 As with all members of the Retrovirus family, HIV contains 
three polyproteins, Gag, Pol, and Env, which serve prototypic functions regarding structure, 
enzyme synthesis, and envelope formation, respectively.18,19 Specifically, the Gag gene encodes 
for structural matrix (p17), capsid (p24), nucleocapsid (p7), p6, and spacer proteins which 
comprise all necessary components for virus-like particle formation and nuclear genomic 
stabilization.20–22 In contrast, the Pol region encodes for viral enzymes, such as reverse 
transcriptase, ribonuclease H, protease, and endonuclease, which are implicated in viral 
maturation and infectivity.23 The final polyprotein, Env, is responsible for viral entry via the 
production of envelope glycoprotein, gp120, and its associated protein, gp41. These proteins 
ultimately determine viral tropism and mediate fusion between the virus and target cell.24 To 
incorporate the necessary proteins involved in viral infection and production of progeny virus, 
HIV employs alternative splicing, a process that produces more than 100 different mRNAs from 
a single primary RNA transcript.25,26 For alternative mRNA production to occur, HIV utilizes the 
cellular spliceosome, which can recognize several unique 5’ and 3’ splicing motifs to produce 
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alternative resultant mRNAs.27,28 Using this method, splicing can produce both singly-spliced 
(~2kb) and multiply-spliced (~4kb) mRNAs.29 The production of the regulatory proteins, tat and 
rev, as well as the accessory protein, nef, are produced via complete splicing initiated at 3’ motifs 
located centrally within the RNA genome, followed by subsequent translation in the cell 
cytoplasm.25,29 Briefly, Tat protein functions through binding of the trans-activation response 
(TAR) element and recruitment of the RNA Polymerase II elongation factor, P-TEFb, which is 
necessary for viral mRNA production.30,31 The regulatory protein, Rev, engages with a cis-acting 
Rev response element (RRE) to facilitate RNA trafficking and nuclear export to the cell 
cytoplasm.32–34  
Accessory proteins, including vif, vpr, vpu, and nef, have been well-characterized in regards to 
their involvement in immune evasion, antiviral resistance, replication, and dissemination.35 These 
proteins often modify the local environment to increase suitability for the infecting virus. The nef 
protein is expressed early after onset of infection and is heavily implicated in pathogenicity, as 
long-term survival is seen in individuals infected with HIV-1∆nef mutants in the absence of 
cART.36 Furthermore, nef downregulates cell surface proteins, such as CD4, through an 
interaction with the protein’s cytoplasmic tail, and subsequently transports the protein to the 
endosome for degradation.37,38 The function of downregulating host CD4 is also seen in Vpu, 
although the mechanism and location of the interaction differs from nef.35 Furthermore, Vpu, 
and Vif are capable of suppressing host restriction factors such as the lipid raft protein, tetherin 
(BST-2), and the cytidine deaminase, APOBEC3G, respectively.39,40 Similarly, Vpr, despite some 
ambiguity on various functions, is surely implicated in G2 cell-cycle arrest via the engagement of 
a cullin-RING ubiquitin ligase, DCAF1.41,42 The summative function of these accessory proteins 
allows for continued persistence of HIV-1 through interruption of host immune mechanisms 
otherwise designed to clear infection.  
1.2.2 HIV Infectious Cycle 
It is important to acknowledge the contribution of the HIV-1 viral proteins in the context of the 
virus’ replication cycle during natural infection (Figure 1-1). By ‘natural’, this refers to HIV-1 
infection in the absence of cART. The replication cycle of HIV-1 can be stratified into early and 
late phases. The early phase is defined as the period from viral entry up until proviral integration 
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in the host genome. Subsequently, late phase refers to the period of proviral transcription up 
until release of HIV-1 progeny. The duration of this entire process takes approximately 1-2 days 
and, during this time, is capable of producing up to 2x109 progeny virions per day.43 The resulting 
virus lacks uniformity due to the extremely high mutation rate (1/10 000 nucleotides) of the 
virally-encoded reverse transcriptase enzyme. Because of this, HIV-1 infection is not typically 
characterized by a single viral clone, but rather as quasi-species comprised of many HIV variants. 
The high sequence variability within the HIV quasi-species contributes to difficulties achieving 
efficacious vaccine strategies, as each viral variant can potentially exhibit altered peptide 
antigens. Thus, the pool of target cells becomes exponentially higher than in the case of a single 
viral clone. It is worth noting, however, that many mutations are lethal and prevent infectious 
particle formation and release. In support of this, a 44-fold decrease in mutation rate was 
observed in viral sequences derived from supernatants as compared to those derived 
intracellularly, suggesting a high occurrence of deleterious mutations.44 
1.2.3 The Early Phase of Replication 
Due to the short half-life of cell-free infectious virions – approximately 20-30 minutes – it is 
imperative that HIV-1 can rapidly identify and infect permissive cellular targets.43 Viral 
attachment is determined through targeting of CD4, the primary receptor, and one of two co-
receptors, CCR5 or CXCR4. Cells expressing the appropriate receptor/co-receptor are 
susceptible to infection, although attachment is typically inefficient due to low Env density on 
the HIV-1 surface. Following attachment, fusion is facilitated through an interaction with virally-
derived gp120 and host CD4. This binding interaction creates a conformation change within the 
Env protein trimer, which subsequently binds to either the CCR5 or CXCR4 co-receptor. 
Following co-receptor engagement, another conformational change occurs which reveals the 
gp41 transmembrane protein. The fusion peptides present on gp41 can interact with the host 
cell and ultimately allows gp41 to create a 6-helical bundle which facilitates viral-cell fusion. 
Upon membrane fusion, viral contents can freely be released into the cell. Virally-derived 
positive-sense RNA, with the help of the reverse transcriptase enzyme, can then utilize cell-host 
machinery to reverse transcribe into dsDNA. HIV uncoating likely occurs during the transition 
from reverse transcription to loading into pre-integration complexes (PICs).45 The PIC is  
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The HIV-1 life cycle is a multi-step process which can be divided into distinct phases, as denoted 
by the numbering (1-12) above. The early and late phases of viral replication are denoted by 
numbers 1-6 and 7-12, respectively. The classes of antiretroviral drugs designed to target 
specific stages of the life cycle are denoted by red circles. NRTI, nucleoside reverse 
transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; INSTI, integrase 
strand transfer inhibitor. 
Figure 1-1: A schematic of the HIV-1 life cycle and points of therapeutic inhibition 
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transported across the nuclear membrane via a nuclear pore. Through utilization of the protein, 
integrase, viral dsDNA can incorporate itself into the host cell genome.  
Integration into the host genome is a critical time for HIV-1 and, specifically, strategies targeting 
the virus for eradication. It is at this point that the virus has two fates, depending on the status 
of the infected host. The first fate is to continue into the late phase of viral replication, in which 
new viral RNA is transcribed along with the host genome. The alternative, however, is that 
integration occurs in the absence of late phase replication due to low transcriptional levels 
within the host. It is in this second scenario, where HIV-1 has successfully integrated but 
remains transcriptionally inactive, that viral latency occurs. Viral latency continues to persist for 
the lifetime of the infected cell.  
1.2.4 The Late Phase of Viral Replication 
During productive infection, HIV provirus utilizes cellular Pol II polymerase to transcribe 
messenger/genomic RNA. Transcriptional initiation and elongation begin at the viral promoter 
site present within the HIV-1 5’LTR U3 region but, initially, viral transcription is limited due to 
inefficient elongation. Therefore, transcriptional elongation is largely dependent on viral Tat 
protein, which provides a positive feedback loop to facilitate efficient processing. Tat-mediated 
transcriptional synthesis ultimately produces full-length transcripts and several different 
mRNAs with various degrees of splicing. mRNA products are then transported to the cell 
cytoplasm via the viral Rev protein. Within the cytoplasm, full-length mRNAs expressing Gag 
and Gag-Pol precursors are then processed into key structural proteins. Following 
multimerization of Gag and Gag-Pol-derived proteins, viral Env glycoproteins and genomic RNA 
are recruited to the assembling virion. Immature virions subsequently bud from the surface of 
the cell and, only after fully budding, mature via processing of the Gag and Gag-Pol precursors. 
1.2.5 HIV Entry and Infection 
Sexual intercourse is by-and-large the main source of HIV-1 spread worldwide and has been 
implicated in 70-80% of total infections worldwide. Despite this, the rate of infection per coital 
act is remarkably low, with likelihoods of 0.06% and 0.01-1% for anal and vaginal penetration, 
respectively. Surely, an interplay of variables must explain the discrepancy between the high 
contribution to total infections and the low risk of exposure. By looking at the site of primary 
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infection, it is possible to determine many of the factors that may contribute to HIV-1 
susceptibility.  
Initially, HIV-1 must penetrate the vaginal epithelium and access underlying target cells that are 
permissive to infection. The vaginal epithelium varies from thick, stratified squamous epithelium 
in the ectocervix to single layered columnar cells within the vaginal endocervix. The thickness of 
the vaginal ectocervix poses a difficult physical barrier for HIV-1 to overcome, and contains a 
subset of DCs called Langerhans cells. However, unlike traditional DCs that are implicated in viral 
presentation to CD4 T cells, Langerhans cells inhibit HIV-1 infection via the type II transmembrane 
protein and C-type lectin receptor, Langerin.46 When T cells were exposed to low concentrations 
of virus in the presence of various DC subsets, only Langerhans cells prevented efficient infection 
from occurring.46 At higher concentrations, infection could efficiently establish itself without DCs, 
but was still inhibited by the presence of Langerhans cells which internalized and degraded HIV-
1 in Birbeck granules. Due to overwhelming immune pressure present within the ectocervix, the 
current belief remains that HIV accesses target cells through micro-abrasions in the columnar 
epithelium of the endocervix. The virus can then disseminate via locally draining lymph nodes, 
thus establishing systemic infection.  
1.3 Understanding HIV-1 Latency 
1.3.1 Establishment of the Latent Reservoir 
A difficulty with defining the mechanism behind HIV-1 latency is the inability to study 
establishment ex vivo, as, by definition, cells isolated from an infected individual will already be 
latent.47 Despite this, studies of resting cells harboring integrated provirus provide us with an 
invaluable tool on how this process might occur. Resting memory CD4 T cells harboring integrated 
provirus are of notable importance, due to their prolonged lifespan relative to other cellular 
subsets.  
When a dendritic cell interacts with a T cell via antigen presentation, naïve CD4 T cells become 
activated and subsequently undergo differentiation into various effector T cell subsets: Th1, Th2, 
Th17, and Treg cells.48 At this point, effector cells responding to infection represent highly 
susceptible targets for viral entry and proviral integration. Most of these cells will subsequently 
undergo productive infection, during which the production of viral transcripts and proteins 
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occurs (Figure 1-2). This productive cellular subset is primed for clearance via immune-mediated 
or cytotoxic effects and, therefore, is unlikely to contribute to HIV persistence in vivo.49,50 Rather, 
viral latency most likely occurs within ‘resting’ cells with low metabolic states. Of importance are 
resting memory CD4 T cells, which are distinguishable from activated cells through i) decreased 
expression of activation markers, ii) low RNA content, iii) smaller cell size and, iv) a lack of cell 
cycling.51 The combination of low transcriptional activity and high lifespan of these memory T 
cells provides an optimal environment for prolonged viral persistence. Clearance of these cells 
through immune-mediated mechanisms is difficult to achieve due to the absence of viral proteins 
and the prevalence of escape mutations within the integrated provirus.52 
There are two distinct methods which may contribute to the establishment of latency within 
resting memory CD4 T cells. As alluded to previously, the first method is through viral infection 
of effector T cells which subsequently revert to a resting memory state. This is commonly 
accepted as the most predominant method of latency establishment, as effector cells exhibit 
greater permissiveness than resting cells. If this theory is true, most HIV provirus should persist 
within the memory CD4 T cell reservoir, making these cells a priority target for novel vaccine 
regimens.47 Alternatively, latency could also result from the direct infection of resting cells, which 
could include either naïve or memory subsets. In this model, the viral reservoir would persist in 
an expanded, less specific pool of cells. Although this is a potential explanation, factors including 
low CCR5 expression, limited dNTP availability, and poor integration efficiency all contribute to 
worsened efficiency of infection.53–55 
The memory CD4 T cell reservoir represents the predominant HIV-1 reservoir, although it is worth 
mentioning that other cellular subsets have been shown to harbour latent provirus, as well. Two 
other T cell subsets, naïve CD4 T cells and γδ T cells, have also been shown to harbour latent 
provirus.56,57 Furthermore, in vitro studies have identified macrophages as permissive target cells, 
however, it is uncertain whether macrophages can harbour HIV provirus in the presence of 
cART.58 The contribution of each of these subsets of cells towards the latent reservoir is 
controversial, as they either have a short half-life or do not produce daughter cells to carry on 
infection. 
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Permissive host CD4 T cells are susceptible to HIV-1 infection and integration. These cells have 
two fates, productive infection (top) or latent infection (bottom). Transcriptionally active, 
infected cells produce viral proteins and progeny virions and subsequently lead to host cell 
death. Latent cells (purple) are devoid of transcriptional products and can reactivate in the 
presence of antigen re-exposure. Latent cells are maintained through clonal expansion and 
homeostatic proliferation.  
Figure 1-2: Establishment of quiescent HIV-1 within host CD4 T cells. 
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1.3.2 The Contribution of HIV-1 Tat to Latency 
Out of all the proteins produced by HIV-1, the Tat protein is the most heavily implicated in the 
establishment and maintenance of viral latency. Specifically, through the regulation of RNAP II 
elongation on the viral 5’ LTR, Tat functions as the virus’ transcriptional switch. To initiate viral 
transcription, Tat must bind the TAR hairpin present within the RNA transcript, while 
simultaneously engaging with p-TEFb, composed of Cyclin T1 (CycT1) and cyclin-dependent 
kinase 9 (CDK9). This interaction leads to the phosphorylation of C-terminal RNAP II, thus 
initiating transcriptional elongation at the promoter site.59 In studies evaluating HIV infection in 
the absence of functional Tat, transcripts were short (<100 nucleotides), non-polyadenylated, 
and contributed to a decrease in viral replication capacity.59,60 Such transcriptional deficiencies 
reveal that the Tat protein serves as a virally-endogenous mechanism to mediate the productive 
or quiescent status of HIV-1.  
The Tat protein poses a challenge to a commonly accepted hypothesis that latent infection is 
controlled exclusively through environmental factors, such as cellular metabolic state. In this 
model, HIV latency is merely a tangential phenomenon arising from a cellular transition between 
active and resting states. In actuality, this does not appear to be the case. In a study by Razooky 
et al., the Tat-positive feedback circuitry was sufficient to induce viral transcription in the absence 
of cellular activation.61 This means that a virally-encoded Tat-dependent mechanism, rather than 
the cellular environment, sufficiently regulates viral transcription and, in essence, latency. More 
specifically, positive feedback of Tat is critical for productive infection to occur. To show this, a 
study by Lassen et al. revealed that a break in the Tat-mediated feedback loop via the retention 
of HIV msRNA encoding tat/rev contributed to non-productive infection ex vivo.62 Alternatively, 
the removal of host factors responsible for the interruption of Tat’s translocation activity, such 
as non-coding RNAs, lead to a pronounced increase in proviral reactivation within HIV-infected 
CD4 T cells.63 Finally, the introduction of exogenous Tat into the Jurkat cell line, a model for HIV 
latency, was also shown to recover transcriptional reactivation within the latent population.64 It 
is difficult to dismiss the evident role Tat plays in HIV-1 latency and, by extension, transcriptional 
reactivation of dormant provirus. For this reason, emphasizing strategies which maintain or assist 
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in Tat-dependent feedback are of considerable value when developing latency reversing 
regimens.  
1.4 The Search for a Cure 
1.4.1 CCR5∆32 Hematopoietic Stem Cell Transplantation (HSCT) 
To date, there are two reported events of HIV-1 cure, the Berlin Patient and the London 
Patient.65–67 These seminal cases provide hope that an HIV-1 cure will be realized, however, they 
provide limited feasibility in most other cases due to i) procedure-associated risks, ii) high 
procedure-associated costs and, iii) limited scalability. Take the case of Timothy Ray Brown, more 
commonly known as the Berlin Patient. Mr. Brown had chronic HIV infection when he was 
diagnosed with acute myeloid leukemia. During the treatment, Timothy received a 
hematopoietic stem cell transplant from a patient with homozygous, CCR5Δ32 alleles – a deletion 
that ultimately renders CCR5-tropic viruses, such as most HIV-1 variants, unable to infect target 
cells.65 Importantly, the procedure’s success relied on a stem cell transplant preceded by 
irradiation of immune cells to prevent graft-versus-host disease. In other words, Timothy lacked 
a functional immune system. Typical pathogens, ones that commonly go unnoticed due to rapid 
clearance by immune-mediated mechanisms, could freely infect Timothy during this time. This, 
along with the procedure itself, nearly killed Mr. Brown. Clearly, for most individuals, the 
procedure itself is inhibitory in nature, especially with the prevalence of life saving combination 
antiretroviral therapy (cART) that can be taken indefinitely with minimal risk. The success of the 
Berlin Patient was consequently translated into a second success, the London Patient. Like its 
former, this individual was HIV-positive while being treated for Hodgkin’s Lymphoma, and 
similarly underwent a homozygous CCR5∆32 stem cell transplant. Importantly, the London 
Patient received a less toxic regimen, i.e. lymphoma-targeting chemotherapy agents, alone. 
Although the London Patient experienced grade-1 graft-versus host disease, followed by viral 
recrudescence of Epstein-Barr virus (EBV) and cytomegalovirus (CMV) several months post-
transplant, the effects were less severe than that of the Berlin counterpart.67 As of April 2019, 
the London Patient has been in remission for 18 months (<1 HIV copy/mL). 
Other attempts have been made to replicate the success of the Berlin and London Patients, 
however, several factors have posed limitations to the aforementioned approach. Although the 
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procedure has been repeated at least half a dozen times since the Berlin Patient, four out of six 
(4/6) patients died shortly thereafter due to either i) transplant-associated infections or, ii) cancer 
relapse.68 The other two instances provide learning moments regarding the complicated nature 
of transplant-associated cure strategies. Of note, the presence of a secondary co-receptor for 
HIV-1, CXCR4, provides an alternative avenue for target cell entry in the absence of CCR5, and 
may provide a viral escape mechanism that undermines the CCR5 knockout strategy.69,70 One 
such instance occurred in the Essen Patient, a CCR5 knockout transplant recipient being treated 
for anaplastic large-cell lymphoma.70 Viral RNA extracted from this individual prior to transplant 
indicated that the infecting virus was largely CCR5-tropic, based on analysis of the HIV-1 Env V3 
region. However, proviral DNA extracts from the same donor had an intermediate phenotype – 
a mixture of CCR5 and CXCR4-tropic viruses. After 3 weeks post-transplant, the Essen patient had 
to re-initiate ART due to a substantial rebound in viremia (93,390 copies/mL).70 This viral escape 
mechanism, wherein the infecting virus utilizes an alternative co-receptor, complicates 
transplant-based cure strategies. Indeed, the viability of a co-receptor-centric approach may 
require a dual-knockout of both CCR5 and CXCR4 to confer absolute resistance to HIV-1 
infection.71,72 The failure of the Essen patient is further confounded by variability in the transplant 
methodology. Hütter discerns between the Berlin and Essen patients on one particular metric, 
the presence or absence of prolonged ART during transplantation.68 Perhaps, in the Berlin case, 
the extended duration of ART contributed to stabilization of donor transplant cells – something 
that was absent in the Essen case. Furthermore, in addition to finding homozygous CCR5∆32 
donors, HLA-matching between donor and recipient will surely contribute to graft success.73 
Although evidence strongly suggested that the homozygous CCR5∆32 deletion was a 
fundamental characteristic of a successful HSC transplant, a subsequent study was performed in 
two individuals receiving transplants with wild-type co-receptor alleles.74,75 Of interest, Henrich 
et al. sought to determine if  a wild-type HSCT could contribute to viral reservoir reduction in the 
prolonged absence of cART. If true, this finding would offer a greatly expanded pool of potential 
donors, as finding individuals with homozygous knockout mutants remains a bottleneck in the 
treatment pipeline. Unsurprisingly, however, rebound viremia occurred within 12 to 32 weeks, 
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respectively, upon cART cessation.75 Therefore, inhibition of viral entry mechanics via co-receptor 
modulation is surely implicated in both cases of cure thus far.  
1.4.2 An Overview of Antiretroviral Therapy 
The advent of combination antiretroviral therapy (cART) has, to date, been one of the largest 
successes when addressing the HIV-1 epidemic. Most notably, individuals with access to cART 
experience less, if any, CD4 T cell depletion and subsequently do not transition into AIDS. As 
immune system function is relatively well-maintained in the presence of cART, these drugs 
prevent the onset of opportunistic infections which typically lead to AIDS-associated morbidity 
and death. Due to its acknowledged importance, the world health organization (WHO) has 
made antiretroviral therapy a cornerstone feature of their 90-90-90 initiative. This initiative 
aims for 90% of HIV-infected individuals to receive antiretroviral therapy and, of these 
individuals, for 90% to experience prolonged viral suppression. Currently, approximately 2/3rds 
of HIV-infected individuals are currently accessing these life-saving drugs.  
Antiretroviral therapy functions through the inhibition of key steps within the HIV-1 life cycle. 
Specifically, antiretrovirals can be distinctly broken down into several classes: fusion inhibitors, 
co-receptor antagonists, reverse transcription inhibitors, integrase strand transfer inhibitors, 
and protease inhibitors. The combination of several drug classes can help prevent against drug-
resistance in viral populations. To date, the FDA has approved 222 antiretroviral drugs for the 
treatment of HIV, including 23 combination-drug products. 
1.4.2.1 Inhibitors of Viral Entry 
 
Starting at the earliest stage of the viral life cycle are fusion inhibitors, which, as the name 
suggest, function through the disruption of viral machinery required for entry into an 
uninfected cell. Enfuvirtide (T20; Fuzeon, Roche) is a peptide mimetic that serves as a 
prototypic, FDA-approved fusion inhibitor. More specifically, this mimetic compound covalently 
interacts with the N-terminal region of HIV-1 gp41 to prevent pore formation at the surface of 
non-infected cells.76 In addition to its usefulness in antiretroviral regimens, enfuvirtide provides 
utility in latency reversing assays designed to induce latent provirus or estimate reservoir 
size.77,78 Due to its unique ability to stop viral entry, enfuvirtide helps prevent against the 
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overestimation of reservoir size, infected cell frequency, and latency reversing potential of 
therapeutic candidates.  
In addition to fusion inhibitors, CCR5-receptor antagonists, such as maraviroc, are also capable 
of preventing viral entry into a host cell. The development of this drug class resulted from an 
observation that individuals with homozygous polymorphisms within CCR5 were resistant to 
infection by R5-tropic virus.79,80 For maraviroc, function is conferred through its binding to the 
transmembrane cavity of CCR5, thus altering the receptor’s conformation.81 Due to its specific 
function as a CCR5 agonist, maraviroc-resistant HIV-1 populations have arisen which target the 
alternative, less commonly utilized co-receptor, CXCR4.82 Additional efforts have identified 
mutations within the HIV constant region 4 (C4), such as N425K, that also convey resistance to 
maraviroc treatment.83 Ultimately, this drug class can provide substantial benefit in the context 
of an antiviral therapeutic regimen, but information regarding viral tropism is essential.  
1.4.2.2 Inhibitors of Reverse Transcription 
As the seminal drug class for HIV-1 antiviral therapy, nucleoside reverse transcriptase inhibitors 
(NRTIs) are a cornerstone in most combinational regimens. NRTIs function through competitive 
inhibition of the reverse transcriptase enzyme and ultimately prevent chain elongation of DNA 
products.84 The addition of purine and pyrimidine nucleosides is essential for the 3’ elongation 
of the newly-developing DNA. An NRTI’s function is analogous to that of other nucleosides but 
lacks a 3’-hydroxyl group required for chain elongation.85 Therefore, incorporation of the 
nucleoside analogue terminates reverse transcription. As of 2016, clinical guidelines 
recommended that individuals on first-line antiretroviral therapy should take two NRTIs 
accompanied by a protease inhibitor (PI), non-nucleoside reverse transcriptase inhibitor 
(NNRTI), or an integrase strand transfer inhibitor (INSTI).86 This is notable since NRTIs are less 
potent than alternative drug classes with more favourable inhibitory dose kinetics, including 
NNRTI and PI.87 Despite this, eight NRTIs have become FDA-approved and several of them, such 
as emtricitabine (FTC) and tenofovir DF (TDF), are routinely incorporated into combinational 
therapies (Figure 1-1).  
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NNRTI-class drugs exhibit increased inhibitory capacity relative to NRTIs but similarly function 
to inhibit reverse transcription.87 The virally-derived reverse transcriptase contains two 
subunits, p66 and p51. Rather than functioning directly on the active site of the enzyme, 
NNRTIs non-competitively bind to the p66 subunit to induce a conformational change that 
abrogates enzymatic function.88 Importantly, these drugs are susceptible to variability within 
the reverse transcriptase gene as multiple individual mutations can alter or diminish NNRTI 
binding potential.89 
1.4.2.3 Integrase Strand Transfer Inhibitors 
Integrase strand transfer inhibitors (INSTIs) convey several advantages that make them 
important in many antiretroviral regimens. In a viral integration event, HIV-derived integrase 
transports proviral DNA to the host cell chromosome, which then incorporates via a 2-step 
catalytic reaction.90 First, the proviral 3’ end is processed in the host cell cytoplasm. This is 
subsequently followed by strand transfer and covalent linking of proviral DNA products to host 
cell DNA. As the name would suggest, INSTIs, such as dolutegravir or raltegravir, function 
through competitive inhibition of the strand transfer process by blocking the active site of 
integrase.91 Interestingly, humans lack a homologue for HIV-derived integrase and, as a 
consequence, INSTIs are generally well-tolerated.92 Like NNRTIs, resistance can arise from 
genetic mutations within the viral integrase gene. Despite this, INSTIs appear to be highly 
efficacious. In a large clinical study, raltegravir+abacavir(NRTI) achieved viral suppression of 
~88% whereas Atripla (tenofovir, emtricitabine, efavirenz) only achieved 81% suppression at a 
48-week follow-up.93 This finding provides strong evidence that INSTI-based therapeutic 
regimens may replace, or provide an alternative to, current gold-standard antiretroviral 
therapies.  
1.4.2.4 Protease Inhibitors 
The viral protease is responsible for the maturation of viral particles via systematic cleavage of 
the gag and gag-pol polypeptides. This cleavage event results in the formation of protein 
products necessary for the proper assembly of new infectious virions. Protease inhibitors (PIs) 
function through the competitive inhibition of the HIV-1 protease enzyme, thus preventing the 
processing of viral polypeptides.94 Importantly, protease inhibitors may also exhibit off-target 
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effects, such as altering the ability of dendritic cells to process and present peptide antigens.95 
Despite this caveat, eight different PIs have become FDA-approved since 1995. Each of these 
drugs, while having mechanistically similar or identical effects, each have relatively different 
pharmacokinetic profiles.96 
 1.4.2.5 The Shortcomings of ART 
Antiretroviral therapy provides a substantial improvement to individuals affected by HIV-1 but, 
unfortunately, is not feasible as a permanent solution to the HIV-1 epidemic. One of the most 
striking characteristics of ART is the requirement to take it daily, for life. This inherent feature 
comes with several drawbacks. Firstly, providing cART to low- and middle-income countries is 
logistically difficult and expensive. In 2020 alone, UNAIDS estimates that the ongoing AIDS-
response effort will cost ~$26.2 billion USD.97 Secondly, individuals taking cART must ensure 
that they are in constant access of these drugs. ‘Drug holidays’, where an individual takes a 
break from therapy for an undetermined period, can lead to viral resistance and rebound 
viremia. Ultimately, ART-associated non-adherence is difficult to address due a diverse number 
of factors, including: lack of accessibility, drug-associated toxicity, patient-related drug/alcohol 
abuse, pill burden, and inconvenience.98 Due to a large degree of interpatient variability, it is 
difficult, if not impossible, to address many of the shortcomings associated with a daily 
therapeutic regimen, such as ART. Therefore, finding alternatives that either facilitate, i) a 
reduced frequency of drug administration, or ii) increase ease of drug use, are of high priority. 
More modern drug formulations, such as Atripla, overcome some of these barriers by reducing 
pill burden and eliminating the confusing drug-timing intervals associated with older 
regimens.99 This is accomplished by combining the three component drugs at clinically relevant 
dosages within a single capsule. Newer two-drug regimens are now under evaluation due to 
their potential to reduce ART-associated costs and toxicity.100 
Despite a significant decrease in AIDS-associated illness and death, individuals on antiretroviral 
therapy still experience an increased risk of morbidity relative to the general population.101,102 
This includes an increased occurrence of myocardial infarctions, osteoporosis, and diabetes 
mellitus within cART-receiving cohorts.103–105 In some instances, such as atherosclerosis in HIV-
infected individuals, heightened inflammation and ongoing immune activation likely contribute 
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to the disease phenotype.106,107 Such individuals experience heightened levels of secreted 
interleukin-6 (IL-6) and cell-expressed intercellular adhesion molecule 1 (ICAM-1), which are 
prevalent in instances of coronary blocking or stenosis.107 Heightened immune activation in this 
cohort may be due to several mechanisms including, i) ongoing, low level viral replication, ii) 
viral protein production, or iii) ART-associated inflammatory lipids.108–110 It is worth noting, 
however, that although immune activation is heighten relative to HIV-uninfected individuals, 
ART decreases immune activation relative to HIV-infected individuals lacking therapy.111 
Fortunately, as therapeutics continue to improve, drug-associated morbidity will continue to 
decrease. These therapeutic advances likely coincide with fewer people discontinuing ART due 
to drug-associated toxicity and contribute to an overall improvement to quality-of-life. 
1.4.3 Limiting Establishment – Initiation of cART During Primary Infection 
Upon initiation of cART, a small subset of HIV-infected lymphocytes revert to a low metabolic 
state, trapping HIV-1 provirus within the cell. It is theorized that early initiation of cART may limit 
the size of the quiescent proviral reservoir, and thus limit the degree of viral recrudescence post-
treatment cessation. Furthermore, cART initiation during primary infection may help preserve 
immune responsiveness and prevent chronic immune activation.112 In the instance of the 
Mississippi Child, a baby born to an HIV-positive mother was at high risk of HIV-infection, and 
subsequently initiated cART 30 hours after birth.113 If infection did, in fact, occur, the pool of virus 
capable of establishing a long-lived reservoir would be minimal. Treatment continued up until 18 
months of age, after which treatment was interrupted. Analysis of plasma HIV RNA and proviral 
DNA at 30 months remained negative, providing evidence that early treatment initiation may 
provide long-lasting protection against infection.113 Although plasma viremia remained 
undetectable at a 21.9 month follow-up, viral loads rebounded to 16,750 copies/mL by 27.6 
months and cART was immediately re-initiated.114 Despite requiring re-administration of cART, 
the Mississippi child furthered our understanding of HIV-1 infection and establishment. For 
instance, the timeline for HIV-1 establishment outpaces rapid administration of cART and limits 
the opportunity to utilize post-exposure programmes as a reliable method for HIV prevention. 
However, in such instances, early initiation of cART may contribute to long-term remission post-
therapy interruption. These findings, in summation, suggest that early access to cART may 
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substantially limit, but not prevent, HIV-1 reservoir establishment while preserving immune 
function. This finding is further supported by findings in the VISCONTI cohort, which involves 
fourteen (14) post-treatment controllers who initiated cART early after primary infection, and 
maintained prolonged control of viremia upon treatment cessation.112 The study concluded that 
early treatment may permit up to 15% of individuals to maintain viral control for greater than 24 
months, which is substantially higher than individuals treated later during infection.  
 
1.5 Achieving HIV-1 Latency Reversal 
1.5.1 The Shock and Kill Strategy for HIV-1 Eradication 
 
The latent reservoir likely establishes during a change in metabolic status, wherein HIV infects a 
cell transitioning from an effector to a memory subset. As shown in a macaque model, the 
formation of viral reservoirs within the host CD4 T cell population can occur within the initial 
days of infection.115 Early ART initiation, despite minimizing the reservoir size, is incapable of 
preventing its establishment.116,117 Notwithstanding, ART represents a crucial timepoint, as 
majority of the replication competent reservoir is seeded around the time of cART initiation.118  
Due to the inability to access cell host machinery, integrated provirus is trapped in a state of 
dormancy devoid of RNA and protein production. The lack of transcription factors, prevalence 
of epigenetic modifications, and impaired nuclear export may all contribute to this latent 
cellular phenotype.119,120 Because these cells do not produce viral transcriptional products, 
current therapeutic strategies are unable to effectively target these cells for removal. 
Furthermore, it is unlikely that the reservoir will extinguish spontaneously due to its long half-
life of approximately 44 months.121 It is because of this persistent pool of provirus that cART 
remains necessary for life – it prevents bystander cell infection from reservoir-derived virus. 
Conversely, in the presence of cART cessation, latently infected cells can initiate 
transcription/translation of new viral particles to establish de novo infection within its cellular 
targets. Despite the tremendous contribution of cART to inhibit progression from HIV to AIDS, 
cART is not a sustainable answer. This is because of cART-induced toxicity and immune 
dysregulation within the patient, and the lack of resources required for cART to be a long-term 
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solution. Therefore, it is pertinent that we investigate strategies that contribute to a disease-
free status.  
The most commonly investigated approach for removing the latent reservoir is the ‘shock-and-
kill’ strategy for HIV-1 eradication. In this strategy, HIV-infected cells are ‘shocked’ into a state 
of transcriptional activity using a latency reversing agent (LRA). Upon reactivation, the 
production of viral RNA and protein facilitates recognition and killing via immune-mediated or 
viral cytotoxic effects (Figure 1-3). This process is contingent on maintained anti-retroviral 
therapy to prevent the establishment of new reservoirs, as mentioned previously. Many 
different LRAs have been investigated for their potential ability to induce HIV-1 transcriptional 
reactivation, many of which are described below.   
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Latently infected cells are targeted for reactivation by using a latency reversing agent (LRA), or 
‘shock’, to re-initiate transcription. Transcriptionally active virus produce viral proteins and 
virions which lead to infected host cell death via i) immune mediated killing, ii) viral cytopathic 
effects (vCPE) and/or, iii) apoptosis. Progeny virions are unable to infect bystander cells due to 
the presence of antiretroviral inhibition.  
  
Figure 1-3: The shock-and-kill method for HIV-1 transcriptional reactivation 
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1.5.2 Histone Acetylation 
The acetylation status of the HIV-1 LTR regulates viral transcriptional activity and, therefore, 
modulates viral latency. Modification of the LTR occurs through the enzymatic function of either 
histone acetyltransferases or histone deacetylases (HDAC), which promote or suppress 
transcription, respectively (Figure 1-4).122–124 Histone acetyltransferases, which are antagonized 
by HDAC, open the chromatin conformation and can promote complexes essential for 
transcriptional activity. This is accomplished by the remodeling and hyperacetylation of 
nucleosome-0 (nuc-0) and nucleosome-1 (nuc-1) within the 5’ LTR, which act as ‘switches’ to 
initiate virus production.125 The   opposing HDACs alternatively promote a heterochromatic 
environment and transcriptional downregulation via the removal of acetyl groups from lysine 
residues on histone tails, thus causing chromatin compaction.126,127 Downregulation is 
accomplished both directly and indirectly through i) deacetylation at HIV-integrated sites and, ii) 
modification of transcription factors, such as NF-B p50 subunit.77,128 The continual interplay 
between these enzymes ultimately dictates cellular chromatin conformation and are worth 
investigating as potential targets to induce transcriptional upregulation.  
In order to create a favourable environment for cellular transcription, histone deacetylase 
inhibitors (HDACis) have been extensively studied for their ability to induce latency reversal and 
have formed the basis of numerous clinical trials worldwide. HDACi prevent silencing of the HIV-
1 proviral genome through direct inhibition of the enzyme, histone deacetylase, thus facilitating 
hyperacetylation and remodelling to an open chromatin formation.129  
This family of small molecule inhibitors have been targets of investigation for their potential role 
as latency reversal agents , with valproic acid (VA) becoming the first HDACi to enter clinical 
trials.78 Despite its high tolerance, chronic VA therapy did not significantly decrease the detection 
of latently infected cells when compared to patients on prolonged cART alone.130 The first ‘next-
generation’ HDACi, suberoylanilide hydroxamic acid (SAHA, Vorinostat), was initially approved 
for the treatment of T cell lymphoma before being investigated for its potential role as an LRA.131  
In 2012, Archin et al. described the single-dose effects of Vorinostat in eight patients, following 
proof-of-concept studies identifying latency disruption in vitro.129,132–134 The drug’s bioactivity 
was determined using measurements of histone acetylation in vivo. Archin demonstrated a mean 
 
23 
 
4.8-fold increase in the amount of HIV-1 RNA being produced six hours post infusion with a single 
dose of VOR. Following a multiple dose regimen, VOR maintained high tolerance, although cell-
associated HIV RNA stimulation was greatly stunted following the initial dose, potentially 
resulting from a drug related refractory period.135 Of importance, new findings may suggest SAHA 
increases the susceptibility of target cells to HIV-1 infection.136 
The chemotherapy drug, Panobinostat, has also been implicated as a potential LRA. Fifteen 
individuals on suppressive ART received oral Panobinostat three times weekly for eight weeks, 
with cell-associated viral RNA measured at each time point.137 The mean maximum increase in 
HIV-1 RNA associated with the Panobinostat treatment regimen was 3.5-fold (range 2.1-14.4), 
showing latency disruption in vivo, but failed to reduce the detection of latently infected cells. 
Nine individuals partook in treatment interruption, with mean viral rebound occurring within 17 
days. Only grade I adverse events were noted, indicating high tolerance for Panobinostat.  
The HDACi, Romidepsin, disrupts latency in HIV-1 infected cells and has shown greater potency 
than Vorinostat and Panobinostat in vitro.138,139 Consequently, Søgaard et al conducted a clinical 
study in which six patients on suppressive ART received weekly injections of Romidepsin 
(5mg/m2) intravenously for three weeks.140 On average, HIV-1 transcription increased nearly 
four-fold from baseline levels when observing levels of unspliced, cell-associated HIV-1 RNA. In 
five out of six individuals, plasma HIV-1 RNA became readily detectable compared to baseline 
levels of <20 copies/mL. Infusions of Romidepsin did not decrease detection of HIV-1 specific 
CD4+ T cells in vivo.  
Despite the numerous trials at the clinical and pre-clinical stages of development, none of these 
treatments can clear the infected cells. Clearly, a disparity exists between the in vitro and in vivo 
models. It would appear unusual that, despite in vitro success, the models fail to make any 
noticeable difference in viral clearance. To amend this conflict, several different hypotheses have 
been formed. First, certain HIV-specific cell lines over-express Bcl-2, a protein responsible for cell 
survival. As a result of this over-expression, cells do not undergo viral cytolysis in the presence of 
HDACis.141 Additionally, the function of cytotoxic cells varies between in vitro and in vivo models, 
thus altering the ability to ‘kill’ latently-infected cells. Whereas in vitro studies of latency reversal 
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report abrogated CD8+ and NK cell function in response to HDACi treatment, no such 
circumstances occurred in clinical trials for the same drugs.140,142,143 Although HDACis may induce 
the production of viral RNAs and proteins from latently-infected cells, such defects in clearance 
would prove detrimental to this approach. Finally, in the case of chronic infection, cells are likely 
to exhibit a high degree of T cell exhaustion and may, as a consequence, impair the clearance of 
infected cells.144 Because multiple mechanisms exists wherein latently-infected cells can persist 
post-reactivation, the success of an HDACi regimen would be contingent upon co-treatment with 
a mechanism to facilitate ‘kill’.  
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Histone deacetylase inhibitors (HDACi), such as Vorinostat, Panobinostat, and Romidepsin, 
function through direct inhibition of the histone deacetylase (HDAC) enzyme. HDAC are capable 
of stripping acetyl groups from chromatin, facilitating a shift from euchromatin to 
heterochromatin. Histone acetyltransferases (HAT) add acetyl groups to chromatin, preventing 
tight compaction and creating a euchromatic environment. Euchromatic environments are 
transcriptionally favourable, thus leading to the production of mRNAs and downstream protein 
production.   
Figure 1-4: Mechanism of the latency-reversing histone deacetylase inhibitor 
 
Figure 1-4: Mechanism of the latency-reversing histone deacetylase inhibitor 
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1.5.3 BET Bromodomain Inhibitors 
The bromodomain protein Brd4 is a major barrier to HIV-1 latency reactivation through its 
competitive inhibition of the Tat-SEC interaction.145 JQ1 is a bromo and extra terminal (BET) 
bromodomain inhibitor capable of Brd4 inhibition and induction of HIV-1 expression in latently 
infected cell lines.145,146 Interestingly, in the absence of Tat, JQ1 is also the only latency reversal 
agent capable of inducing HIV mRNA splicing.147 The selective small molecule is further involved 
in the downregulation of T cell transcriptional genes, while upregulating genes responsible for 
histone modification.148 An ex vivo investigation using CD8+-depleted PBMCs from patients on 
suppressive ART identified that combination JQ1+Bryostatin-1 administered at clinically relevant 
doses stimulated reactivation at the same frequency as the anti-CD3/CD28 positive control, and 
was supported with findings by Laird et al earlier in 2015.146,149 However, the findings of these 
studies are confounded by the results of another ex vivo study that failed to observe any 
significant impact on latency reversal when JQ1 was administered alone.  
1.5.4 Protein Kinase C Agonists 
Bryostatin-1 is a macrocyclic lactone that functions as an agonist to protein kinase C (PKC).150 In 
an ex vivo study of common LRAs, Bryostatin-1 was the only agent shown to effectively reverse 
HIV-1 latency in vivo.151 However, the effect of Bryostatin administration was only 4% when 
compared to maximal reactivation via T cell activation, emphasizing a need for combinational 
drug approaches to overcome the multiple mechanisms dictating latency in vivo.149 This PKC 
agonist, when combined with HDACis or bromodomain inhibitors, was capable of potent re-
activation of HIV-1 transcription.21  Regarding toxicity, a PI clinical trial reported high tolerance 
to single-dose Bryostatin-1 administration in patients on suppressive ART receiving 10ug/m2 or 
20ug/m2.152 Unfortunately, the plausibility of such studies will likely be limited due to reports of 
grade III/IV adverse effects associated with Bryostatin-1 administration at higher doses, as seen 
in clinical trials for various cancer treatments.  
Prostratin has also received attention due to its ability to stimulate HIV-1 transcriptional activity 
whilst preventing de novo infection.153 Like Bryostatin-1, Prostratin is a potent stimulator of NF-
kappaB and consequentially activates the HIV-1 LTR, leading to the viral transcription of latent 
provirus.122 Prostratin was shown to be one of three LRAs (including Romidepsin and Bryostatin-
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1) that induced significant increases in viral mRNA (mean 7.7-fold increase) when administered 
alone.151 Furthermore, intracellular HIV-1 mRNA levels increased further when Prostratin was 
combined with several LRAs, specifically Romidepsin or JQ1, exemplifying the synergistic nature 
of the molecule.151   
Unfortunately, the natural availability of Bryostatin-1 and Prostratin is low, and demand an 
alternative means of acquirement. The development of mechanistically identical synthetic 
analogues has been used to overcome this obstacle.154,155 Surprisingly, the PKC-binding potential 
of the Prostratin analogue is up to 100-fold greater than its naturally occurring counterpart when 
observed in vitro and ex vivo.154 The Bryostatin-1 analogue also shows ≈1000-fold increase in the 
induction of latent HIV-1 when compared to Prostratin in vitro.155 However, neither Prostratin 
nor its synthetic analogue have been tested in humans to determine its safety or efficacy. 
Nevertheless, it may be possible to cautiously infer these consequences in vivo based on the 
mechanistic similarities between Prostratin and Bryostatin-1. 
1.5.6 Virus-Like Particles 
The development of virus-like particle (VLP) formulations provides a powerful alternative to 
contemporary vaccine regimens. More specifically, VLPs deliver an efficacious and flexible 
vaccine platform that, importantly, ensures a high degree of safety due to the innate inability 
for the VLP to replicate.156 This is due to the absence of a viral genome, which is present in viral 
particle (VP) formulations but absent in VLPs. In the context of HIV-1, virus-specific mutations 
are also incorporated to ensure safety, including the lack of a functional packaging sequence 
and absence of the 5’ LTR.157 Virus-like particles traditionally self-assemble with the provision of 
core envelope or capsid proteins and, in the case of HIV-1, only requires Gag protein for 
immature particle assembly.158,159 Despite this, HIV-1 VLPs benefit from the addition of all 
structural proteins, as they can contribute to heightened antigenicity. By ensuring the presence 
of all viral proteins, a VLP can appear morphologically similar, if not identical, to its wild-type 
counterparts.160 This includes the presence of identical surface proteins and particle size. 
Production methods can widely vary, with VLP production occurring in plants, yeast, and 
bacterial/insect/mammalian cell lines.161–163  
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Virus-like particles express T cell epitopes, which can activate different T cell subsets, including 
Type-1 T helper cells (TH1) and CTLs.164 The subsequent functioning of these cells is implicated 
in pro-inflammation, cytokine secretion, cell killing, and APC activation. As an exogenous 
antigen, VLP formulations primarily utilize major histocompatibility complex II (MHC-II) to signal 
T helper cells in an MHC-restricted manner. As MHC:TCR interactions are highly specific, this 
provides a tool for the targeting of virus-specific T cells.165 Moreover, studies have also shown 
that VLPS can cross-present to MHC-I through a TAP-independent endosomal pathway, thus 
simultaneously stimulating CTL activation.166,167 The CTL/TH1-stimulatory effect of VLPs is 
further complemented through the incorporation of various stimuli. In one such instance, 
incorporation of TLR7 and TLR9 agonists provided a boosting effect to a norovirus VLP vaccine 
formulation.168 The ability to adjuvant VLP-based vaccine regimens provides additional avenues 
for investigation and may drastically impact vaccine efficacy.  
In addition to their ability to efficiently target T cells for activation, VLPs can also contribute to 
the induction of B cell responses. This can be through the induction of complement-dependent 
cytotoxicity, T cell regulation, and antibody-dependent cellular cytotoxicity (ADCC).164 Of 
notable importance, VLPs exhibit a high degree of organization and display geometric pathogen 
associated structural patterns (PASP) on their surface.158,164 Such patterns may efficiently cross-
link BCRs, which can heightened B cell induction.169 In the context of HIV-1, increasing the 
prevalence of envelope proteins on the cell surface may contribute to improving B cell 
responsiveness. In one such study, a 10-fold increase in surface envelope glycoprotein spikes 
significantly upregulated Env-specific B cell responsiveness.170 Alternatively, peptides and 
proteins can be linked to the surface of the VLP without significantly altering the size of the 
particle.171,172 In all such instances, B cell activation will ultimately induce antibody production, 
which can be used to specifically target virally-derived antigens. By modifying the antigens 
present on the surface of a VLP, it becomes possible to create a highly tailored antibody 
response to a region of interest. Moreover, by adjuvanting virus-like particles with stimuli, such 
as TLR7/8 RNA, it is possible to drive isotype switching to IgG.173 
Currently, little is known about the efficacy of a virus-like particle formulation as a vaccine for 
HIV-1 prophylaxis or cure. Due to high mutation rates within the HIV-1 genome, a virus-like 
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particle formulation would need to present a disperse array of peptides to ensure optimal 
presentation via the MHC:TCR complex. In such a way, it is possible to target HIV-specific Th1 
cells for activation which, coincidentally, also serve as the primary reservoir for quiescent 
provirus. However, due to the low surface expression of envelope trimers on wild-type HIV-1 
and, by extension, native VLPs, it is unlikely that BCRs will efficiently cross-link, thus limiting the 
production of protective antibodies. As such, VLP-mediated antibody responses may require 
that the VLP express more viral proteins on its surface. 
Although the use of virus-like particles for HIV-1 curative therapy is relatively novel, an 
increasing amount of evidence suggests that HIV-1 VLPs would be effective latency reversing 
agents. Originally, researchers found that HIV-1 preferentially infects HIV-specific CD4 T cells 
over CD4 T cells with alternative TCR specificities.174,175 This finding was compounded by studies 
revealing that latency reversal was efficiently achieved through TCR stimulation using HIV-
derived peptides.176,177 Therefore, VLPs targeted to MDDC for presentation to HIV-specific T 
cells represents an exciting avenue for latency reversal research.  
1.6 Adaptive Immunity and HIV-1  
1.6.1 Dendritic Cells – Characteristics and Functions 
Dendritic cells have a critical role as an intermediary between the innate and adaptive immune 
systems. These cells are capable of sensing pathogen-/danger-associated molecular patterns 
(PAMPS/DAMPS) to induce acute inflammation and mediate adaptive responsiveness in the 
context of antigen processing and presentation.178 Typically, immature dendritic cells (iDCs) 
provide key surveying and phagocytic functions, whereas mature DCs mediate antigen 
processing and presentation in the context of MHC-I/II. Maturation is also accompanied by up-
regulation of the co-stimulatory molecules CD80 and CD86, which contribute to the activation 
of T lymphocytes.179 There are three primary DC subsets, including: plasmacytoid DCs (pDCs), 
conventional/myeloid DC1 (cDC1s), and DC2s. Of importance, DC1 cells are known as such due 
to their ability to drive naïve T cell differentiation into Th1 T cells in a cytokine-independent 
process.180 This is important because, during natural infection with HIV-1, CD4+ Th1 cells are the 
primary target for viral infection. In the context of the work herein, we focus on monocyte-
derived dendritic cells (MDDCs), which are routinely used in vitro due to their similarities with 
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conventional myeloid-derived DC1s, including morphology and function.179 By contrast, MDDCs 
are not typically present in steady state, but are more readily produced in pro-inflammatory 
environments.181,182 The MDDC subtype is further differentiated by the expression of DC-
SIGN/CD209a on the cell surface.182 These cells are readily differentiated from monocytes in the 
presence of IL-4 and GM-CSF, making them a useful for studies of dendritic cell function.  
1.6.2 Dendritic Cells in HIV-1 Processing  
Dendritic cells typically utilize two pathways for antigen processing, one for exogenous antigens 
and the other for endogenous antigens. In the context of HIV-1 viral particles, uptake will occur 
via the exogenous pathway (Figure 1-5). Typically, dendritic cells begin uptake through either 
receptor-mediated endocytosis or, less often, pinocytosis. Upon internalization, the HIV 
particle/antigen is degraded into peptides through a series of endocytic compartments of 
sequentially increasing acidity. Degradation is first initiated within the early endosome (pH 
~6.0-6.5) before transitioning to the late endosome (pH ~4.5-5.0), and ultimately the 
endolysosome (pH 4.5). During this time, antigen is processed into peptides ranging from 13-18 
residues, which is ideal for binding to MHC II within the MHC-II-containing endosomal 
compartments (MIIC). Importantly, this processing pathway is dependent on i) hydrolytic 
enzymes within endosomal compartments and, ii) low pH. As a consequence, this process can 
be disrupted through inhibitors of protease activity (e.g. Pepstatin A) or through increasing the 
pH within endosomal compartments (e.g. chloroquine).95,183 
Before MHC-II can interact with peptides within the MIIC, the molecules must first be 
synthesized and transported. MHC-II αβ chains are synthesized within the rough endoplasmic 
reticulum (RER), as are MHC-I molecules from the endogenous pathway. In order to shuttle out 
of the RER, MHC-II molecules must interact with the invariant chain, CD74, which interacts with 
the peptide binding groove to prevent MHC-II molecules from interacting with peptides 
destined for MHC-1 presentation. Upon MHC-II:CD74 engagement, the complex shuttles 
through the golgi complex and into the endocytic compartment. As proteolytic activity 
increases, the invariant chain is cleaved except for the class-II associated invariant chain 
peptide (CLIP). CLIP remains within the MHC-II peptide-binding pocket, and prevents pre-
mature binding. HLA-DM catalyzes the response which removes the CLIP in exchange for 
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antigenic peptides. The MHC-II:peptide complex is shuttled to the plasma membrane, where it 
can interact with lymphocytes in a MHC-restricted context.  
Dendritic cells have become an increasingly desirable strategy for many vaccine regimens due 
to their ability to present antigen peptides in a highly specific context. By pulsing dendritic cells 
with a specific antigen, we can mediate MHC-II presentation to activate particular subsets of 
CD4+ T cells. In the context of latency reversal, this provides a strategy to specifically target T 
cells expressing HIV-specific TCRs.  
 
32 
 
 
Figure 1-5: The exogenous dendritic cell processing pathway. 
Endocytosis occurs via internalization of antigen-bound receptor molecules via clathrin-coated 
vesicles. The pH of the endosome decreases, allowing for antigen processing into smaller 
fragments. MHC:II molecules are produced in the endoplasmic reticulum and shuttled through 
the Golgi complex. The invariant chain (Ii) is cleaved, leaving CLIP in the receptor binding site of 
the newly formed MHC II molecule. CLIP is replaced with processed peptide before the complex 
is shuttled to the surface of the dendritic cell for presentation. Ii, invariant chain; MHC, major 
histocompatibility complex. 
  
 
33 
 
1.6.3 T Cells – Characteristics and Function 
T cells are one of the functional cornerstones of adaptive immunity, with roles in immune 
mediation, homeostasis, and immunological memory. Furthermore, these cells have highly 
diverse TCRs and can detect up to 100 million different specificities.184 T cells are also a 
necessary component that mediate immune tolerance. As such, T cells are a vitally integrated 
part of human immunity, and dysfunction of these cells can lead to autoimmune disease or 
pathogen susceptibility.  
In the beginning, hematopoietic stem cells (HSCs) differentiate into multipotent progenitor cells 
that follow either the myeloid or the lymphoid lineage. These cells arise within the bone 
marrow and, in the case of T lymphocyte development, migrate to the thymus to undergo 
maturation and selection. Knowledge of the underlying process, referred to as thymopoiesis, 
has largely been investigated in mice due to the ability to perform thymectomies and bone 
marrow reconstitutions.185 In the thymus, CD4-CD8- progenitor cells experience T cell receptor 
(TCR) rearrangement to yield double positive (DP) thymocytes.186 DP thymocytes subsequently 
engage in positive selection, wherein the CD4+CD8+ cells are subjected to MHC-I and MHC-II 
class molecules.187 During positive selection, cells can either i) fail to bind MHC-I/II and undergo 
apoptosis, ii) bind MHC-I and mature into a CD8+ T cell or, iii) bind MHC-II and mature into a 
CD4+ T cell. Positive selection permits the survival of any T cell capable of binding MHC, 
irrespective of binding affinity. This process ultimately yields single-positive thymocytes that 
upregulate the CCR7 chemokine for migration to the medulla. In this region, negative selection 
permits the removal of high affinity, self-reactive clones. Interestingly, the thymus is largest at 
birth and experiences changes to volume, epithelial density, and fat content over time.188 It is 
expected that thymopoiesis begins to significantly decrease at ~40 years old based on studies 
investigating DP thymocyte prevalence within the thymus.189 
In the periphery, naïve T cells undergo effector and memory differentiation in a triphasic 
process. First, clonal expansion occurs in response to TCR-mediated antigen recognition, 
followed by the contraction phase, during which most effector cells die via apoptosis and, 
finally, the memory phase, which contributes to primed immune reactiveness in response to 
repeat infection.190,191 In studies evaluating CD8+ memory cell persistence, it was found that 
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approximately 5-6% of effector cells transitioned to a memory phenotype and were detectable 
at 25 years post-vaccination.192,193 Such studies have been recapitulated across a multitude of 
acute viral infections, all of which exhibited similarities in T cell response kinetics and 
magnitude.186 
Of notable importance are CD4+ T cells that engaged with MHC-II during thymic selection. These 
cells, known as T helper (Th) cells, can be stratified into several distinct groups: TH1, TH2, TH17, 
and TFH cells.  
1.6.4 T Cells in HIV-1 Pathogenesis 
HIV-1 is heavily implicated in the depletion of CD4+ T cells over the time-course of infection. 
This depletion ultimately compromises adaptive immunity and leads to the onset of acquired 
immunodeficiency syndrome (AIDS). During AIDS, the body is more susceptible to co-infection 
with opportunistic pathogens, which depend on an abrogated adaptive immune response to 
establish and disseminate infection. As such, although HIV-1 weakens adaptive immunity 
through T cell destruction, it is often the opportunistic infection that directly contributes to 
severe morbidity or mortality. Studies of how CD4+ depletion occurs may shed light on potential 
avenues to reduce T cell depletion. It is important to note, however, that sustained cART 
therapy can maintain relatively stable T cell numbers.  
Unsurprisingly, many studies have contributed T cell decline to apoptosis in both the 
productively-infected and bystander CD4+ or CD8+ T cell cohorts.194–196 Early investigations into 
the cause of T cell decline, specifically within the bystander population, identified antigen-
presenting cells, such as monocyte-derived macrophages, as key players in indirect 
apoptosis.195 Other mediators of apoptosis, such as Fas, a receptor for cell death signaling, are 
upregulated in the CD4+ and CD8+ populations within HIV-infected individuals.197,198 This 
correlates with increased FasL expression in cells such as, natural killer (NK) cells, macrophages, 
and monocytes.198 Despite this finding, it is worth noting that HIV-infected cells expressing Fas 
are not the predominant cells succumbing to apoptosis in vivo, and many apoptotic cells from 
infected patients lack Fas expression.199,200 Fas:FasL interactions may also contribute to 
apoptosis during the contraction phase of infection, when expanded populations undergo 
activation induced cell death (AICD).201 Interestingly, more recent investigations have identified 
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decreased thymic output of T cells in response to HIV-1 infection, likely resulting from i) direct 
viral cytopathic effects and ii) increased levels of indirect apoptosis within the immature 
thymocyte population.201 This decrease in T cell output may subsequently contribute to the 
overall loss of circulating T cells detected in the blood and atrophy of the thymus. A good 
indicator of this phenomenon is the number of T-cell receptor rearrangement excision circles 
present in circulating cells, which is inversely correlated with HIV-1 viral load.202  
Viral proteins also contribute to pathogenesis within HIV-infected individuals. For instance, 
upon binding of envelope gp120 protein, cellular apoptosis is initiated through either, i) Fas 
upregulation and engagement, ii) upregulation of TRAIL death receptors 4/5 (DR4/5), or iii) 
upregulation of proapoptotic transcription factors, such as NF-kB and p53.203–205 The relative 
contribution to each of these pathways in the context of gp120:CD4+ engagement remains 
unknown, however, it is important to appreciate the polyfunctional nature of gp120 
pathogenicity. Conversely, Tat protein functions through its production and secretion within 
infected cells, and can subsequently enter uninfected cells via clathrin-mediated endocytosis.206 
Additionally, studies utilizing exogenous tat on monocytes and macrophages have shown TRAIL 
upregulation and apoptosis of bystander cell populations.207 Another viral protein, nef, can 
similarly upregulate expression of Fas on CD4+ T cells.208 Additionally, nef contributes to the 
heightened expression of programmed death 1 (PD-1) which, as its name implies, modulates 
CD4+ T cell survival.209 Nef is further capable of entering uninfected cells via the secretion of 
endosomes from HIV-infected CD4+ T cells, and likely facilitates bystander cell death.210 
Interestingly, viral Vpr exhibits antiapoptotic characteristics until after G(2) arrest, after which 
Vpr can mediate the release of cytochrome c and elicit caspase 3/9 function.211,212 It is evident 
that HIV-1 has several mechanisms which can kill CD4+ T cells, both directly and indirectly. This 
can be problematic in the case of uncontrolled infection; however, the advent of antiretroviral 
therapy can regulate the pathogenicity of HIV-mediated apoptotic mechanisms.  
More recent studies suggest that CD4+ T cell depletion may not be fully attributable to 
apoptosis. In fact, estimates suggest that only 5% of virally-mediated cellular depletion is due to 
apoptosis, while the remaining 95% results from pyroptotic events.213 This claim can be 
substantiated upon closer analysis of CD4+ T cell death and, specifically, by looking at the 
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necessary steps of the viral infectious cycle required to mediate death. Through such 
investigative efforts, it was shown that bystander cells receiving entry inhibitors (AMD3100) or 
fusion inhibitors (T20) could withstand death while, conversely, nucleoside reverse 
transcriptase inhibitors (NRTIs) and inhibitors of upstream processes did not protect cells from 
destruction.214 As an exception, NNRTIs, which directly inhibit the function of reverse 
transcriptase, could protect against cell death. This indicates that some form of transcriptional 
elongation must be necessary to initiate a death response.215 Evidently, there is a period of time 
after entry but before integration wherein the necessary components for cellular death occur. 
Specifically, CD4+ T cell loss is likely attributed to non-productive HIV-1 infection within resting 
cells.214,216 To address this phenomenon, Monroe et al. performed studies using affinity 
chromatrography and mass spectrometry to identify a cellular censor and ultimately identified 
IFI16.217 The IFI16 protein is capable of detecting the accumulation of viral DNA fragments 
within the cell cytoplasm and, upon reaching a threshold concentration, forms an 
inflammasome to initiate caspase-1 mediated pyroptosis.213 shRNA-induced knockdown of the 
inflammasome or caspase-1 protein both prevented cell death within abortively infected cells, 
whereas caspase-3 inhibition was non-protective. In summation, a majority of CD4+ T cell loss 
during HIV infection is likely due to abortive infection of resting and bystander cells with low 
transcriptional activity, wherein the accumulation of viral DNA fragments triggers a pro-
pyroptotic response.  
1.6.5 T Cell Signalling 
TCR signalling is initiated when the TCR engages with a peptide-MHC-II complex presented by 
an antigen presenting cell, such as an MDDC. The TCR, itself, is sufficient for recognition and 
engagement of the peptide:MHC complex, however, signalling requires the ζ chain and CD3 
molecules due to the ‘immunoreceptor tyrosine-based activation motifs’ (ITAMs) present 
within their cytoplasmic domains (Figure 1-6).218 The co-localization of the CD4 coreceptor is 
sufficient to recruit Lck, which is responsible for phosphorylation of tyrosine residues within the 
ITAMs. Phosphorylated residues can interact with the Zap70 molecule via the SH2 region. Zap70 
engagement on the cell surface is sufficient for its activation, which is stabilized by 
phosphorylation and is responsible for ‘linker of activation of T cell’ (LAT) activation.219 These 
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sites of phosphorylation are responsible for i) calcium provision for Ras/MAPK pathway 
activation and, ii) Grb2/Gads recruitment for downstream Ras/Rac/Rho GTPase activation.220 At 
the cellular membrane, interactions with CD28 and the TCR cause concurrent downstream 
signalling. CD28 activates PI3K and, through a series of phosphorylation events, induces the 
PIP2/PIP3/ITK kinase/PLC1 cascade.221 PLC1 subsequently generates the DAG and IP3 substrates. 
DAG interacts with protein kinase C (PKC) to activate Ras. Alternatively, IP3, upon binding its 
cognate receptor, is responsible for Ca2+ release and is implicated in the production of 
transcription factors, such as NFAT. These concurrent signaling pathways ultimately contribute 
to T cell fate in regards to proliferative ability, transcriptional activity, and cell survival. 
Inhibition across multiple pathways can contribute to a highly abrogated T cell expression 
phenotype.   
Understanding the metabolic tendencies of T cells throughout HIV infection is also necessary 
when attempting to understand viral latency and re-activation. Following TCR stimulation, the 
metabolic transport protein, Glut1, is upregulated via the Myc protein.222 The degree of cellular 
metabolism further drives T cell activity in vivo. Increases in glucose uptake and glycolysis, 
determined through experiments involving the transporter protein Glut1, reveal that glucose 
metabolism contributes to cellular proliferation, survival, and cytokine production.222 T cell 
metabolism can be further complemented with CD28 co-stimulation, which subsequently 
activates the mTOR pathway and mediates surface localization of Glut1.223 The inability of an 
effector T cell to upregulate glucose metabolism is implicated in cellular inactivity and 
promotion of cell death.224 Cells that survive are prone to anergy, as are cells exhibiting 
deficiencies in mTOR signalling.225,226 Therefore, latency reversing strategies designed to target 
the latent reservoir must also consider the metabolic state of the cell, as unfavourable 
conditions will surely hinder transcriptional reactivity.  
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MHC:peptide interaction with the T cell receptor (TCR) initiates T cell activation and is 
dependent on CD4 engagement. Phosphorylation on the cytoplasmic tail triggers the activation 
of downstream signalling molecules. TCR signalling induces production of cytokines responsible 
for cell survival, proliferation, and transcriptional activation. Solid arrows indicate a direct 
interaction. Broken arrows indicate that intermediate steps are involved.   
Figure 1-6: A schematic of T cell signalling through the T cell receptor 
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1.7 Rationale, Hypothesis, and Objectives: 
Statement of Importance: The establishment of replication-competent provirus in resting CD4+ 
T lymphocytes represents a significant barrier to HIV-1 curative research. The viral reservoir is 
highly stable, and infected cells are phenotypically indistinguishable from uninfected CD4+ T 
cells – thus making it difficult to selectively target these cells for eradication. Therapeutic 
interventions designed to eliminate this cellular reservoir have largely failed, emphasizing the 
need for more innovative and bold strategies to destroy this cellular reservoir. Evidence 
suggests that HIV preferentially infects and establishes latency within HIV-specific CD4+ T cells 
and that HIV latency reversal can be achieved using HIV derived proteins. Therefore, a 
therapeutic vaccine that represents the entire proteome of HIV within a given individual, 
immediately prior to antiretroviral therapy, might activate the entire cellular reservoir and 
initiate proviral gene transcription.  
Since the discovery of the latent reservoir in the late 1990s, many strategies have been 
employed in attempt to reduce or eradicate these pools of latent provirus. Though many of 
these regimens remain unsuccessful, one strategy, aptly called the ‘shock and kill’ strategy for 
HIV eradication, is being critically investigated. Our activation vector, ACT-VEC, is a novel 
therapeutic vaccine strategy designed to reactivate, or ‘shock’, latently infected cells back into 
transcriptional activity. Preliminary studies reveal that ACT-VEC can potently reactivate HIV-
specific CD4+ T cells, and outperforms many single and dual-drug regimens currently under 
clinical investigation. 
Statement of Hypothesis: HIV latency reversal may be maximally achieved by using a highly 
diverse, heterologous formulation representing a host of patient-derived viral antigens to 
activate the HIV-specific memory CD4+ T cell reservoir. 
Experimental Aims: 
Aim 1: Develop a heterogenous virus-like particle (VLP) vaccine for HIV-1 latency reversal 
ACT-VEC is a heterologous virus-like particle (VLP) formulation that encompasses the quasi-
species of five chronically infected individuals.157 We aim to utilize a yeast recombination 
system to ensure maximum diversity within each of the five individual donor VLPs which, in 
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combination, form the basis of ACT-VEC. As part of development, our ACT-VEC formulation 
requires genomic modifications rendering it non-infectious, including i) removal of the 5’ LTR of 
HIV-1, ii) abrogation of the packaging signal via modification of stem loop 1 within Gag (dS.1 
mutation), and iii) removal of viral RNA from the particles. Herein, we aim to perform 
preliminary investigations regarding phenotypic characteristics, safety, and diversity of the 
formulation following successful development.  
Aim 2: Evaluation of ACT-VEC VLP as a latency reversing agent in donors infected and treated 
during the acute stage of infection 
Following development, we seek to investigate the impact of a highly heterogenous virus-like 
particle formulation in the context of acute-stage infection. During this stage, latent reservoirs 
are more likely restricted to HIV-specific CD4+ T cells, providing an optimal model for a targeted 
latency reversal investigation. Using an in vitro MDDC-T cell co-culture assay, the 
immunogenicity and latency reversing potential of our ACT-VEC vaccine candidate is compared 
to the most relevant LRAs currently under clinical investigation. Genomic readouts, including 
replication-competent induced virus, are determined via deep gene sequencing. Cellular 
readouts are determined using IFN-γ ELISpot and culture supernatant qRT-PCR. Furthermore, 
this study aims to identify potential mechanisms contributing to transcriptional reactivation of 
latent provirus.  
Aim 3: Perform latency reversal on chronically infected, heterologous donor samples 
Following the findings present within Aim 2, it is important to evaluate the effect of our VLP 
candidate in the context of individuals infected and diagnosed at the chronic stage of infection. 
As most HIV-infected individuals are diagnosed at this stage, this model is the most biologically 
relevant in regard to determining vaccine efficacy. Moreover, many potential complications 
arise that are unique to this stage of infection, including, i) the potential of T cell 
exhaustion/anergy, ii) higher diversity in the viral quasi-species, and iii) the establishment of 
alternative reservoirs due to co-infection. Taking these complications into account, it will be 
interesting to compare the efficacy of ACT-VEC during the acute and chronic stages of infection. 
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Similar to Aim 2, all latency reversal assays will be performed in vitro using PBMCs from 
consenting individuals within this respective cohort.  
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2.1 Introduction 
Since it’s identification as the etiological agent behind Acquired Immunodeficiency 
Syndrome (AIDS), HIV-1 has become a global pandemic and major public health concern. 
Despite the success of antiretroviral therapy (ART) at reducing viral loads and preventing CD4+ T 
cell loss, infection endures owing to the establishment of a transcriptionally silent latent 
reservoir in CD4+ T cells1. As natural immunity is not protective against HIV-1, the development 
of an effective vaccine strategy remains the best countermeasure to the advancing pandemic. 
 Despite a lack of natural immunity against HIV-1 infection and few correlates of 
protection to guide vaccine development, it is anticipated anti-HIV-1 vaccines should elicit 
potent cellular and humoral immune responses. Apart from the modest protection observed in 
the RV144 trial, HIV vaccines have failed to induce any protective efficacy in clinical trials2,3. 
Alternatively, there is a renewed focus on therapeutic HIV vaccine development and the 
elimination of cell-associated or cell-free HIV in patients treated with ART. Thus, it is a priority 
to develop improved vaccine immunogens that can activate both cellular and humoral immune 
responses with a view to not only protect against HIV acquisition, but also to eliminate viral 
reservoirs such that viral remission or even a cure is achieved. A significant impediment to 
vaccine efficacy is thought to be the sheer HIV-1 sequence diversity4. A therapeutic vaccine 
must elicit an immune response that overcomes the high intra-patient sequence diversity and 
any immune-escape mutations. Polyvalent Env vaccines are one approach designed to 
overcome the viral diversity and involves the use of heterologous HIV-1 Env mixtures to expose 
developing immune responses to diverse Env conformations5–8. Nonetheless, a monovalent, let 
alone polyvalent, native Env structure is difficult to achieve outside of the HIV particle. 
Polyvalent Env vaccines may provide vaccine breadth, and harness the elusive neutralizing 
antibody response, which has both therapeutic and preventative benefits9–11. This does not 
discount that non-neutralizing antibodies may play a vital role in vaccine-mediated protection12. 
From another standpoint, eliciting broad cellular immune responses through vaccination is also 
highly desirable considering CTL responses can reduce viral loads, thereby contributing to the 
elimination of productively infected cells13. 
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 In pursuit of more efficacious HIV vaccines, efforts have focused on virus-like particles 
(VLPs), due to their capability of presenting native Env spikes on their surfaces as well as their 
capacity to be endocytosed and presented to T cells in the context of both MHC class I and II14. 
VLPs are defined as viral particles that have undergone protein and lipid self assembly to 
generate non-infectious viral particles (VPs) devoid of any viral genetic material. Furthermore, 
VLPs may be morphologically indistinguishable from wild type infectious virus and present the 
entire HIV proteome as antigen.  
Herein we describe a safe, chimeric HIV-1 VLP vector system, capable of accommodating near 
full-length HIV genomes and captures the HIV diversity present within patient samples. The 
vector system was designed to generate VLPs for testing as anti-HIV therapeutic purposes15. 
Viral RNA from plasma of HIV-infected volunteers was reverse transcribed and cloned into a 
DNA vector for yeast-based recombination/gap repair. Full-length patient-derived HIV-1 
genomes were mutated during the cloning process to stop reverse transcription, integrase (IN) 
activity, and genomic RNA packaging into VLPs. The VLPs express the processed HIV-1 
proteome, were morphologically indistinguishable from HIV VPs, and were capable of 
stimulating both CD4 T cell and cytotoxic responses in heterologous patient samples. Finally, 
the VLPs were combined to form a highly diverse vaccine formulation called Heterologous 
Clade B Activating-Vector (Het_B_ACT-VEC), which shared the phenotypic and antigenic 
properties of the aforementioned VLPs.  
2.2 Results 
2.2.1 Yeast-based gap/repair recombination to clone full length HIV genomes from patients 
Here we describe the ease of full genome cloning to produce patient-derived viral particles (VP, 
containing the viral genome) and virus-like particles (VLPs, lacking virus genome), the latter of 
which is currently being tested as a therapeutic vaccine (Mann; Manuscript Accepted). In 
addition, we will describe the representative sampling of the HIV population from plasma of 
infected patients into DNA vectors used to produce the vaccine constructs.  Ultimately, the VP 
of different patients can be combined to generate heterogenous, near full length, multivalent 
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vaccines for both therapeutic (as part of amfAR preclinical studies) and preventative modalities 
(as part of the European HIV Vaccine Initiative).  
A total of five HIV+ plasmas from infected volunteers, diagnosed at chronic stage of 
infection, were used to generate our vaccines. Due to the sheer genetic heterogeneity of HIV-1, 
chronic samples were chosen to clone viral particle preparations as they exhibit extensive 
diversity compared to acute samples or transmitted/founder clones, and therefore, may 
provide better vaccine breadth. Following reverse transcription (RT), we used external-nested 
PCR to amplify the full genome of HIV in two halves, overlapping by 113 bp within integrase. 
These overlapping 5’ and 3’ patient-specific HIV-1 DNA fragments were transfected into S. 
cerevisae along with linearized pREC-nflgenome/URA3. Following a double recombination 
event in yeast all resulting colonies were harvested to acquire maximum viral diversity – a 
process well described in multiple articles (Figure 2-6S)16–18. The DNA’s were then transfected 
into 293T cells to produce VPs. As shown in Fig.2-1 A-C, we detected significant levels of HIV-1 
capsid p24 and RT activity in the cell-free supernatants with each of the pREC-nfl plasmids 
containing the genomes of the patient-derived HIV (VP1, VP2, VP3, VP4 and VP5).   
We also assessed and verified the presence of p24 and reverse transcriptase activity in 
293T cells transfected with pREC-nfl plasmids (Figure 2-1A and B). Env expression was 
confirmed using a viral tropism (Veritrop) assay (Figure 2-1C). The Veritrop assay was done by 
transfecting 293T cells with the pREC-nfl plasmids and mixing the cells with CD4+/CCR5+ U87 
cells which harbor the pDM128FLUC plasmid as previously described19.  Here cell fusion and 
light emission occurs when 293T cells express functional HIV-1 gp120/gp41 Env, Rev, and Tat 
from the pREC-nfl vectors. Env binds CD4+/CCR5+ and mediates 293T/U87 cell fusion, permitting 
luciferase protein expression. All VP and VLP pREC-nfl vectors had similar levels of light 
emission, indicative of similar levels of Env, Rev, and Tat.      
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pREC_nfl VP (red) and pREC_nfl_dS.1/mutIN VLP (blue) DNA constructs were used to transiently 
transfect 293T cells in 24-well tissue culture plates for 48 h. After 48h, culture supernatants were 
assessed for viral p24 production (A and D) using a p24 ELISA kit. Results shown represent mean 
p24 values (+/- SEM). Culture supernatants were also harvested to asses’ VP and VLP reverse 
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Figure 2-1: Viral particle (VP) and virus-like particle (VLP) formulations express similar viral 
protein concentrations. 
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transcriptase activity in counts per minute (CPM) using an in-house radioactive RT assay (B and 
E). To demonstrate the presence and functionality of HIV Env on VP and VLP, an HIV-1 co-receptor 
tropism assay was used (C and F). The 293T cells were transfected with the VP and VLP pREC-nfl 
plasmids and mixed with CD4+/CCR5+ U87 cells harboring the pDM128FLUC plasmid.  Cell fusion 
elicits luciferase expression if the 293T cells express functional HIV-1 gp120/gp41 Env 
glycoproteins, Rev, and Tat from the pREC-nfl vectors. Results are represented by mean relative 
light units (RLU) (+/-SEM) with background luminescence subtracted from positive and negative 
results.    
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2.2.2 Vaccine VP and VLP are phenotypically identical to wild type virus and diverse 
As described above, the dS.1/mutIN VLPs and wild type VPs contained similar amounts of Gag 
and Env proteins and similar levels of RT activity.  However, the dS.1/mutIN VLPs were 
genetically formulated to 1) lack IN activity 2) to have reduced HIV-1 RNA, and 3) reduced 
ability to initiate and reverse transcribe (-) strand strong stop DNA. However, the general 
morphology of the VLPs compared to wild type HIV is unknown. Thus, we performed 
Transmission Electron Microscopy (TEM) on 293T cells transfected with our pREC_nfl 
constructs. All VP and dS.1/mutIN VLP pREC-nfl DNAs produced vesicular structures around the 
cells with some appearing to bud from the cell surface (Fig 2-2A). These circular structures 
contained electron-dense membrane layers and were ~100nm in diameter, akin to HIV 
particles. Tetherin, is constitutively expressed in restrictive human cells and cell lines such as 
HeLa, H9, Jurkat, Molt4, primary T cells, and primary macrophages20. As Tetherin activity is 
absent in the 293T producer cell line, we did not expect, nor did we observe any VP or VLPs 
“tethering” on the surface of transfected cells. However, since the full HIV-1 proteome is 
produced by transfection with pREC_nfl DNAs, we suspect that HIV-1 Vpu is produced and 
should down-regulate/degrade BST2/Tetherin21 - supporting the use of the pREC-nfl as DNA 
vaccine vectors.  
The size of the purified VP and VLP was verified by Dynamic Light Scattering (DLS). DLS 
depends upon Brownian motion and any resulting photon interference/deflection in liquid 
systems can be used to determine particle size and polydispersity. Following purification, the 
VP and VLPs had an average diameter centred around 100nm (Fig 2-2B), which agreed with the 
prior TEM measurements.   
  
 
64 
 
 
Figure 2-2: pREC-nfl derived VP and VLPs are morphologically similar to wildtype virus. 
293T cells were transfected with pREC_nfl plasmids encoding VPs (- dS.1/mutIN) and VLPs 
(+dS.1/mutIN). Samples were fixed and embedded in Resin-Araldite Embed 812 before imaging 
via transmission electron microscopy (Philips CM10 TEM). Scale bar, is 100nm or 500nm (A). 
Purified VP and VLP preparations were analysed by dynamic light scattering at 25 °C using a 
Malvern Zetasizer Nano (Malvern Instruments Ltd). The intensity of the laser light scattered by 
the sample preparations was detected at 90° to the incidence beam. Data was analysed using 
Malvern software. (B). 
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2.2.3 Genetic diversity of patient-derived HIV-1 genomes with the pREC nfl vector.  
The sheer genetic quasi-species of HIV-1 present within infected individuals, owing to a 
combination of low fidelity RT activity and genetic recombination, is a significant obstacle in the 
pursuit of viable therapeutic HIV vaccines. Thus, a successful vaccine might need to be 
sufficiently “rich in diversity” to have adequate protective coverage. Several vaccine studies 
have evaluated heterologous, polyvalent and sequential vaccine strategies to promote B cell 
affinity maturation and enhanced antibody production. Yeast-based recombination/gap repair 
is a highly efficient cloning technique and can yield hundreds of yeast colonies carrying pREC 
clones with HIV genomes. To determine the relative genetic bottlenecks in the cloning strategy, 
we RT-PCR or PCR amplified the C2-V3 env fragment from the patient plasma, from the 
recombined and purified pREC-nfl vector, and from the gRNA contained in the VLPs.  These env 
PCR products were then subject to next generation sequencing (NGS) and analyzed using the 
methods described previously22. The dS.1/mutIN VLPs contain reduced gRNA, so we could not 
estimate genetic diversity within the patient derived VLP preparations. We did compare the 
genetic diversity within the VP pREC and subcloned dS.1/mutIN pREC by PCR amplification and 
NGS of the C2-V3 of Env.  The topology of the phylogenetic trees is similar for VP pREC-nfl and 
sub-cloned dS.1/mutIN pREC-nfl for each patient (Figure 2-3).  On average, each VP and VLP 
pREC_nfl contained 65 (range = 49 - 98) and 30.6 (range = 22 - 29) unique sequences, 
corresponding to an average of 0.006 (range = 0.00192 – 0.022) and 0.0178 (range = 0.0013 – 
0.082) substitutions/nucleotide (Table 2-7S). 
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Figure 2-3: VPs and VLPs are genetically diverse preparations. 
Neighbor joining trees of nucleotide sequences were generated with MEGA6 and visualized with 
FigTree 1.4.2 to highlight sequence heterogeneity. Phylogenetic trees were reconstructed for 
viral particles (red) and for virus like particles (blue). VLP pREC_nfl DNAs were combined to 
generate Het_B_ACT-VEC. 
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2.2.4 Reducing genomic RNA packaging and inactivating integrase 
Full genome amplifications of the 5 patients were repeated but using primer sets to disrupt the 
gRNA packaging signal and/or the integrase active site (Figure 2-6S).  The 5’ primer of fragment 
1 contained either 9 point mutations in stem loop 1 (698C>T, 718C>G, 719G>T, 720G>C, 
721C>G, 722A>T,  723A>T 724G>C and 731G>A, herein designated dS.1) or a 33 bp deletion 
within stem loop 3 (nucleotides 755-787, herein designated SL3) as described previously by 
Clever et al., 199723. This work was initially carried out to identify the minimal gRNA packaging 
element of HIV-1 using HXB2 pseudotyped with amphotropic murine leukemia virus. However, 
in our system it was necessary to confirm that these mutations would reduce gRNA 
encapsidation in our patient-derived VLP.  Thus, our VLPs would be inherently safer vaccine 
constructs compared to our VP formulations. Initially, the dS.1 mutation and SL3 deletion was 
introduced into the pREC-nflNL4-3 and used to transfect 293T cells (Figure 2-7S A, C and E). 
Resulting particles were harvested and purified from cell free supernatants and found to have 
142- and 11.6-fold less gRNA with the dS.1 and SL3 mutations, compared to NL4-3-viral 
particles. This work was further verified using HIV-1 clade C Env 1086 (Figure 2-7S B, D and F). 
We then mutated the patient-derived viruses, VP3, VP4, and VP5 and again found that the dS.1 
mutations impaired gRNA packaging more so than the SL3 mutations (Fig 2-4A & Figure 2-8S 
C).   
With evidence that dS.1 reduced gRNA packaging in primary vaccine particles, we 
proceeded to introduce both the dS.1 mutation and the RRK>AAH integrase mutations via 
primer-related replacement during PCR amplification of the 5’/upstream genome half and the 
integrase mutations into the 3’/downstream half of the genome. The two overlapping PCR 
products representing the halves of the genome with these mutations were then cloned into 
our pREC vector by yeast recombination/gap repair as described above. Following plasmid 
purification and particle production from transfected 293T cells, we tested these dS.1/mutIN 
mutated VLPs for CAp24/Gag content by ELISA and Western Blot, encapsidated gRNA by real 
time RT-PCR, endogenous RT activity using exogenous poly(rA)oligo(dT) template or the 
endogenous gRNA template (Figure 2-1), and finally, integrase activity by using VLPs soaked in 
lysis buffer containing radiolabelled substrates for dinucleotide cleavage by IN (data not 
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shown).  The addition of the RRK>AAH IN mutations, removal of the 5’LTR, and introduction of 
the dS.1 mutations did not impact Gag/CAp24 levels or RT activity on an exogenous template in 
the VLP preparations.  However, none of these mutated VLPs had dinucleotide cleavage 
activity/end processing as mediated by functional IN, as observed and compared with wild type 
HIV particles (data not shown).  
Finally, we repeated the cell-to-cell fusion assay by transfecting 293T cells with the pREC-
nfl vectors harboring the mutations with the patient-derived sequencing. Evidence of wild type 
cell fusion suggest that Env is expressed from pREC and can bind to CD4+/CCR5+ on the U87 
cells.  Western blots show the presence of Env in cell-free supernatant.  Previous studies using a 
Vpr-bla construct expressed in trans and encapsidated into VLPs24, clearly show VLP entry into 
CD4+/CCD5+ cells and that the levels of VLP entry correlated with the levels of cell-to-cell fusion 
mediated by pREC-nfl (used to produce the same VLP).  
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Figure 2-4: Virus-like particle formulations are non-infectious due to engineered RNA 
packaging defects and deletion of the HIV-1 5’ LTR. 
 
70 
 
RNA packaging knockdown in individual VLP formulations (VLP1-4 + Het_B_ACT-VEC) were 
compared against near-full length viral particles (VP) formulations lacking mutations in the RNA 
packaging sequence by first isolating viral RNA and then by qRT-PCR using a gag primer set (A).  
The VLP encoding pREC_nfl DNA’s were evaluated for the presence/absence of HIV-1 gag, env 
and 5’ LTR by PCR and gel electrophoresis using gag, env and 5’LTR – gag primer sets. Samples 
derived from the same experiment and gels were processed in parallel (B). VP (-dS.1/mutIN) and 
VLP (+ dS.1/mutIN) formulations were compared to infectious B4 virus for infectivity using 
luciferase expressing TZM-bl cells (C). Infectivity results are represented by relative light units 
(RLUs). luciferase quantification in a Synergy H4 Hybrid microplate reader using 50 μl of luciferase 
assay reagent. 
  
 
71 
 
2.2.5 VLPs are non-infectious, devoid of 5’LTR and have reduced viral RNA packaging  
While inactivated (killed) whole virus particles have been used to prevent a wide range of viral 
diseases, the use of AT-2 inactivated, UV-irradiated whole HIV particles as a vaccine has been a 
concern due to safety but has recently undergone a phase I clinical trial evaluation showing no 
residual vaccine replication or any evidence of vaccine viral genetic material25.  Given the 
enhanced safety considerations in our preparation, it is important to note that previous 
generations of the VPs have been tested in mice, rabbit, and macaques with no adverse effects 
noted. Furthermore, the new generation of VLPs are currently being prepared for phase I 
clinical trials.  Both the VP formulations and the dS.1/mutIN VLPs were unable to infect and 
replicate in a permissive luciferase expressing TZM-bl cell line. This contrasts with B4, an 
infectious subtype B chimeric virus (Env from a primary isolate placed into an NL4-3 backbone), 
which was readily able to infect this highly susceptible cell line in a concentration dependent 
manner (Fig 2-3C).              
2.2.6 Both VP and Het_B_ACT-VEC can stimulate antigen-specific memory T cell responses. 
The five volunteer-derived dS.1/mutIN pREC-nfl plasmid DNAs were all combined to generate a 
highly heterogeneous and polyvalent Het_B_ACT-VEC VLP preparation. This was used to 
transfect 293T cells and produce Het_B_ACT-VEC VLP formulations. We PCR amplified and 
sequenced the VP, dS.1/mutIN (VLP) and Het_B_ACT-VEC pREC-nfl sequences using NGS.  
Phylogenetic trees reveal a topology similar to a tree containing the population of all other 
pREC-nfl as expected (Figure 2-3).   
To determine whether VP and Het_B_ACT-VEC were antigenic and capable of stimulating 
antigen-specific T cell recall responses, we assayed the formulations in a MDDC – CD4+ T cell co-
culture assay using cells derived from HIV infected volunteers (Figure 2-5A). PBMCs from seven 
volunteers were purified by negative selection to generate isolated, untouched CD4+ T cells 
with purity >95%. Patient derived MDDCs were grown by plastic adherence and in the presence 
of IL-4 and GM-CSF for 6 days. Resulting MDDCs were checked for phenotypic markers of 
differentiation such as HLA-DR, CD83 and CD209 (Figure 2-9S B). MDDC were pulsed overnight 
with VP 5 or Het_B_ACT-VEC before washing and co-culturing with autologous CD4+ T cells in a 
human IFN- ELISpot assay (Figure 2-5). As shown, the VP 5 (**p<0.005) and the Het_B_ACT-
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VEC (*p<0.05) were antigenic and generated significant numbers of SFU/106 CD4+ T cells when 
compared to the unstimulated MDDC-CD4+ T cell co-cultures (Figure 2-5B). No statistical 
difference in the generation of SFU was observed between VP 5 and the Het_B_ACT-VEC 
formulation (p>0.05). Thus, demonstrating that the Het_B_ACT-VEC vaccine construct is 
antigenic and can stimulate memory CD4 T cell recall responses in primary human cells. We 
further verified the ability of Het_B_ACT-VEC and VP’s to stimulate primary and secondary 
immune responses using our MDDC-CD4 T cell co-culture assay and PBMC from healthy donors 
using intracellular cytokine staining flow cytometry (Figure 2-9S A-B). In this instance, 
Het_B_ACT-VEC was able to induce TNF-α and IL-2 cytokine responses (average 2-fold increase 
over media control) with only a low-level increase in IFN-. The VPs tested, especially VP2,4 and 
5 were also capable of eliciting primary CD4 T cell responses with the magnitude greater than 
that seen with Het_B_ACT-VEC. Again, no statistical difference in the generation of cytokine 
responses was observed between the different VP’s and the Het_B_ACT-VEC formulation was 
detected (Figure 2-9S B). 
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Figure 2-5: Purified VP and Het_B_ACT-VEC formulations are capable of human CD4+ T cell 
activation in vitro. 
PBMC from fully consented HIV+ volunteers were used to generate monocyte derived dendritic 
cells (MDDC), which were pulsed overnight with Het_B_ACT-VEC VLP or VP 5 and co-incubated 
with autologous purified CD4+ T cells (A). Cells were cultured overnight in a human IFN- 
ELISpot assay and the IFN- spot forming units were enumerated per 106 CD4+ T cell using 
ImmunoSpot S5 UV Analyzer and ImmunoSpot 5.0.9 software (B). Results shown are mean 
SFU/106 CD4+ T cells (+/- SEM).  Graphics depicted in this figure were generated by the authors.  
 
74 
 
2.3 Discussion 
Over the last few centuries, empirically derived vaccines have slowly been replaced by 
rationally designed vaccines. During this time, killed/attenuated vaccines have demonstrated 
huge success in providing protection from a range of communicable diseases. However, safety 
concerns regarding insufficient attenuation and inactivation processes still remain. In the 
context of HIV-1 vaccines, attenuated versions of HIV raises serious ethical concerns due to the 
fear of reversion to virulence following vaccination, or the potential for recombination with 
resident HIV following therapeutic vaccination26,27. Methods to inactivate HIV-1, such as AT-2 
treatment and UV irradiation, may result in a safe vaccine25, but these conditions may also alter 
antigenicity and could affect the conformation of viral glycoproteins. As such, research into 
safer and stronger alternatives to the killed/attenuated HIV-1, has gained significant traction. 
This study describes the development of non-infectious VPs derived from infected patients, and 
their reformulation into VLPs that are then used to produce a heterogeneous VLP formulation 
called Het_B_ACT-VEC. The Het_B_ACT-VEC is currently being tested as a therapeutic vaccine. 
In the latter case, the Het_B_ACT-VEC is being used as a latency reversal agent as part of the 
“Shock and Kill Strategy”, the aim being to trigger proviral transcription and the elimination of 
infected cells15,28.  
 Our first prototype of this HIV-1 vector, termed VP, was derived from the pREC-nfl 
construct17.  HIV-1 mRNA is transcribed off pREC-nfl (near full length) from a minimal CMV 
promoter, deleting the 5’LTR promoter/enhancer region such that transcription is initiated at 
the first nucleotide of the primer binding sequence. Aside from deleting the Tat-transactivating 
response element (TAR) found within the 5’LTR, all other RNA regulatory sequences remain 
intact such that all HIV-1 mRNA species (un-spliced, singly spliced, and multiply spliced) are 
expressed, the full HIV-1 proteome translated, and virus particles assembled and released from 
these cells. We have previously shown that the nfl virus particles released from this system 
cannot initiate reverse transcription (i.e. no minus strong stop DNA synthesis), are non-
infectious, and cannot be complemented by superinfection with a wild type HIV-117. 
Despite rendering the lentiviral VPs non-infectious, the presence of nfl viral genomic 
RNA within vaccine formulations still poses a concern in vaccine development. Therefore, we 
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introduced extensive mutations into the stem loop 1 (dS.1) of the RNA packaging element 
which strongly reduced genomic RNA encapsidation in VLPs, paralleling observations made by 
Clever and Parslow with a lab-adapted HIV-1 clone23. In our studies, the dS.1 mutations coupled 
with the deletion of the 5’LTR did not impact p24 content or RT activity in the VLPs but 
depleted gRNA encapsidation and resulted in non-infectious particles. Finally, during the 
amplification of the patient-derived HIV-1 genomes, we introduced a 262RRK>AAH mutation into 
the active site of HIV-1 integrase. In contrast to the nfl VPs, the dS.1/mutIN VLPs and 
Het_B_ACT-VEC (with 5’LTR/mutIN/dS.1) harbored a defective IN incapable of the 
dinucleotide cleavage, which ensured the nullification of viral infectivity.  
In the absence of Gag-gRNA complexes, Gag can still oligomerize to produce virus-like 
particles of varying size and structure whereas the inclusion of the full proteome (including the 
Env glycoprotein) appears to generate more uniform virus particles, which was evident from 
our electron microscopy images on all formulations. While HIV viral particle formation is 
dependent only on Gag production, Env is required for virus entry into host cells and could elicit 
protective antibody responses. We propose that these fully processed wild type virus particles 
may be highly immunogenic and could induce neutralising responses, considering the viral 
proteins should be in a native “wild type” structure, and can even undergo conformational 
changes related to viral entry, core deposition and dissolution in the cell cytoplasm. However, it 
should be pointed out that not all VPs or VLPs will carry intact, native-like trimers, nor will all 
the expressed Env become appropriately cleaved, and a fraction would certainly exist as 
monomers, dimers and gp41 stumps29. The development of a neutralizing antibody response 
would of course be highly beneficial for an anti-HIV prophylactic vaccine, enabling the 
neutralization of transmitted founder viruses at the earliest time points following virus 
exposure; however, anti-HIV antibody and neutralizing antibody responses would also be 
beneficial for therapeutic vaccines. In the latter case, it is envisaged that either an elicited 
neutralizing or antibody-dependent cell cytotoxicity response could aid therapeutic vaccination 
by blocking de novo infections occurring in response to latency reversal (Shock) and also in the 
eradication (Kill) of virally infected cells.15,28  
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While B-cell immunogens are important in providing protection through the generation 
of neutralizing and non-neutralizing antibody production, T-cell immune responses play an 
important role in controlling viral loads and priming B-cell responses. Therefore, it stands to 
reason that an efficacious therapeutic vaccine should elicit both T- and B-cell responses to 
either prevent infection at the level of the mucosa or eliminate infection through sterilizing 
immunity. Hence, it is important that our formulations can elicit both CD4 T helper cell and GzB 
cytotoxic functions in PBMC. Until such time that a broadly neutralizing antibody response can 
be successfully elicited through vaccination, anti-HIV cytotoxic responses could be highly 
beneficial in therapeutic vaccine settings, i.e in controlling/eradicating productively infected 
cells within HIV-infected individuals15,30,31. Attenuated viral vectors (e.g., ALVAC or Ad5) 
expressing more conserved HIV-1 proteins (e.g., Gag) or protein motifs (e.g., repeated strings of 
immunodominant/conserved HIV peptides) have been tested as CTL-based vaccines with 
moderate success in animal models but mostly failed in human clinical trials32. Although many 
factors led to these vaccine failures, CTL escape mutations rapidly appear in the infecting HIV 
during both preventative and therapeutic vaccine trials. These studies, as well as the failure of 
most humoral based vaccines, have prompted us to construct and test a heterogenous HIV 
vaccine, which consist of “dead” HIV-1 particles lacking undesirably foreign vector components. 
Our yeast recombination system produces vectors that harbor the same HIV-1 quasi-
species diversity found within patient samples. By combining the subtype B HIV quasi-species 
from 5 patients, we have generated a heterogenous dS.1/mutIN VLP (termed Het_B_ACT-VEC). 
To further develop our therapeutic and cure based vaccine strategies, we screen patients for 
subtype infection and then employ the respective ACT-VEC, currently being tested in ex vivo 
experiments with the aim of selecting the most effective vaccine modalities for use in a future 
clinical trial.  
  We are currently testing different heterogenous forms of this dS.1/mutIN VLP as an 
anti-HIV therapeutic/cure strategies, designed to elicit T cell responses for activating the latent 
HIV pool and for reducing viral loads. The DNA vector pREC-nfl is also being tested as a DNA 
vaccine administered by intramuscular electroporation in animal models, and may be very 
effective in combination with the VLP and Het_B_ACT-VEC for prime-boost therapeutic 
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vaccinations. As described in a recent study, Het_B_ACT-VEC may also lead to latency reversal 
and elimination of much of the HIV-1 reservoir that remains in these HIV-infected patients 
receiving cART. In conclusion, our dS.1/mutIN VLP formulations appear safe in vitro, and we 
anticipate that VLPs and Het_B_ACT-VEC formulations will be safe for use in humans; however, 
this will need to be confirmed in future planned non-human primate (NHP) studies and human 
clinical trials. The VLPs and Het_B_ACT-VEC also present the entire HIV proteome in the correct 
conformation, reflect the HIV-1 genetic diversity within infected individuals and consequently, 
have wide range of uses.                    
2.4 Materials and methods 
2.4.1 Ethics statement: 
For antigenicity studies, either HIV-positive volunteers were recruited from the HIV adult 
clinical St Mary’s Hospital (Imperial College NHS trust), through a protocol approved by the NHS 
Health Research Authority (protocol number: 14SM1988) or healthy volunteer PBMC were 
purchased from Canadian Blood Services under institutional REB approval (no: 106951). Written 
informed consent was provided by all HIV+ study participants prior to the study start. The 
peripheral blood mononuclear cells (PBMC) from HIV+ volunteers used in these studies had 
suppression of viremia to <50 copies HIV-1 RNA/ml for > 6 months on ART. For viral particle 
(VP), virus like particle (VLP) and Het_B_ACT-VEC production, HIV+ sera from five consenting 
HIV+ adult volunteers were obtained under internal review board approval (AIDS125) at Case 
Western Reserve University, (CWRU, USA). Methods were performed in accordance with 
relevant regulations and guidelines. 
2.4.2 Viral Particle (VP) and Virus-like particle (VLP) vaccine production: 
All formulations were cloned using a similar protocol to that previously described and 
schematically depicted in Figure S116–18. Briefly, sera-derived viral RNA was isolated using a viral 
RNA isolation kit (Qiagen, USA) and reverse transcribed to cDNA (Agilent Technologies, USA) 
using two primers to generate a 5’ (5020R) and 3’ (1.R3.B3.R) fragment encompassing the 
entire HIV-1 genome. The two overlapping cDNA fragments were then PCR amplified in a 
nested PCR protocol using 5’ and 3’ primer pairs described in Table S1. The two fragments were 
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then transfected into Saccharomyces cerevisiae in a 1:1 ratio with 2 g SacII linearized plasmid, 
pRECgag-U3/URA3. Yeast colonies were selected on complete medium lacking leucine (C−Leu) 
plates supplemented with fluoroorotic acid (FOA). The resulting plasmid vectors were isolated 
by an in-house yeast miniprep and used to transform bacteria to amplify the DNA plasmid for 
purification as described previously. It is important to note that the PCR products harbored the 
amplified patient quasispecies, and as such, >100 yeast colonies were removed from Leu−/FOA 
plates for bulk plasmid purification and eventual reconstitution of sample quasi-species. The 
resulting plasmid constructs were isolated and then then used to transfect 293T cells with 
Fugene 6 transfection reagent (Promega, USA) to produce viral VP and VLPs. This procedure of 
highly efficient yeast-based recombination/cloning followed by 293T transfections is believed 
to preserve the HIV-1 quasi-species population better than a similar approach using bacterial 
restriction enzyme cloning. VP and VLPs were then purified by centrifugation through 100 KDa 
MWCO centrifuge tubes (Amicon, USA) and re-suspended in sterile PBS. 
2.4.3 Vaccine quantitation and protein production assessment 
 VP and VLP production from 293T cells was monitored for transfection efficiency by p24 ELISA 
assay, provided under an MTA by the AIDS Vaccine Program, National Cancer Institute (NCI) at 
Frederick, MD, USA.  A radioactive reverse transcriptase (RT) assay was also used to measure VP 
and VLP levels in cell-free supernatants as described previously18. Viral proteins in formulations 
were also analyzed by Western Blot. using NuPAGE™ Novex™ 3-8% Tris-Acetate Protein Gels 
(Thermo-Fischer Scientific) and a 1:100 dilution of heat-inactivated serum derived from SHIV 
infected macaques, before addition of a 1:2000 dilution of goat anti-monkey IgG: HRP (Bio-
Rad). Samples were then developed with DAB SK-4100 (Vector Laboratories).  
2.4.4 Size estimation of vaccine particles 
VP and VLP size and particle distribution were measured using dynamic light scattering with a 
Malvern Zeta-Sizer Nano (Malvern Instruments Ltd) at 25 °C. Briefly, purified VP and VLPs were 
diluted into 1ml PBS and placed into 4.5 ml polystyrene analysis cuvettes (Fisher Scientific, Ca). 
The intensity of laser light scattered by the sample preparations was measured at 173° to the 
incident beam. The data were analyzed using proprietary Malvern software, DTS (Nano Version 
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5.0), supplied with the machine. The size distribution and the polydispersity were measured 
using non-invasive back scatter (NIBS). 
2.4.5 Next generation sequencing analysis of vaccine formulations 
 
The C2-V3-C3 region of envelope was amplified by an external-nested PCR amplification using 
the primers forward EnvB and reverse ED14 (external) and forward E80 and reverse E125 
(nested) using PCR cycle conditions as described previously33. To prepare the amplicon library 
for 454 sequencing, fusion primers including the Roche 454 titanium key sequence, a multiplex 
identifier (MID) sequence for forward and reverse primers, followed by the template specific 
forward (E110) and reverse (E125) sequences were generated. The nested products were re-
amplified with barcoded MIDs. The PCR products were run on a 1% agarose gel to verify the 
406 bp size then purified with the Agencourt AMPure XP bead system with a bead : DNA ratio 
of 0.7:1 according to the Roche manual. Following purification PCR amplified sample libraries 
were quantified using the Quant-iT PicoGreen ds DNA assay kit (Invitrogen), diluted and pooled 
together at 106 molecules/µl for pyrosequencing as per Roche 454 instructions.   
Following emulsion PCR (emPCR) at a ratio of 0.5 molecules of sample library per bead, 
5x105 enriched beads were loaded onto the titanium picotiter plate which was run on the 
Roche 454 GS Junior instrument. Raw sequence data were extracted by the MID tag using a 
custom analysis pipeline. The 454 amplicon adapters were trimmed and sequences of less than 
200bp were discarded. Sequences were edited using BioEdit v7.2.5 and aligned using maximum 
likelihood methods (MUSCLE)34,35. Neighbor joining and maximum likelihood trees were 
constructed with SEAVIEW 4 and visualized with FigTree 1.4.2. Kimura genetic distance analysis 
within each sample were calculated using MEGA 6 and is expressed as substitutions per 
nucleotide (s/nt)36,37.  Any genetic variants with hypermutations at homopolymeric tracts 
and/or appearing less than 3 times were removed from the analyses. 
2.4.6 Isolation of resting CD4+ T lymphocytes and Monocyte Derived Dendritic Cells. 
 
CD4+ T lymphocytes were enriched from peripheral blood mononuclear cells (PBMC) by 
negative depletion (Miltenyi Biotec) using magnetic microbeads. To obtain immature DCs, 
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PBMC were plastic adhered at 37 ˚C for 2 h. Adhering monocytes were washed to remove non-
adherent cells then differentiated into monocyte derived dendritic cells (MDDC) by culturing in 
complete RPMI (10% FCS + 2 mM L-Glutamine) supplemented with GM-CSF and IL-4 (1,000 and 
500 U/ml respectively) for 6 days.  
2.4.7 TZM-bl infectivity assay 
 
The infectivity of viral particle and VLP preparations were estimated in TZM-bl cells by 
luciferase quantitation of cell lysates (Promega, Madison, WI). Briefly, TZM-bl cells were seeded 
at 1 × 104/well prior to addition of 50 ng/ml (based on p24) viral particles and VLP formulations. 
After 48h incubation, cells were washed with PBS and lysed with 100 μl of lysis reagent. A 50 l 
volume was used for luciferase quantification in a Synergy H4 Hybrid microplate reader (BioTek 
Instruments, Inc., Burlington, VT) using 50 μl of luciferase reagent. The extent of luciferase 
expression was recorded in relative light units.  
2.4.8 Transmission Electron Microscopy  
VP and VLP transfected 293T cells were collected in 15ml tubes before pelleting at 1250 rpm for 
10 min. Cells were washed with sodium cacodylate (pH 6.5) before re-suspending in 500ul of 
2.5% glutaraldehyde in sodium cacodylate. Supernatants were removed, and pelleted cells re-
suspended in 1% osmium tetroxide in sodium cacodylate for 1 h with shaking. Samples were 
then centrifuged and washed with deionized water. Dehydration was performed by re-
suspending samples in 1 ml of increasing concentrations of acetone (30%, 50%, 70%, 90%, 95%, 
100%) for 10 min each. Serial resuspensions with acetone : TEM Resin-Araldite EMbed 812 (2:1, 
1:1, 1:2, whole TEM resin) followed, until all acetone was replaced by resin. Samples were then 
baked at 60 oC for 48 h and resin embedded samples cut into 70 nm wide sections using an 
UltraCut UltraMicrotome (Sorvall) before copper mesh mounting and staining with Uranyl 
Acetate. Samples were dried and stained with Lead Citrate before washing thoroughly with 
sterile water. Samples were air dried then imaged on a Philips CM10 TEM.  
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2.4.9 Immunogenicity assays  
Human IFN-γ enzyme-linked immunosorbent spot (ELISpot) assays (Mabtech, USA) and 
intracellular cytokine staining flow cytometry were carried out on MDDC-CD4+ T cell co-cultures. 
ELISpot were carried out as per the manufacturers instructions. Briefly anti-IFN- pre-coated 
plates were washed with sterile PBS and then blocked for 30 min using complete RPMI. Plates 
were again washed before addition of 1 × 106 cells/ml CD4+ T cell. The MDDC stimulated CD4+ T 
cells were then incubated for 16 h to assess the number of HIV-specific CD4+ T cells. Unstimulated 
and 5 μg/ml phytohemagglutinin (PHA)/ionomycin (Iono) (Sigma, USA)-stimulated cells served as 
controls. To detect spots, biotinylated anti-IFN-γ antibody was added at 1 μg/ml for 2 h before 
washing and incubating with streptavidin-HRP for 1 h. Plates were washed and 100 μl/well of 
TMB substrate was added. Spot forming units (SFU) were enumerated per 106 CD4+ T cell using 
ImmunoSpot S5 UV Analyzer (Cellular Technology Ltd., Cleveland, OH) and ImmunoSpot 5.0.9 
software. Results are mean values (+/- SEM). For flow cytometric analysis of T cell activation, 
CD4+ T cells, were incubated for 2 h with ACT-VEC or VP pulsed MDDCs before 4h incubation with, 
monensin. Samples were washed using FACs buffer (2.5% FCS in PBS) and surface stained with 
anti-CD3, anti-CD4 and anti-CD69 antibody. Samples were washed again before permeabilising 
using a BD FACS Fix Perm kit (Becton Dickinson, USA). The samples were then incubated with 
anti-IFN-, anti-TNF-α and anti-IL-2 antibody in FACS perm wash solution before washing in FACs 
buffer and then fixing in 1.5% methanol-free paraformaldehyde (Polysciences, USA) in PBS. 
Samples were analyzed on a FACS LSR II instrument with FACS Diva software. Data analysis was 
performed with FlowJo (Treestar Inc., OR, USA). 
2.5 Acknowledgments 
This work was funded by awards from the NIH (AI49170) and amfAR ARCHE (108838-55-RGRL 
and 108686-54-RGRL) to EJA and from CIHR (PJT 149075) to JFSM. The authors would like to 
thank CHERUB (Collaborative HIV Eradication of viral Reservoirs: UK BRC) for their advice and 
both the SPARTAC (Short Pulse Anti-Retroviral Therapy at HIV Seroconversion) study participants 
and Canadian Blood Services volunteers for their provision of blood samples. 
 
82 
 
2.6 Competing Interests 
The authors declare no conflicts of interest. 
2.7 Author Contributions 
JFSM, JP, RS, DC, SF, and EJA designed experiments. JFSM, YG, KK, TB, and JP built the VP, VLP 
and ACT-VEC constructs. JP, KK, JFSM performed all qRT-PCR experiments and analysis. KK, KB 
and JP performed deep gene sequencing and both JFSM and KB performed all the radioactive RT 
assays. KK and EJA performed NGS analysis. JK and JP did Veritrop assays. JP did the zeta sizing 
and electron microscopy work. SF, RS, PM and DK, recruited, consented and processed blood 
samples. JFSM, KK and JP did the immunogenicity studies and JP, KK, JFSM and EJA wrote the 
manuscript. The manuscript was reviewed by the authors. 
 
83 
 
2.8 Supplementary Figures (2-6S to 2-9S) 
Figure 2-6S: Schematic of the VP and VLP cloning protocol 
Schematic representation of the VP and VLP cloning strategy. Serum from consented HIV+ 
volunteers was used to extract viral RNA and generate two overlapping cDNA fragments. The 
cDNA is then used in a nested PCR reaction to generate two overlapping fragment of viral DNA 
for recombination in yeast using our in-house developed pREC_gag-U3 recombination vector. 
In the nested PCR, mutagenic primers dS.1 or SL3 insert extensive nucleotide substitutions in 
stem loop 1 of the RNA packaging sequence or delete stem loop 3. Successful recombination in 
yeast and subsequent bacterial amplification results in pREC_nfl or SL3/mutIN pREC_nfl or 
dS.1/mutIN pREC_nfl DNA for use in VP and VLP production. Areas where modifications to the 
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viral genome were introduced are indicated by red shading. Graphics depicted in this figure were 
generated by the authors. 
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pREC_nfl plasmid constructs using NL4-3 and HIV 1086 as the vector backbone were constructed 
with mutations in stem loop 1 (SL1, VLP) or deletion of stem loop 3 (SL3). The ability of the SL1 
or SL3 modifications to impact RNA packaging in NL4-3 and HIV 1086 were assessed using 293T 
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Figure 2-7S: Comparison of the impact on RNA packaging by differently engineered RNA 
packaging mutations. 
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cell transient transfections and qRT-PCR with a gag primer set (A and B). The mean RNA copes/ml 
(+/-SEM) are shown. Viral particles (VP) lacking modifications to the RNA packaging sequence and 
media were used as positive and negative control respectively. Reverse transcriptase activity in 
the NL4-3 and HIV 1086 VP and VLP formulations were assessed using radioactive reverse 
transcriptase assay and densitometry readings on radiographical film (C and D). The ratio of RNA 
to reverse transcriptase activity was calculated for the SL1 VLP and SL3 modified NL4-3 and HIV 
1086 formulations (E and F). 
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Figure 2-8S: The deletion of stem loop 3 (dSL3) causes RNA packaging defects in viral 
particles. 
The SL3 mutagenic primer was used in the nested PCR reaction for the five cDNA’s derived from 
HIV+ volunteer samples. Of the five SL3 VPs, only SL3 VP 3, 4 and 5 resulted in successful 
recombinants in yeast. The DNAs were then used to transfect bacteria and subsequently 
transfect 293T cells. The purified SL3 VP 3-5 were assayed for p24 content (A) in culture 
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supernatants by ELISA and for reverse transcriptase activity using a radioactive RT assay (B). The 
percentage RNA in SL3 VP 3-5 were determined, by first isolating viral RNA and generating 
cDNA, before using qRT-PCR and a gag primer set to quantify viral genomic levels (C). Results for 
SL3 VP 3-5 RNA levels are shown as percentage RNAs relative to the volunteer matched and 
unmodified VPs. 
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Figure 2-9S: Characterization of various PBMC cellular subsets. 
Cryopreserved PBMC from fully consented HIV naïve volunteers under continuous anti-retroviral 
treatment where used in these studies. PBMC were defrosted and CD4+ T cells isolated by 
magnetic isolation and negative selection. The purity of the isolated CD4+ T cells was determined 
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by live/dead cell gating prior to CD3+ and CD4+ gating. A representative flow cytometry plot is 
shown (A). PBMC were defrosted to generate MDDC. Initially, PBMC were allowed to plastic 
adhere in tissue culture flasks monocytes before incubation for 6 days in the presence of IL-4 and 
GM-CSF. Immature DC were then phenotypically characterized by flow cytometry using HLA-DR, 
CD83 and CD209 antibodies (B). To evaluate Het_B_ACT-VEC and VP immunogenicity, the 
formulations were used to pulse the prepared MDDC overnight, followed by co-incubating the 
MDDC with autologous CD4+ T cells. The flow cytometry gating strategy used to characterize 
define the CD4+ T cells used in the immunogenicity studies is shown (C).     
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3.1 Research in Context 
Evidence before this study: The HIV-1 latent reservoir becomes established early after primary 
infection and remains despite continuous cART administration. Numerous approaches have 
sought to induce transcriptional activity of latent provirus, including: HDAC inhibitors, TLR 
agonists, PCK agonists, BET bromodomain inhibitors, etc. These approaches have had variable 
degrees of success in vitro but are largely ineffective at either the clinical or pre-clinical stages of 
development. Historic and emerging studies suggest that i) HIV-1 latency reversal can be 
achieved via TCR engagement, ii) latency reversal can be achieved using HIV-derived peptides, 
and iii) latent provirus has a high concentration within the HIV-specific T cell population. The 
effect of a polyvalent stimulator capable of specifically targeting the predominant reservoir is 
largely unknown.  
Added value of this study: Unlike other latency reversing agents to-date, ACT-VEC is a polyvalent 
formulation that can specifically target HIV-specific CD4+ T cells for transcriptional reactivation. 
Our study identifies a novel immunotherapeutic strategy that is at least an order of magnitude 
more potent than other drugs currently under clinical development. Additionally, we show that 
the inducible HIV-1 proviral reservoir is enriched within HIV-specific CD4+ T cells. Our study 
further elucidates several mechanistic steps that contribute to an optimized latency reversing 
response via antigen presentation. 
Implications of all the available evidence: The ability of HIV-1 to establish latent provirus within 
the CD4+ T cell reservoir is a major reason for virus recrudescence upon cessation of cART. 
Identifying novel mechanisms to deplete this reservoir are of great research priority, as current 
methods fail to effectively target latently infected cells for reactivation and eradication. 
Importantly, our work shows that the proviral reservoir established during acute infection is non-
random and enriched for TCRs specific to HIV antigens. Furthermore, we are the first to describe 
a method to induce HIV latency reversal by targeting HIV-1 specific T cells using an 
immunotherapeutic approach.   
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3.2 Introduction 
 
Despite the success of combination antiretroviral therapy (cART) at reducing HIV viral loads 
to undetectable levels, cART remains non-curative1. During HIV infection, rare integration events 
of replication-competent virus occurs, and for reasons not fully understood, remain as 
transcriptionally silent provirus within regions of host DNA. The resulting viral reservoir is 
transiently non-replicating, temporarily hidden from immune surveillance and not susceptible to 
the protective actions of cART2–5. Following cART initiation, latent HIV undergoes a multiphasic 
decay, with the majority of provirus being present in long lived memory CD4 T cells6,7. Upon cART 
cessation, rapid viral recrudessence and resumption of disease occurs.   
Many curative approaches during cART have been centred on “Shock and Kill”, where latency 
reversal agents (LRAs) reactivate transcription and translation of the otherwise latent provirus8. 
In theory an effective LRA therapy should induce de novo HIV-1 protein expression within 
previously latently infected cells, enabling their immune recognition and destruction, with any 
released virus neutralized by ongoing cART9. Histone Deacetylase Inhibitors (HDACi) are potential 
LRAs, based on their histone hyperacetylation, chromatin remodeling and pleotropic induction 
of gene expression. Potency of the HDACi shock can be significantly enhanced when combined 
with protein Kinase C (PKC) agonists10. However, high toxicity/low therapeutic index of most PKC 
agonists and HDACi, combined with their negative immuno-modulatory effects and lack of 
specificity has raised questions on their utility11–13. The modest effects of these LRAs to impact 
the reservoir size in clinical studies has renewed the urgent need to develop novel, safe, 
efficacious and targeted LRA approaches. 
CD4 T cell populations are the major proviral reservoir, but only a fraction of these cells harbors 
inducible, replication competent virus (0.0001%). In fact, more recent studies have suggested 
that a mere 2.4% of proviruses are intact with the reminder harboring fatal mutations and 
deletions14.  Prior studies have suggested that latent HIV may be concentrated in CD4 T cells 
bearing T cell receptors (TCRs) specific for HIV antigens15,16. During acute/early infection, HIV 
drives clonal expansion of HIV-specific T cells, thereby providing an abundance of susceptible 
target cells to fuel exponential increase in HIV load17.  By extension, in patients starting a cART 
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regimen at acute/early infection, the latent HIV may be housed in the HIV-specific memory CD4 
T cells. Interestingly, despite evidence suggesting the latent reservoir is established early after 
infection, data now supports that within infected individuals, the virus that was replicating 
immeditaley prior to suppressive cART may predominate within the HIV-1 DNA reservoir18,19. 
We therefore asked the question, could an immunotherapy based on a heterogeneous, 
polyvalent, HIV-1 vaccine consisting of HIV virus-like-particles (VLPs) (termed activating vector, 
ACT-VEC), serve as a highly specific and effective LRA “shock”? In this scenario, ACT-VEC would 
be presented to HIV-specific memory CD4 T cells, with signaling through the TCR activating 
transcription of the otherwise latent HIV-1 provirus, ultimately leading to expression of viral 
proteins and possible release of HIV. To address this question, we recruited HIV+ volunteers 
that were diagnosed and cART treated during acute/early infection (AC-cART). Purified CD4 T 
cells from these volunteers (AC-cART CD4 T cells) were either presented with a heterologous 
ACT-VEC VLP formulation or other non-HIV recall antigens by autologous monocyte-derived 
dendritic cells (MDDCs). We measured T cell stimulation and any HIV RNA production due to 
latency reversal. PMA/Iono, Bryostatin, various HDACi and non-HIV viral particles were used as 
LRA controls. These results show that ACT-VEC is a promising immunotherapeutic LRA for the 
induction of replication competent HIV-1 from latently infected CD4 T cells and that the 
inducible reservoir may indeed be enriched within HIV-specific CD4 T cells. 
3.3 Results 
3.3.1 HIV+ volunteer characteristics  
The primary objective was to determine if heterologous ACT-VEC VLPs are an effective LRA for 
CD4 T cells derived from HIV+ volunteers (N=9, mean age of 38), diagnosed and receiving cART at 
acute/early stage of infection (AC-cART patients) (Table 3-1). The average time between the 
estimated date of HIV seroconversion (EDS) and diagnosis was 69 days (range = 6.5 – 207.5 days) 
while the time between HIV diagnosis and first line cART initiation was 32 days (range = 18-54 
days). During cART treatment, volunteers rapidly suppressed viral loads to <50 copies/mL and 
maintained suppression throughout the study (Figure 3-1). Average duration of cART treatment 
(with undetectable viremia) prior to PBMC sampling for this study was 884 days (range = 618-
1206 days). At the time of PBMC sample collection, CD4 counts ranged from 456 – 1179 cells/μl 
 
98 
 
(mean = 772 cells/μl). All volunteers were Hepatitis B and C negative at enrollment (Table 3-1). 
The mean frequency of HIV DNA+ cells, representing the full spectrum of the proviral reservoir 
(i.e. replication competent, replication defective and graveyard viruses) was determined to be 
1/4133 CD4 T cells by qRT-PCR.        
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Figure 3-1: Figure 1. All nine HIV volunteers enrolled in this study durably suppressed viremia 
upon cART initiation. 
A total of nine HIV infected individuals that were diagnosed and treated during acute/early stage 
of HIV infection were enrolled into this study. Upon diagnosis and initiation of cART, the treated 
HIV+ volunteers durably suppressed viral replication to <50 HIV copies/mL (    ). All volunteers 
were fully consented to provide a large blood draw (300-500mL) for PBMC isolation and use in 
the latency reversal studies. The estimated date/time of seroconversion (EDS) was calculated as 
the midpoint between the most recent negative and the first positive test for the volunteers and 
is shown by the green shaded window (    ). The time window in which HIV diagnosis and cART 
treatment occurred is shown by the blue shaded area (    ).  
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3.3.2 ACT-VEC can cause HIV-1 latency reversal in CD4 T cells.   
During acute HIV infection, the population of CD4 T cells with TCRs specific to viral antigens 
expands significantly. These activated CD4 T cells either: 1) provide help for anti-viral immune 
responses and eventually undergo caspase 3-mediated apoptosis, 2) revert to a resting memory 
phenotype and avoid apoptosis, 3) become productively HIV-infected and die via viral cytopathic 
effects (vCPE) or cytotoxic responses or 4) become latently infected during the transition into a 
memory phenotype20–25. Based on these cellular fates and because HIV preferentially infects 
activated CD4 T cells, we propose that initiation of cART during acute/early infection may trap 
latent HIV within the HIV-specific CD4 T cell population. Therefore, cellular reactivation via the 
TCR and associated co-stimulatory molecules should lead to the initiation of multiple intracellular 
signaling cascades and increased expression of a plethora of cellular transcription factors, which 
may in turn, lead to mRNA transcription from the HIV proviral DNA26.  
The heterologous ACT-VEC LRAs used in this study are VLPs derived from the quasi-species 
of patients infected with subtype B HIV-127. ACT-VEC is morphologically indistinguishable from 
wild type virus, containing all viral proteins, but is devoid of HIV RNA27. Monocyte derived 
dendritic cells (MDDC), derived from the PBMCs of AC-cART patients, were antigen-loaded with 
ACT-VEC (ACT-VEC+MDDC) overnight before washing the MDDC and then co-culturing with the 
autologous purified AC-cART CD4 T cells for three days (Figure 3-8S). When ACT-VEC+MDDC were 
co-cultured with AC-cART CD4 T cells, HIV genomic RNA was readily detectable in culture 
supernatants from each of the nine HIV+ donor samples (Figure 3-2, A and B), representing an 
average 7.1-fold increase in HIV RNA compared to that from T cells incubated with unpulsed 
MDDC (Figure 3-2G). To ensure de novo HIV production was from only latently infected cells and 
not due to HIV propagation, HIV entry inhibitor, Enfuvirtide, was added (20 M) to all samples to 
block new HIV infections.  A 6.8 and 4.98-fold increase in HIV RNA was released from AC-cART 
CD4 T cells into supernatant when they were treated with ACT-VEC+MDDC than when treated 
with polyclonal T cell activator PMA/Iono, or when MDDC were antigen loaded with a cocktail of 
CMV peptide, Tetanus Toxoid, and Flu M1 (CTF) (Figure 3-2G). To exclude the possibility that ACT-
VEC-associated increases in HIV RNA resulted from heightened levels of MDDC maturation, we 
measured the surface maturation markers CD40, CD80, and CD83 before and after stimulation  
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Figure 3-2: ACT-VEC induces potent latency reversal within patient-derived CD4 T cells. 
cART treated HIV+ volunteers (n=9) with durable viral suppression (<50 HIV copies/mL were 
enrolled in this study. ACT-VEC (5ug / mL) or a cocktail of Flu M1, Tetanus toxoid, CMV peptide 
pool (CTF) were used as HIV-specific or non-specific stimuli to pulse volunteer MDDCs. The pulsed 
MDDC were then co-incubated with autologous CD4 T cells. PMA/Iono and media served as assay 
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positive and negative controls, respectively. (a) After 3 days of co-culture, mean viral copy 
number was determined via qRT-PCR from culture supernatants. (b) Copy numbers derived from 
culture supernatants were represented as fold increase over the media control. (c) Cells 
stimulated with ACT-VEC, CTF and PMA/Iono were cultured overnight in an IFN- ELISpot to 
determine the CD4 T cell antigenicity. (d) Volunteer-specific IFN- spot forming units (SFUs) were 
counted /106 CD4 T cells, and fold increase calculated over the media control (±SEM). Statistical 
significance was calculated using a Wilcoxon matched pairs signed rank test. (e) The relationship 
between CD4 T cell activation and the quantity of induced HIV-1 virus is shown.  Grouped samples 
were used to determine the mean effect (±SEM) of the stimulations on antigenicity and induced 
copy number (f and g) with statistical significance ascertained by Mann-Whitney unpaired t-test.  
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via flow cytometry. Maturation induction in response to ACT-VEC particles was compared to both 
i) pre-processed peptide, in the form of Env/Gag/Pol pooled peptide and ii) a mixed 
peptide/protein formulation of CTF. Compared to CTF, ACT-VEC expressed similar levels of MDDC 
maturation across all three markers, indicating that any increased detection of HIV RNA in these 
studies were not, due to drastically differing levels of maturation of the MDDC (Figure 3-9S, A 
and B). To determine the potential of contaminating CD4+ T cells within the plastic-adhered 
MDDC population, flow cytometry was routinely performed using HLA-DR, CD80, CD83, CD40 and 
CD11c. In all instances, the purity of the MDDC population 6-days after plastic adherence was 
between 95-99%. As additional non-HIV based latency reversal controls, and to help demonstrate 
the antigen-specificity of the observed latency reversal associated with ACT-VEC VLP, SIVmac251 
and FIV viral particles were made and both failed to induce detectable amounts of HIV-1 RNA 
(>30 copies/reaction) within culture supernatants (Figure 3-11S G). This further suggests that 
only HIV and no other related lentiviruses presented by MDDC, can trigger HIV latency reversal 
in AC-cART CD4 T cells.  
It is important to note HIV-1 RNA was measured in supernatant with a qRT-PCR assay 
targeting the gRNA 5’LTR region (R-U5) found only within inducible wild type HIV-1 but absent in 
genomeless ACT-VEC VLPs27. In support of this detection specificity, no induced HIV-1 or 
contaminating ACT-VEC was detected in any HIV- donor control experiments using this qRT-PCR 
assay (Figure 3-10S, A and E). As a further verification that the HIV-1 RNA detected by qRT-PCR 
was not derived from ACT-VEC, we RT-PCR amplified and then sequenced the HIV-1 5’LTR region 
derived from supernatant following latency reversal with the CD4 T cells.  Illumina MiSeq 
confirmed the presence of HIV-1 5’LTR sequences and also the absence of our previously 
published mutations introduced into the DNA vector used to generate ACT-VEC VLP27. In the AC-
cART volunteers, only a single HIV-1 sequence was identified/volunteer by sequencing which is 
consistent with the high levels of conservation of the 5’LTR and low levels of diversity of HIV 
provirus within acute HIV infections28. 
We suspect that the ability of ACT-VEC to induce latency reversal relates to the specific 
activation of memory CD4 T cells with TCRs specific to HIV as an antigen. However, HIV-specific 
memory CD4 T cells may only comprise a small proportion of all memory T cells within infected 
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individuals despite large numbers of these cells being generated during early infection15. Our 
adult participants likely encountered flu, CMV and/or tetanus (as well as other antigens) multiple 
times during their life through vaccination, infection or environmental exposure. Based on these 
assumptions and the fact that standard vaccines such as Influenza, Hepatitis B, Pneumococcus 
and oral cholera vaccine have been described to cause transient elevations in HIV expression 
within individuals on suppressive antiretroviral treatment, we measured the number of AC-cART 
CD4 T cells that were responsive to ACT-VEC as well as to common recall antigens, such as CTF29–
34. Additionally, cells were stimulated with the T cell mitogen, PMA/Iono, to determine the effect 
of a potent, non-specific activation on latency reversal. We utilized PMA/Iono as our assay 
positive control over other strong T cell mitogens such as αCD3/CD28, and PHA-L, based on our 
preliminary findings using flow cytometry (Figure 3-9S, C to E) and IFN-γ ELISpot based protocols 
(Figure 3-9S, F and G). In these initial experiments, the culminative result demonstrated that 
PMA/Iono was the most potent control stimulation, followed by aCD3/CD28 and PHA-L. This was 
corroborated by findings from other research groups showing PMA/Iono has accelerated latency 
reversing kinetics when compared to the other stimulations, while reaching a similar level of peak 
activation35,36. As shown, ACT-VEC+MDDC was clearly antigenic when presented to the CD4 T 
cells with generation of approximately 4-fold more CD4 T cell spot forming units (SFU)/106 cells 
relative to the untreated controls (average of 891 versus 222 SFU/106, **p< 
 
 
VP0.0296) (Figure 3-2, C and D). Stimulation of T cells with CTF+MDDC (**p=0.0012) and 
PMA/Iono (****p=0.0001) resulted in 7.31 and 36.4-fold increases in IFN-γ SFU relative to the 
untreated controls (Figure 3-2F) and were stronger stimuli than ACT-VEC+MDDC (1.8 and 9.1-fold 
increase in SFUs, respectively).  
We next measured the ratio of HIV-1 RNA production versus CD4 T cell activation (Figure 
3-2E and Figure 3-10S, C).  If latent HIV is housed primarily in HIV-specific CD4 T cells, the virus 
released into supernatant per activated CD4 T cell should be greatest under the MDDC+ACT-VEC 
conditioning, which was indeed the case (Figure 3-2G). The numbers of ACT-VEC activated CD4 T 
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cells (based on SFU/106) correlated with the induced HIV copy number (**p=0.0045) (Figure 3-
11S, A and B). Significantly less HIV-1 RNA in culture supernatant was observed per activated CD4 
T cell when treated with either unpulsed MDDC, CTF+MDDC, and even PMA/Iono controls (Figure 
3-2G). As a non-specific CD4 T cell activator, the mitogen PMA/Iono stimulates substantially more 
cells that either ACT-VEC or CTF and yet, less HIV is released from reactivated latent pool in these 
PMA/Iono activated T cells. This finding coupled with the inability of CTF to trigger significant HIV 
latency reversal supports our hypothesis that a sizable reservoir of latent HIV is housed primarily 
in HIV-specific CD4 T cells of volunteers treated with cART at acute/early infection.  As expected, 
no HIV-specific CD4 T cell activation or induced HIV genome was detectable in CD4 T cells of HIV- 
donors cocultured with autologous MDDC pulsed with ACT-VEC (Figure 3-10S, A and E). 
3.3.3 ACT-VEC mediated latency reversal induces replication competent virus.  
Within HIV infected individuals receiving cART, proviral DNA integrated into host DNA may be 
inert or can be induced to produce replication competent as well as defective and dead HIV. 
While reactivation and elimination of all inducible, replication competent provirus will be 
necessary for a sterilizing cure, any reductions in proviral reservoir might significantly reduce the 
length of time individuals may be required to take cART for the chances of viral rebound to be 
diminished. To evaluate whether HIV antigens delivered by ACT-VEC induces replication 
competent HIV from activated CD4 T cells, we monitored HIV propagation following ACT-VEC 
stimulation (in the absence of T-20; enfurvitide (fusion inhibitor)) in an assay where MDDC+ACT-
VEC/CD4 T cells were separated by a 0.4µm membrane from the permissive MOLT4 CCR5 cells 
(Figure 3-3A). In this assay, HIV produced from activated T cells in the apical chamber can flow 
through, infect and propagate in the susceptible MOLT4 CCR5 cells in the basolateral chamber. 
By removing the apical chamber, we can accurately quantify the induced and replication 
competent virus in the basolateral chamber without a continuous influx of virus from the apical 
chamber confounding the results. Furthermore, the format of this viral outgrowth experiment 
enabled us to propagate virus indeterminately, using a low number of stimulated cells (1x105 T 
cells) and without the need for sub-culturing. Culture supernatants were collected every 3 days 
and assessed for viral RNA using qRT-PCR (Figure 3-3B). If replication competent virus was 
induced by the stimuli and subsequently infected the MOLT4 CCR5 cells within the basolateral 
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chamber, we would expect a logarithmic increase in the amount of viral RNA in culture 
supernatants between early and later time points. In this outgrowth format, we detected a 
pronounced increase in HIV-1 RNA via qRT-PCR by day 6, while day 3 was undetectable. This 
represents 2-3 log amplification of virus. After day 6, there was a marked reduction in detectable 
viral RNA (Figure 3-3B). The detection of virus on day 6 compared to day 3 represented a slight 
delay when compared to the previous latency reversal ELISpot format (Figure 3-2), which can be 
explained by the greater volume of culture supernatant involved in the assay and the fact that 
the induced virus is infecting the MOLT4 CCR5 cells. To further evaluate this finding, we 
conducted latency reversal experiments on samples from two volunteers under sub-culturing 
conditions (1/3 split) to determine if we could detect viral propagation (Figure 3-3C).  As shown, 
we detected significantly increasing levels of HIV-1 p24 and viral RNA in culture supernatants 
over time (**p=0.0078), which culminated at days 9 and 12 (Figure 3-3, C and D).  The increased 
production/propagation of HIV over time in this sub-culturing experiment suggests ACT-VEC 
induces infectious virus from the latent pool. 
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Figure 3-3: MDDC presentation of ACT-VEC to T cells induces replication competent virus 
though contact dependent mechanisms. 
ACT-VEC pulsed MDDC were used to stimulate autologous CD4 T cells in Spin-X columns. (a) 
MOLT-4/CCR5 cells were added to the basolateral chamber of the column to propagate induced 
virus capable of replicating. After 3 days of stimulation and co-culture, the inserts containing 
MDDC-CD4 T cells were removed and MOLT-4 CCR5 cells were plated into a 24 well plate and 
cultured for a further 12 days. (b) MOLT-4 CCR5 cells from outgrowth experiments were cultured 
for 15 days and viral copy number was analyzed in the culture supernatants every three days 
(n=3). (c) A similar viral outgrowth assay was set up whereby after 3 days of MDDC-CD4 T cell co-
culture, the MDDC-CD4 T cell insert was removed and the MOLT4/CCR5 cells were split evenly 
into three plates. Samples were subsequently sub-cultured at 3-day intervals. (d) The two donor 
(n=2) samples tha t were sub-cultured were maintained over time to observe if viral propagation 
would occur. Viral p24 was measured by ELISA every 3 days. Viral p24 results are shown for days 
9 and 12 (+/- SEM) (e) Viral copy numbers in culture supernatants were also determined by qRT-
PCR every 3 days. Results for qRT-PCR are shown for days 9 and 12 (+/-SEM). Statistical 
significance was ascertained by Mann-Whitney unpaired t-test. 
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 Deep gene sequencing of the propagated virus (C2-V3 region of Env) following ACT-VEC 
stimulation revealed 2 distinct virus clusters (Figure 3-4, A and B).  For each of two AC-cART 
patients, replicate ACT-VEC stimulations (x7) of a limited number of CD4 T cells resulted in the 
propagation of a population of related HIV clones as well as some HIV-1 clones unique to only 
specific replicates. Of note is the identification of cellular proviruses (Red) with genetic homology 
to the induced viruses (Blue) in both volunteer samples (Figure 3-4B). Within each latency 
reversal assay (LR1-7) and excluding for the possibility that latently infected CD4 T cell clones 
might be represented more than once in each well37, if each unique virus was induced from one 
latently infected CD4 T cell, we can extrapolate the data and estimate the minimal ACT-VEC 
inducible reservoir to be ~14 cells/million. This is substantially greater than the 1 cell/million cited 
in earlier publications and less than the 60 cells/million that has been estimated in other 
studies38–40.              
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Figure 3-4: ACT-VEC-induced HIV-1 exhibits limited genetic diversity. 
ACT-VEC pulsed MDDC were used to stimulate autologous CD4 T cells in Spin-X columns. MOLT-
4/CCR5 cells were added to the basolateral chamber of the column to propagate induced virus 
capable of replicating. After 3 days of stimulation and co-culture, the apical insert containing the 
MDDC-CD4 T cells was removed and the MOLT-4 CCR5 cells were plated into a 24 well plate and 
cultured for a further 12 days. (a) Illumina MiSeq deep gene sequencing of the C2-V3 region of 
Env from ACT-VEC induced HIV-1 was carried out on day 12 culture supernatants. (b) 
Monophyletic viral clusters corresponding to the induced HIV-1 (Blue), were compared to HIV 
DNA from isolated provirus (Red) to demonstrate genetic homology. Reference sequences for 
subtypes A,B,C and D were added for comparison. (c) Latency reversal assays (LR1-7) were 
conducted multiple times with the induced virus sequenced to determine the number of times 
and variability that a particular viral sequence cold be identified within culture supernatants. 
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3.3.4 ACT-VEC is a more promising LRA compared to HDACi’s and PKC agonist monotherapies.    
ACT-VEC as a promising LRA was compared to the clinically relevant LRAs including Panobinostat, 
Vorinostat, Romidepsin and Bryostatin. (Figure 3-5). We initially tested the various HDACi and 
PKC agonists on the J-Lat 6.3 cell line to verify concentrations of drug that enable detectable 
latency reversal. As shown, the PKC agonist and HDACi alone or in combination, induced HIV-1 
latency reversal in the J-Lat cell line (Figure 3-12S, F and G), consistent with previous studies. 
However, while we were able to detect latency reversal in the J-Lat cell line, we were unable to 
detect significant levels of HIV-1 RNA release from AC-cART CD4 T cells treated with HDACi’s or 
Bryostatin monotherapies. While HDACi and PKC agonists were poor inducers of HIV in primary 
cells, ACT-VEC+MDDCs (*p= 0.0159) again showed significant latency reversal properties (Figure 
3-5, A and B). Interestingly, ACT-VEC did not induce latency reversal in the J-Lat cell line, which 
suggests that, by itself, it is unable to induce latency reversal, probably because there is no 
MDDC-mediated presentation. Of note, Bryostatin in combination with Panobinostat (*p=0.031) 
or Romidepsin (**p=0.0079) was able to induce significant levels of detectable HIV-1 latency 
reversal, but this was less than observed with ACT-VEC. These findings demonstrate that ACT-
VEC treatment of latently infected CD4 T cells is a stronger LRA than the tested HDACi and PKC 
agonists in primary human cells.  
In these studies, ACT-VEC+MDDC was also found to be slightly more antigenic than the 
unstimulated control and individual HDACi’s (Figure 3-5, C and D) as measured by IFN- ELISpot 
analyses. However, when comparing Bryostatin alone (*p<0.05) and the combination of 
Bryostatin with Romidepsin or Panobinostat, ACT-VEC was found to be less immune-stimulatory 
for AC-cART CD4 T cells. Again, when ACT-VEC latency reversal is evaluated based on the number 
of activated CD4 T cells, we demonstrate that ACT-VEC induces substantially more HIV-1 release 
on a per T cell basis than these HDACi or PKC agonists, suggesting ACT-VEC might be specifically 
targeting latency reversal in HIV-specific cells.      
  
 
113 
 
ACT-VEC+MDDC were used to stimulate autologous CD4 T cells from HIV infected donor cells 
(n=5). ACT-VEC stimulations were compared to Bryostatin, Vorinostat, Romidepsin and 
Panobinostat monotherapies as well as Bryostatin/Vorinostat, Bryostatin/Romidepsin and 
Bryostatin/Panobinostat combination therapies. (a and b) The induced viral copy number was 
determined after 3 days of cell culture in HIV donor samples by qRT-PCR. (c and d) To determine 
CD4 T cell activation, IFN- ELISpot was performed (100,000 cells/well) on  HIV+ cells after 
overnight incubation. Results are shown as fold increase over media or group means of IFN- 
SFUs /106 CD4 T cells (±SEM). Statistical analysis was assessed by Mann-Whitney unpaired t-test 
(* p<0.05 and ** p<0.005). 
  
Figure 3-5: ACT-VEC is a more robust LRA than HDACi and PKC agonist regimens. 
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3.3.5 ACT-VEC mediated HIV latency reversal is partially controlled by MDDC mediated contact 
with CD4 T cells and signaling through the Src family member Lck.  
Understanding exactly how ACT-VEC functions as a latency reversal agent is now a priority, 
as is determining the fate of the cell reservoir upon ACT-VEC mediated latency reversal. Antigen 
processing, cell-cell contact, TCR-MHC II and co-stimulatory interactions, as well as soluble 
secreted factors are all likely to be important mediators involved in latency reversal. With that 
said, we noted that volunteer P7, whose CD4 T cells were consistently the weakest responders 
to ACT-VEC + MDDC (Figure 3-6A), was the only donor to be on a cART regimen involving a 
protease inhibitor (PI). The fact that PIs 1) have previously been shown to alter antigen processing 
and presentation, leading to changed frequencies and patterns of MHC displayed peptides and, 
2) have reduced HIV reactivation potential, further suggests that antigen presentation and 
contact between MDDC and CD4 T cells may be important41–43. To confirm the role of MHC 
presentation on T cell activation and subsequent latency reversal, we performed our latency 
reversal assays in the presence of either the PI, Pepstatin A, or Chloroquine (CQ). Chloroquine is 
a lysosomotropic agent that prevents acidification of the endosome44, and further prevents the 
fusion of the endosome and lysosome. This ultimately leads to insufficient peptide processing 
and poor presentation by MHC complexes. By limiting MHC II presentation of HIV derived 
peptides with either Pepstatin A or CQ, CD4 T cell activation was reduced by 72.9% and 96.2%, 
respectively, as compared to ACT-VEC stimulation in the absence of an inhibitor (Figure 3-6B). 
This marked reduction in T cell activation also had implications on latency reversal, wherein ACT-
VEC+PI and ACT-VEC+CQ conditions both reduced HIV copy number by approximately 55% 
(Figure 3-6C). To build upon the previous result, we sought to determine the importance of MDDC 
- CD4 T cell contact at influencing HIV-1 latency reversal. Therefore, we co-cultured ACT-
VEC+MDDC/CD4 T cells or separated the cells using a 0.4µm membrane. As expected, we show 
that MDDC-CD4 T cell contact is important for the high levels of latency reversal and viral budding 
seen in these studies (Figure 3-6, D and E).  It is, however, difficult to sort out the master 
“regulator” of latency reversal by ACT-VEC, considering the multipronged signaling cascade from 
the TCR, co-stimulatory molecules and cytokine/chemokine receptors following this antigen 
presentation. This is further complicated by the diversity in proviral integration site, meaning 
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multiple signals are probably required to initiate latency reversal. Despite this, we evaluated the 
impact on ACT-VEC mediated CD4 T cell activation and latency reversal by using an inhibitor of T 
cell activation i.e. Dasatinib. The T cell mitogens used as controls in these latency reversal studies 
act through differing mechanisms. As shown in Figure 3-6F, and as reported by others45, Dasatinib 
works through inhibition of Lck, which is a protein tyrosine kinase that acts proximal to the TCR. 
Hence, it is unsurprising that Dasatinib was ineffective at inhibiting T cell activations when 
PMA/Iono was the stimulus, as PMA/Iono is a known PKC agonist and triggers T cell activation 
downstream of the TCR signaling cascade. This contrasts with the other mitogens tested that 
stimulate through the TCR, and where activation was severely impeded by Dasatinib. 
Interestingly, when Dasatinib was used as an inhibitor in our latency reversal reactions, a marked 
reduction in induced virus was detected in culture supernatants, approaching ~40% (Figure 3-
6G). This indicates the importance of signaling through the TCR which is likely the mechanisms 
employed by MDDC pulsed with ACT-VEC. 
While contact and signaling through the TCR appear important, inhibition of JAK-STAT and 
TNFR mediated signal transduction did not significantly reduce ACT-VEC mediated latency 
reversal in our hands, suggesting that cell secreted factors alone are not responsible for the 
observed latency reversal (Data not shown). Additional support for this is shown by ACT-VECs 
comparatively lower capacity to induce IFN-γ, TNF-a and IL-2 production from activated CD4 T 
cells compared to the polyclonal stimulator PMA/Iono (Data not shown). The latter being a poor 
latency reversal agent in these studies. 
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Figure 3-6: MDDC presentation of ACT-VEC to T cells induces replication competent virus 
though contact dependent mechanisms. 
(a) PBMC from volunteers treated with cART containing a protease inhibitor induced the lowest 
fold change in viral reactivation by qRT-PCR. (b) MDDCs were pulsed with ACT-VEC in the 
presence or absence of either the protease inhibitor, Pepstatin A, or the lysosomotropic agent, 
Chloroquine (CQ), and subsequently co-cultured with autologous CD4 T cells. IFN-γ ELISpot SFUs 
were used to evaluate the percent (%) change in activation between conditions. (c) After 3 days 
in culture, supernatants were collected and viral copy number determined via qRT-PCR. (d) To 
evaluate if MDDC-CD4 T cell contact was necessary for HIV latency reversal, the MDDC-CD4 T 
cells were either cocultured in the apical insert of the Spin-X columns or separated by seeding 
them in the basolateral and apical chambers of the columns, respectively. (e) After MDDC were 
pulsed with ACT-VEC and the MDDC used to stimulate autologous CD4 T cells, induced virus in 
culture supernatants was quantified by p24 ELISA.  (f) To evaluate the effect on latency reversal 
by stimulating through the TCR, we used an inhibitor of the TCR signaling pathway, Dasatinib. To 
determine the best concentration of Dasatinib to use in latency reversal studies, we titrated 
Dasatinib on CD4 T cells at varying concentrations (0nM, 1nM, 10nM) prior to activation with 
either PHA-L, αCD3/CD28, or PMA/Iono. Percent activation was determined via flow cytometry. 
(g) ACT-VEC-pulsed MDDCs were co-cultured with CD4 T cells in the presence or absence of 
Dasatinib, and supernatants were analyzed for viral RNA  concentrations (copy number +/- SEM) 
after 24 hours.   
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3.4 Discussion 
Development of an HIV-1 cure is a significant challenge. Currently, only the Berlin patient has 
been cured of HIV-1, although it has recently been reported that a London patient and Düsseldorf 
patient have also been described to be in HIV-1 remission46–48. However, the myeloablation/stem 
cell transplantation therapy used to achieve these remarkable feats are impractical for global roll 
out or use in the cART era46. Regardless, the addition of the London and Düsseldorf patient does 
add further credibility to the HIV cure effort and also adds supportive evidence that the cure seen 
in the Berlin patient was not an anomaly, despite the lack of HIV eradication seen in other clinical 
examples such as the Mississippi Child and the Boston patients. Alternative approaches to HIV 
cure have been based on in vitro stimulation of latently HIV infected cell lines and primary T cells 
using a diverse array of chemotherapeutic and immunomodulatory agents49,50. However, the 
initial promising in vitro effects of HDACi and PKC agonists on latency reversal have parlayed to 
less effective activation in primary CD4 T cells of cART-treated volunteers; resulting in subtle to 
no changes in the size of the latent HIV pool.     
For full HIV latency reversal, an LRA must overcome key epigenetic barriers. The latent HIV 
genome is typically integrated into heterochromatin or genomic regions of limited transcriptional 
activity. TCR mediated stimulation induces a complex signaling cascade leading to increased 
levels of transcriptional factors NF-kB, NFAT, AP-1, p-TEFb, and Ets-1 as well as other host factors, 
all of which interact with the promoter/enhancer elements in the LTR to activate, enhance and/or 
elongate HIV-1 mRNA transcription51,52. In the studies presented herein, we stimulated the T cells 
through HIV-specific TCRs using a targeted approach employing MDDC and a susceptible HIV VLP 
formulation.  We chose AC-cART samples for this study as the minimal genetic diversity and lower 
reservoir size is likely to play a significant role within immunotherapeutic cure strategies. This 
differs significantly from most cure studies that evaluated latency reversal in samples derived 
from individuals diagnosed and treated at chronic stage of infection, where reservoirs and 
diversity are going to be larger. Our HIV-specific, CD4 T cell-targeted approach was based on 
several studies suggesting that these HIV-specific T cells may be the primary “fuel” for HIV 
production, especially during acute/early infection15,16. HIV antigens, however would only be an 
effective transcriptional shock if CD4 T cells expressing HIV-specific TCRs served as a significant 
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reservoir for latent HIV, which is indeed the phenomenon that we observed. Simply put, ACT-
VEC+MDDC resulted in the production and release of HIV from CD4 T cells of volunteers receiving 
cART during early infection (AC-cART).  This latency reversal and release of HIV-1 by our 
immunotherapy was significantly greater than that observed when the same AC-cART CD4 T cells 
were treated with common recall antigens, HDACi and even potent mitogens.  
Using deep gene sequencing of the induced, propagating virus, we were able to estimate the 
numbers of latently infected cells that were inducible within patient samples. Our results suggest 
there are ~14 CD4 T cells per million with infectious but latent HIV provirus that can be stimulated 
to produce HIV in our acute samples. This falls within current estimates in the literature of 
between 1-60 CD4 T cells /million harboring latent but potentially infectious HIV provirus during 
stable cART38–40. Interestingly, a study by Baxter et al demonstrated that in a FISH/Flow assay, 
the median frequency of PMA/Iono inducible cells harboring latent HIV was 3.56 CD4 T cells/106, 
which is substantially less than our calculated 14 cells/million and agrees with the low level 
reactivation that we see in these studies53. In the future, studies using more powerful 
technologies, such as the before mentioned FISH/Flow, and newer assays that can discriminate 
between intact and defective forms of virus, such as the Intact Proviral DNA Assay (IPDA), would 
likely shed important insights into the effectiveness of our shock approach while more accurately 
characterizing the reservoir size54.   
While the fate of the cellular reservoir upon viral reactivation is unknown, activation of HIV-
specific memory CD4 T cells by ACT-VEC could provide a strong T helper response for CTL or 
antibody-based immune control of this reactivated latent HIV. Therefore, it is important to note 
that we have previously shown ACT-VEC induced cell-mediated cytotoxic Granzyme B responses 
in these AC-cART treated volunteer PBMC27. In the context of immunotherapeutic cure, 
particularly in patients treated during acute/early infection, an antiviral cytotoxic response 
induced by ACT-VEC may be very effective in eliminating the relatively homogenous HIV-1 
presented by infected cells via MHC I. Thus, ACT-VEC, delivered via adoptive transfer of in vitro 
generated, antigen-loaded DCs, or in situ targeting of DCs could prime for a possible “kill” along 
with the observed “kick” that we see. Over the years, a number of studies have used DC-based 
approaches to present HIV-1 antigens in the non-human primates and in clinical trials to enhance 
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an immune activated “kill” of the cell reservoir and/or residual virus55–59. Notable reductions in 
viral RNA and DNA levels were observed in the cells from various anatomical compartments of 
the vaccinated animals, a finding that has yet to be substantiated in human trials. However, these 
studies were focused on a “kill” by CD8+ T cytotoxic lymphocytes rather than exploring how DC 
mediated presentation of these SIV antigens may have activated virus-specific CD4 T cells and 
thereby triggering latency reversal.  
 While these studies were conducted using samples from patients, cART-treated at acute 
stage of subtype B infection, it should be noted that the vast majority of individuals are diagnosed 
much later in infection. During chronic stage of infection, untreated individuals would have been 
exposed to a plethora of opportunistic infections which might change the TCR demographics of 
cells harboring latent provirus. Equally, it should be considered that subtype B infection accounts 
for a considerably smaller proportion of HIV infection, with subtype C constituting the majority 
of the global epidemic. Therefore, in the future it would be interesting to evaluate the 
effectiveness of ACT-VEC at mediating a latency reversing shock in both chronic and acute patient 
samples as well as evaluating the effects of ACT-VEC at triggering latency reversal of differing 
subtypes of HIV. 
In conclusion, we demonstrate that ACT-VEC efficiently reactivates transcriptionally silent 
HIV-1 from CD4 T cells of patients treated at acute/early infection. Furthermore, we can show 
viral translation occurs and that the released virus is replication competent. Our study also 
demonstrates that this immunotherapy is targeted to HIV-specific CD4 T cells, which may house 
a large proportion of the latent HIV reservoir. Taken together, this approach establishes ACT-VEC 
as a highly promising immunotherapeutic LRA. Future planned in vitro, in vivo non-human 
primate and human clinical studies will suitably address whether ACT-VEC can indeed cause 
reservoir reduction/elimination and whether ACT-VEC can induce protective humoral and 
cytotoxic T cell responses in vivo.  
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Figure 3-7: Schematic representation of latency reversal in human acute/early CD4 T cells. 
Representation of the frequencies (%) of CD4 T cell activation and the quantities of induced HIV-
1 virus detected in culture supernatants using PMA/Iono (    ), Flu M1/Tetanus Toxoid/CMV 
peptide pool (     ) and ACT-VEC (     ). Frequencies of induced virus (below the x-axis) and activated 
CD4 T cells (above the x-axis) are normalized to the condition eliciting the greatest response (i.e. 
ACT-VEC for induced virus and PMA/Iono for activated CD4 T cells). The schematic demonstrates 
that ACT-VEC is a stronger latency reversal agent than non-specific stimuli whilst being 
substantially less antigenic.   
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3.5 Materials and Methods 
3.5.1 Experimental Design 
The activator vector (ACT-VEC) LR agent was developed as an HIV-1 curative strategy. Based on 
previous studies suggesting that HIV-1 preferentially establishes a latent reservoir within antigen-
specific CD4 T cells, we hypothesized that an HIV-1 antigenic formulation containing the epitopes 
that could be presented to cognate TCR bearing T cells, would be a promising transcriptional 
shock tactic. We therefore generated a highly diverse, polyvalent virus like particle (VLP) 
formulation by combining the HIV quasi-species from 5 chronic HIV-infected volunteer’s plasma 
samples, taken immediately prior to cART initiation. The objectives of this study were succinct. 
In the first instance, we aimed to demonstrate a proof of concept that ACT-VEC could efficiently 
trigger viral LR in purified human CD4 T cells from patients receiving cART and show that the 
reservoir was indeed concentrated in HIV-specific memory CD4 T cells. Furthermore, we aimed 
to demonstrate that ACT-VEC induces replication competent virus i.e. the source of recrudescing 
virus upon cART cessation. Finally, we sought to compare the efficacy of ACT-VEC mediated LR to 
that induced by other LRAs such as HDACi and PKC agonists.  To achieve the objectives of the 
study, we recruited cART-treated individuals that were diagnosed with HIV at acute/early stage 
of infection and who were able to durably suppress viremia. The recruited individuals consented 
to supply a large blood draw from which we could evaluate ACT-VEC LR on CD4 T cells ex vivo.   
3.5.2 Ethics statement 
HIV-infected individuals were recruited from the HIV adult clinical services at St Mary’s Hospital 
(Imperial College NHS trust), through a protocol approved by the NHS Health Research Authority 
(protocol number: 14SM1988). Peripheral blood was obtained from infected patient volunteers 
who had suppression of viremia to <50 copies HIV-1 RNA/mL for > 6 months on ART. All study 
subjects used in this manuscript were adults and gave prior written informed consent. 
3.5.3 Virus like particle (VLP) latency reversal agents and their production 
 
A highly diverse virus-like particle (VLP) formulation was constructed from the serum of HIV+ 
subtype B patient volunteers, identified and receiving cART at chronic phase of infection (isolated 
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from patients infected for more than 1 year). Briefly, viral RNA was isolated from a banked plasma 
sample, prior to cART initiation, using a viral RNA isolation kit (Qiagen, USA). Viral RNA was 
reverse transcribed (Agilent Technologies, USA) to full length HIV-1 proviral cDNA as two 
fragments using two reverse primers to generate the 4561 bp 5’ ( region - Integrase) and 4880 
bp 3’ fragment (integrase -3’LTR) regions. The cDNA fragments were then utilized in a nested PCR 
protocol using 5’ and 3’ primer sets to create 5’ and 3’ overlapping fragments. Both the 5’ and 3’ 
overlapping primers for the two genomic halves contained mutations generating a AAH > RRK 
substitution in the Integrase (IN) coding region and destroys IN activity27.  The 5’ fragment ( 
region - Integrase) was amplified with 5’ primer that disrupts the  packaging region, preventing 
genomic RNA encapsidation27.  The two subsequent (5’, 4378 bp and 3’, 4628 bp) half genome 
fragments were transfected into Saccharomyces cerevisiae in a 1:1 ratio (wt/wt) with 2g SacII 
linearized plasmid, pRECgag-U3/URA3. Resulting yeast colonies resulting from a triple 
recombination/gap repair into the pRECgag-U3/URA3 to produce pREC_nfl_UH8.dS1.INAAH>RRK 
were selected on complete medium lacking leucine (C−Leu) plates supplemented with 
fluoroorotic acid (FOA). It is important to note that the pREC_nfl_UH8.dS1.INAAH>RRK also lacks the 
5’ LTR and produces defective gRNA that cannot be packaged (due lack of ) and cannot serve as 
a template for reverse transcription (due to lack of 5’ LTR).  The recombined plasmid vectors were 
isolated by yeast mini-prep, transformed into bacteria, purified using Maxiprep (Qiagen, CA) and 
then used to transfect 293T cells with Fugene 6 transfection reagent (3:1 vol/wt) (Promega, USA) 
to produce VLPs. Viral VLPs were first purified in cell-free supernatant by centrifugation through 
100 KDa MWCO centrifuge tubes (Amicon, USA), before ultracentrifugation at 100,000g 
(Beckman, USA) with the resulting VLP pellet re-suspended in sterile PBS. To verify VLP particle 
production, the formulation was confirmed by dynamic light scattering, transmission electron 
microscopy, p24 production, radioactive reverse transcriptase assay for presence of Rev and Tat, 
Western blot and cell-cell fusion co-receptor tropism assay VERITROP for presence of Env and its 
functionality as described previously27. Following these safety and purity tests, VLPs are referred 
to as ACT-VEC. 
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3.5.4 Isolation of resting CD4 T lymphocytes and Monocyte Derived Dendritic Cells (MDDC) 
 
Peripheral blood mononuclear cells (PBMC) were isolated using density gradient centrifugation. 
CD4 T lymphocytes were enriched by negative depletion (CD4 T cell Isolation Kit, Miltenyi Biotec) 
using magnetic microbeads. The purity of these cells was analyzed by flow cytometry using a LSR 
II (BD Biosciences, USA) and FlowJo software (Treestar). To obtain immature DCs, PBMC were 
cultured for 2 hours in a T-75 tissue culture flask (Sarstedt, Ca) and allowed to plastic adhere for 
2 hours in a 5% CO2 incubator at 37˚C. The adherent monocytes were washed gently with 
complete RPMI to remove non-adherent cells. Isolated monocytes were then differentiated into 
monocyte derived dendritic cells (MDDC) by culturing in complete RPMI (10%FCS + 2mM L-
Glutamine) supplemented with GM-CSF and IL-4 (1,000 and 500 U/mL respectively) in T-75 flasks 
for 6 days with 50% of the media replenished with fresh complete RPMI (IL-4 + GM-CSF) every 3 
days.  
3.5.5 Latency reversal assays 
 
Purified CD4 T cells were co-cultured overnight with day 7, antigen-pulsed, autologous MDDC at 
a ratio of 1 DC per 4 T-cells.  Antigen pulsing consisted of overnight stimulation of MDDC with 
either 1) media, 2) 5 g/mL (based on p24) heterologous ACT-VEC, 3) recall antigen cocktail CTF 
[250 ng/peptide/mL Flu M2 protein (bei Resources, USA), 2 μg/mL Tetanus toxoid (Statens Serum 
Institut, DK) and 5 μg/mL pp65 HCMV peptide pool (NIH AIDS Reagent Program, USA)]. On the 
day of MDDC-T cell co-culture either, 1/5000 phorbol 12-myristate 13-acetate (PMA) + Ionomycin 
(Iono) (ebioscience, Ca), 10 nM PKC agonist Bryostatin-1 (Sigma, USA) or 335 nM Histone 
Deacetylase inhibitor (HDACi) Vorinostat (Caymen Chemicals, USA), 40 nM Romidepsin (Cedar 
lane labs, CA) or 30 nM Panobinosat (Selleckchem), was added to the remaining un-pulsed 
MDDC-T cell co-cultures to serve as controls and competitor LRAs. All HDACi and PKC agonists 
were used at previously published concentrations known to upregulate viral RNA transcripts in 
primary T cells and cell lines. The fusion inhibitor, Enfuvirtide (T-20) was added after 24 hours to 
all co-cultures at a concentration of 10 μM to block any re-infection of T cells by the reactivated 
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latent virus. In all cases, stimulated co-cultures were loaded onto IFN- ELISpot plates to assess T 
cell activation.  
 For studies involving measurements of LR occurring as a result of cell-cell contact or 
soluble secreted factors, ACT-VEC pulsed MDDC were pulsed overnight before, washing and 
incubating with/without autologous CD4 T cells in the apical or basolateral chamber of a 0.4µm 
Spin-X Columns (Sigma, Ca).  For viral propagation studies, MOLT4 CCR5 cells were added to the 
bottom chamber of the Spin-X column to allow the propagation of replication competent virus 
released from patient CD4 T cells. Supernatants were harvested every 3 days and HIV-1 infection 
was determined by p24 ELISA (NCI Frederick, USA) and assessed by qRT-PCR. To evaluate the 
impact of various signal transduction pathways on ACT-VEC mediated latency reversal, 10nM 
Dasatinib (Sigma, Ca), 40nM Methotrexate (Sigma, Ca) and 1.7M R7050 (Santa Cruz, Ca) were 
added to CD4T cells 6h prior to coculture with ACT-VEC pulsed MDDC. For studies involving the 
titration of Dasatinib and stimulation with the T cell mitogens, PMA/Iono, PHA-L, and 
αCD3/αCD28, purified CD4 T cells were culture in the presence of inhibitor overnight prior to flow 
cytometric analysis. For inhibition studies involving Pepstatin A (2µM, Sigma, USA) and 
Chloroquine (100µM, Sigma, USA), inhibitors were added to MDDC overnight prior to overnight 
pulsing with ACT-VEC.  
3.5.6 IFN-γ antigen-specific ELISpot assays 
Human IFN-γ enzyme-linked immunosorbent spot (ELISpot) assays (Mabtech, USA) were carried 
out on MDDC-CD4 T cell co-cultures as per the manufacturer's instructions. Briefly, anti-IFN- 
pre-coated plates were washed with sterile PBS and then blocked for 30 min using complete 
RPMI. Plates were again washed before addition of 1 × 106 cells/mL CD4 T cell. The MDDC 
stimulated CD4 T cells were then incubated for 16 h to assess the number of HIV-specific CD4 T 
cells. Unstimulated and PMA/Iono (eBioscience, Ca)-stimulated cells, diluted 1/500 (v/v) in 
media, served as controls. To detect spots, biotinylated anti-IFN-γ antibody was added at 1 μg/mL 
for 2 h before washing and incubating with streptavidin-HRP for 1 h. Plates were washed as 
described above, and 100 μl/well of TMB substrate was added. 
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3.5.7 Flow Cytometry 
For latency reversal in J-Lat 6.3 (AIDS Reagent Program) cell studies, cells were seeded overnight, 
in a 6 well tissue culture plate, at 2.5 million cells/well along with the various stimuli. Samples 
were washed three times using FACs buffer (2.5% FCS in PBS) and then fixed in 1.5% methanol-
free paraformaldehyde (Polysciences, USA) in PBS. Samples were analyzed for GFP expression on 
a FACS LSR II instrument with FACS Diva software. Data analysis was performed with FlowJo 
(Treestar Inc., OR, USA). 
For evaluation of MDDC primary cell maturation, monocytes from HIV negative donors 
were purified via plastic adherence and matured into MDDCs using IL-4 and GM-CSF as described 
previously. MDDCs were pulsed using either ACT-VEC VLP, CTF, HIV Consensus B Env/Gag/Pol 
peptide pools (2 µg/peptide/mL; NIH AIDS Reagent Program, USA), or remained un-pulsed for 
the negative control. Cells were stained for the cellular maturation markers CD11c (Clone: 3.9, 
eFluoro450; eBioScience, Ca), CD209 (Clone: eB-h209, PE-Cy7; eBioScience, Ca), CD40 (Clone: 
5C3, BV711; BioLegend, USA), CD80 (Clone: L307.4, BD Pharmingen, USA), and CD83 (Clone: 
HB15e, FITC; BioLegend, USA). Samples were fixed and analyzed as described previously.  
For polyfunctional CD4 T cell stimulation studies, purified CD4 T cells were pulsed with 
the various stimuli for 6h and stained using anti-human CD3 (Clone: SP34-2, APC-H7; BioLegend, 
USA) and anti-human CD4 (Clone: L200, BV711; BioLegend, USA), anti-human IFN-γ (Clone: 4S.B3, 
FITC; BioLegend, USA), anti-human IL-2 (Clone: MQ1-17H12, PE-Dazzle 594; BioLegend, USA), and 
anti-human TNF-α (Clone: MAb11, APC; BD Bioscience, USA). Samples were fixed and analyzed 
as described previously.  
3.5.8 Detection and quantification of cell-free supernatant HIV-1 mRNA. 
 
After 18h of stimulation, HIV-1 mRNA was extracted using a Viral RNA extraction kit (Qiagen, CA) 
from 0.2 mL of cell-free culture supernatant, which corresponds to 200,000 purified LRA-
activated CD4 T cells. cDNA synthesis was performed using AccuScript High fidelity RT-PCR system 
kit (AccuScript, USA). Real-time PCR was performed using SensiFAST SYBR™ No-ROX kit (Bioline, 
USA) on a Rotorgene 6000 Real-Time PCR machine (Corbett Research, USA) or QuantStudio5 
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(Applied Biosystems, Ca). Primers sets are listed in table S1. A 2-step cycling condition was carried 
out as follows: 1) 95oC for 2min, 2) 30 cycles of 95oC for 5s and then 63oC for 30s.  Molecular 
standard curves were generated using 1/10 serial dilutions of in house prepared pREC_5’LTR-
SBF-1 plasmid which has a known concentration and contains an intact 5’LTR and gag sequence 
from clade B NL4-3. The human TBP (TATA-box binding protein) primer set and control plasmid 
was used as an endogenous control (a kind gift from Dr Jimmy Dikeakos).  
3.5.9 Verification of LRA-induced HIV-1 RNA by deep gene sequencing. 
3.5.9.1 Library Preparation for Next Generation Illumina Sequencing: 
 
Amplicon products from the 5’LTR to Gag were generated from cDNA by external-nested PCR 
using a hot start polymerase (Platinum Taq, Invitrogen). External PCR primers included 5LTRPA 
and GAGREV. For the nested, PCR primers with Illumina overhang adapter sequences were used: 
MiS_PBSdt-F and MiS_GAGdt-R. Amplicons were further produced for the V2-V3 region of Env 
using the external PCR primers EnvB and ED14. The nested PCR utilized primers with Illumina 
adapter sequences E80_IlluminaTag and E125_IlluminaTag. PCR cycle conditions were 95°C for 
3min, followed by 35 cycles of 95°C for 30s, 55°C for 30s and 72°C for 1min (external) or 45s 
nested, and a final extension of 72°C for 10min. The PCR products were run on a 1% agarose gel 
at 100V for 45min to verify products of 350 bp (5’ LTR-Gag) or 481 bp (Env). Products of the 
appropriate band size were excised from agarose gel using a QIAquick Gel Extraction Kit. 
Concentrations were determined using a NanoDrop 2000c Spectrophotometer (Thermo Fischer, 
USA).  
3.5.9.2 Index PCR for the Illumina MySeq system:  
The Nextera XT Index kit system (NexteraXT Index Kit v2 Set A, Illumina) was used to 
attach the Illumina dual-index sequence adapters to the amplified and purified PCR products 
using a limited cycle index PCR (KAPA HiFi HotStart, Kappa Enzymes). PCR cycle conditions were 
95°C for 2min, followed by 35 cycles of 95°C for 30s, 55°C for 30s and 72°C for 45s, and a final 
extension of 72°C for 10min. The PCR products were run on a 1% agarose gel at 100V for 45min. 
3.5.9.3 Sample library purification and quantification: 
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 All PCR products were purified using Magnetic beads (AMPure XP, Berkin Elmer) with a 
bead:DNA ratio of 1:1. The DNA was eluted in 50 ul 10mM Tris (pH 8.5). Libraries were then 
flourometrically quantified (QuantIT PicoGreen, Invitrogen), normalized to 500ng and pooled 
together.  
3.5.9.4 Illumina Sequencing:  
The pooled samples were processed at the London Regional Genomics Centre (Robarts 
Research Institute, London, Ontario, Canada; http://www.lrgc.ca) using the Illumina MiSeq 
(Illumina, Inc., San Diego, CA). The library was run on an Agilent (Agilent Technologies Inc., Palo 
Alto, CA) High Sensitivity DNA Bioanalyzer chip (Caliper Life Sciences, Mountain View, CA) to 
assess size distribution and qRT-PCR (Kapa Biosystems, Inc., Wilmington, MA) was used to assess 
the quantity. The library was diluted to 4 nM and sequenced (according to the Illumina protocol 
Preparing Libraries for Sequencing on the MiSeq, Rev. C) on an Illumina MiSeq using a 2 x 300 
paired end run with 10% PhiX.  
3.5.9.5 Data analysis:  
Raw FASTQ paired reads (R1 and R2) files were quality checked with FastQC to visually 
evaluate the presence of Nextera paired-end adapters and to use a successive trimming strategy 
for detection and elimination of low quality base calls. Adapter removal and trimming were 
performed with Trimmomatic using the SLIDINGWINDOW option (cutting the remaining 
sequence once the average quality within a window of 4 nucleotides falls below a threshold of 
20). The trimmed FASTQ outputs were then utilized for mapping against HIV reference genome 
HXB2 (GenBank accession number K03455) using bowtie2 with local alignment and using an 
iterative re-mapping strategy to adapt the reference genome to the sample. Finally, the mapping 
results were visualized with IGV for detection of 5’LTR and the dS.1 mutation. 
For env sequence analysis of proviral and induced virus, we analyzed a 277-nucleotide 
long fragment (HXB2, coordinates 6845-7121), which we subsequently collapsed to identify the 
unique sequences using the MiCall pipeline (https://github.com/cfe-lab/MiCall). The multiplicity 
values of the sequences were used to calculate the 1% cut off for the total number of input 
sequences for each sample. The resulting sequences were then defined as “unique sequences”. 
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The unique sequences were analyzed using the Los Alamos National Laboratory (LANL) Neighbor 
TreeMaker tool. The LANL database was used to acquire reference sequences. The output style 
was modified for clarity, to show symbols using Powerpoint. 
3.5.10 Statistical analysis: 
Mann-Whitney non-parametric, or Wilcoxon matched pairs signed rank test was used to 
determine intra- and intersample statistical significance where indicated. We considered P > 0.05 
to be statistically significant. Correlations between sample conditions were evaluated using a 
two-tailed Spearman Rank Correlation where indicated. HIV-1-infected adult volunteers meeting 
the criteria for sustained viral load suppression (>6 months prior to sample donation) and free 
from any viral blips were enrolled. As samples from all patients were handled in the same way, 
there was no randomization or blinding. 
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3.8 Supplementary Figures (3-8S to 3-12S)
 
Figure 3-8S: Schematic of latency reversal studies and ACT-VEC preparation. 
The HIV+ volunteers were recruited based on early HIV diagnosis and cART treatment. Eligible 
volunteers had to have durable suppression of viral loads to below 50 HIV copies/ml for the six 
months preceding enrollment. Peripheral blood mononuclear cells (PBMC) were isolated and 
immediately cryopreserved. On study day 0, PBMC were defrosted and monocyte derived 
dendritic cells (MDDC) generated by 6 days of culture in IL-4 and GM-CSF. On day 6, the MDDC 
were pulsed with stimuli and autologous PBMC were defrosted and rested overnight. On day 7, 
the PBMC were used to isolate CD4 T cells and co-cultured with the pulsed MDDC. (a) The MDDC-
CD4 T cells were then further cultured to determine viral RNA concentrations in culture 
supernatants and for T cell activation by ELISpot and flow cytometry. The activator vector (ACT-
VEC) virus like particles (VLPs) were generated by first isolating HIV RNA from the plasma of HIV+ 
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volunteers. The HIV genome was PCR amplified in two overlapping halves and recombined in 
yeast by gap/repair using an in-house developed recombination vector, pREC HIV-Δ/URA3. The 
PCR process deletes the 5’LTR, inserts extensive nucleotide substitutions into stem loop 1 (SL1) 
of the RNA packaging sequence (ψ) and disrupts integrase activity. Positive recombination results 
in yeast colony formation under 5-Fluoroorotic acid selection on C-leu-URA agar plates. The DNA 
is extracted and amplified in bacteria before being used to transfect HEK293T cell. (b) After 72h 
transient transfection, ACT-VEC VLPs are harvested and purified for latency reversal studies.  
 
 
 
 
 
 
 
 
 
 
132 
 
 
 
133 
 
Figure 3-9S: Determination of MDDC maturation and polyfunctional CD4 T cell induction in 
healthy donors. 
(a) Plastic adhered monocytes, differentiated in the presence of IL-4 and GM-CSF, were evaluated 
for differentiation into MDDCs using HLA-DR, CD11c and CD209 expression via flow cytometry 
(n=3). (b) MDDCs were pulsed with CTF, ACT-VEC, or Env/Gag/Pol peptides and tested for 
maturation using CD40, CD80, and CD83. (c) CD4 T cells, purified by magnetic bead isolation of 
PBMCs, were stimulated with either PMA/Iono, PHA-L, or αCD3/CD28 to determine optimal 
stimulation conditions for use in latency reversal assays (n=3). Purified CD4 cells were run on a 
Flow Cytometer and gated using CD3 and CD4 and their activation determined by positive 
staining for IL-2, IFN-γ, and TNF-α. (d) Stimulated CD4 T cell polyfunctionality was assessed by 
analyzing mono, dual, or triple cytokine function. (e) The mean percentages of total CD4 T cells 
expressing one, two or three functions is shown. (f) Healthy donor cells (n=3) were analyzed via 
IFN-γ ELISpot to reaffirm the activation potency of PHA-L, αCD3/CD28, and PMA/Iono conditions. 
(g) Grouped samples were used to determine stimulation mean (±SEM) effects on antigenicity. 
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Figure 3-10S: Healthy donors lack contaminating viral RNA and exhibit varying degrees of CD4 
T cell activation in response to stimuli. 
MDDC+CD4 T cell cultures from healthy individuals (n=6) were stimulated with ACT-VEC (5ug / 
mL), a cocktail of Flu M1, Tetanus toxoid, CMV peptide pool (CTF), or PMA/Ionomycin. (a and e) 
Culture supernatants were collected after three days of culturing and tested for the presence of 
viral RNA via qRT-PCR. Due to the lack of HIV-infection within these donors, viral RNA was 
undetectable (<5.6 copies/mL) in all stimulation conditions. (b and d) CD4 T cells that were co-
cultured with autologous MDDCs were tested for activation via IFN-γ ELISpot. ACT-VEC exhibited 
low/no activation in most conditions, as compared to the global activator PMA/Iono (**p=0.005), 
or the recall antigen cocktail CTF. (c) The ratio between HIV copy number and activation was 
determined. Grouped samples were used to determine the mean effect (±SEM) of the 
stimulations on antigenicity and induced copy number with statistical significance ascertained by 
Mann-Whitney unpaired t-test.  
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Figure 3-11S: An extended comparison of various stimulations to induce HIV and activate CD4 
T cells. 
(a,c,e) The ability of the various latency reversal agents (ACT-VEC, FTC and PMA/Iono) to 
stimulate HIV induction and detection in culture supernatants was compared against its ability 
to stimulate CD4 T cells. (b,d,f) Correlations between induced virus concentrations and CD4 T 
activations were then assessed. Induced HIV was quantified within 3-day culture supernatants of 
stimuli-pulsed monocyte derived dendritic cells (MDDC) co-cultured with purified CD4 T cells and 
using qRT-PCR. To quantify induced virus, a primer set specific for the 5’LTR was employed. To 
determine the immune-stimulatory potential of the stimuli, IFN-γ ELISpot was used, and the co-
cultured MDDC-CD4 T cells incubated for 19h to determine recall or non-specific responses to 
the stimuli. Results represent data from all 9 volunteers. We further compared ACT-VEC VLPs to 
inert SIVmac251 and FIV viral particles. The FIV in the pREC plasmid backbone was kindly provided 
by Dr Ryan Troyer while SIVmac251 viral particles were generated in house according to the same 
methodology as ACT-VEC. The SIVmac251particles were recombined into a specially synthesized 
pRECgag-U3 vector with flanking regions of homology in the 5’ packaging sequence () and 
3’LTR end. As with ACT-VEC, the resulting SIVmac251 lacked a 5’LTR but in difference to ACT-VEC 
does contain a functional genomic packaging sequence. The ACT-VEC, FIV and SIV particles were 
used to pulse MDDC prior to 72h coculture with purified CD4 T cells. (a) Induced virus was 
quantified in culture supernatants by qRT-PCR. Due to the scarcity of the HIV infected donor 
samples, this experiment was only performed once with two donors. Assay cutoffs for ELISpot 
and qRT-PCR are 50 SFU/106 CD4 T cells and 30 viral copies/reaction.  Results shown are group 
means +/- SEM. (g,h) HIV-1 copy number and antigenicity was ascertained for related, non-HIV 
VLPs using the standard MDDC-T cell co-culture assay, and were subsequently compared to ACT-
VEC.  
  
 
 
138 
 
 
Figure 3-12S: ACT-VEC specifically activates HIV-infected donor samples when compared to 
alternative LRAs. 
(a and b) To confirm the absence of contaminating viral RNA in HIV-naïve donor samples, HDACi 
monotherapies ,PKC agonist, and combinations of HDACi and PKC agonist, were evaluated using 
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culture supernatants via qRT-PCR. (c and d) Negative donor MDDC+CD4 T cell co-cultures were 
tested for IFN-γ production via ELISpot using various latency reversing conditions. (e) The 
presence of viral RNA was quantified using qRT-PCR in five donors (n=5) infected at the acute 
stage of infection. Assay cutoffs for ELISpot and qRT-PCR are 50 SFU/106 CD4 T cells and 30 viral 
copies/reaction.  Results shown are group means +/- SEM. (f) To verify that the concentrations 
of stimuli used could cause latency reversal, we used the J-Lat cell line. The various stimuli were 
incubated overnight with the J-Lat cells and the numbers of GFP positive cells quantified by Flow 
cytometry for three independent experiments. (g) To determine the toxicity of the HDACi and 
PKC agonist drugs, live/dead staining was used to discriminate the populations and the 
percentage of GFP+ cells in drug titration studies plotted (100x - 0.01x).  The blue arrow shows 
the concentration of HDACi and PKC agonist used. 
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3.9 Tables 
Table 3-1:  Baseline characteristic of study volunteers. 
 
Nine HIV-1 infected volunteers were enrolled in this study. Volunteers were identified through 
the SPARTAC (Short Pulse Anti-Retroviral Therapy at HIV Seroconversion) study and recruited 
through the HIV adult clinical services at St Mary’s Hospital (Imperial College NHS trust). All study 
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participants provided written informed consent. All nine volunteers were recruited based on 
early HIV diagnosis and treatment with unabated cART-mediated suppression of plasma viremia 
(<50copies/ml HIV-1 RNA). The participants, age, date of HIV diagnosis, date of cART initiation, 
cART regimen, viral loads, CD4+ T cell numbers, time of enrolment and HepB/C status were all 
recorded. The estimated date/time of seroconversion (EDS) was calculated as the midpoint 
between the most recent negative and the first positive test for patients. 
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Supplemental Table 1. 
q
R
T‐
P
C
R
 
5’ LTR PA CCCACTGCTTAAGCCTCAATAAAGC 
GagR CTTACTTTTGTTTTGCTCTTC 
TBP_F TGCACAGGAGCCAAGAGTGAA 
TBP_R CACATCACAGCTCCCCACCA 
Ill
u
m
in
a 
En
v 
P
C
R
 E80 CCAATTCCCATACATTATTGTG 
E125 CAATTTCTGGGTCCCCTCCTGAGG 
ED14 TCTTGCCTGGAGCTGTTTGATGCCCCAGAC 
EnvB AGAAAGAGCAGAAGACAGTGGCAATGA 
Ill
u
m
in
a 
LT
R
 P
C
R
 
5’LTRPA CCCACTGCTTAAGCCTCAATAAAGC 
GagRev TTCTAGCTCCCTGCTTGCCCATACTA 
MiS_PBSdt‐
F 
TCGTCGGCAGCGTCAGATGTGTATAAGAGACAAAAATCTCTAGCAGTGGCGCCCGAACAG 
MiS_GAGdt‐
R 
GTCTCGTGGGCTCGGAGATGTGTATAAGTGACAGTTTCCAGCTCCCTGCTTGCCCATACTA 
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4.1 Introduction 
 
HIV-1, the causative agent behind AIDS-related illnesses, has remained a global health concern 
for nearly four decades. During this time, the advent of antiretroviral therapy (ART) has 
drastically reduced HIV-associated mortality by abrogating viral replication and facilitating 
immune system recovery.1 Unfortunately, ART remains non-curative due to the establishment 
of stably integrated proviral populations, or reservoirs, within host memory CD4 T cells. In the 
presence of ART, these reservoirs can persist indefinitely due to homeostatic proliferation in 
the absence of viral transcription, viral protein production, and/or virion formation.2,3 This 
quiescent pool is established within the first few days following primary infection.4 Early ART 
administration is insufficient to protect against the establishment of latent HIV-1 provirus, 
although it may contribute to a decrease in the overall reservoir size.5,6 Because of the inability 
to prevent reservoir establishment with currently available therapeutics, many strategies have 
aimed to eliminate the proviral pool. 
The ‘shock-and-kill’ strategy for HIV-1 eradication aims to induce transcriptional reactivation of 
latent provirus so that infected cells may be removed via immune-mediated clearance or viral 
cytopathic effects.7,8 During this time, cART is maintained to prevent de novo infection of 
bystander cell populations by induced HIV-1 virions. Several latency reversal agents (LRAs) have 
exhibited the ability to re-active transcriptionally silent proviral reservoirs. Histone deacetylase 
inhibitors (HDACi) are canonical LRAs capable of enabling reactivation through deacetylation of 
histones involved in chromatin condensation, thus creating a euchromatic environment.9,10 
Such strategies exhibit good tolerance in vivo, but largely fail to reduce the overall reservoir 
size.11,12 Combinational therapies including HDACi and PKC agonists may further potentiate the 
effect of these latency reversing agents (LRA).13 Alternatively, there have been an increasing 
number of studies that achieve in vitro latency reversal by targeting innate immune sensing 
molecules, such as toll-like receptors (TLR).14–17 Despite their modest effects, TLR agonists 
largely lack specificity and require additional investigation. Due to the poor therapeutic index of 
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currently available LRAs, there is an increasing need to discover novel avenues for potent 
induction of proviral transcription. 
The primary challenge with latency reversal is creating a novel therapeutic ‘shock’ that is both 
efficacious and well tolerated. This proves difficult as the predominant reservoir is thought to 
persist in HIV-specific CD4 T cells.18,19 Moreover, only a fraction of CD4 T cells harbour 
replication competent latent provirus, with approximately 97.6% of proviruses containing fatal 
mutations or deletions.20 More studies have recently sought to investigate the potential of DC-
mediated therapies to induce cell transcriptional reactivation, due to their low toxicity and high 
specificity.21 However, such approaches often fail to account for the viral quasi-species and 
therefore, MHC-II:peptide complexes may not sufficiently engage with all the HIV-specific TCRs 
present within the host. This becomes especially difficult with individuals diagnosed and 
treated during the chronic stage of infection, as this population will exhibit more diversity 
within their proviral reservoir. Despite this, evidence suggests that the replication competent 
viral reservoir is seeded around the time of cART initiation.22 With this in mind, we proposed 
that creating a virus-like particle formulation that encompasses the entire host quasi-species 
immediately prior to cART initiation would potently induce latency reversal within the 
replication-competent proviral reservoir. Previously, we have evaluated our activator vector 
(ACT-VEC) in donors diagnosed and treated during acute infection (refer to chapter 3).23 Our 
findings show that ACT-VEC potently stimulates transcriptional reactivation of CD4 T cell-
specific reservoir to a greater extent than clinically relevant HDACi and PKC agonist 
monotherapies. Now, we aim to evaluate ACT-VEC in donors diagnosed and treated during 
chronic infection, which represent the vast majority of individuals currently infected with HIV-1, 
today.  
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4.2 Materials and Methods: 
4.2.1 Experimental Design 
Our activator vector(ACT-VEC) formulation was created to potently induce cell transcriptional 
reactivation as part of a therapeutic HIV-1 curative strategy. These studies are based upon 
literature suggesting that the predominant latent reservoir is established within HIV-specific 
CD4 T cells.18 On this finding, we hypothesized that presenting peptides representative of a 
diverse HIV-1 pool could engage with the maximal number of HIV-specific TCRs on latently 
infected cells. To accomplish this, we developed a diverse virus-like particle (VLP) formulation 
representative of the viral quasi-species from several chronically infected, subtype D 
individuals. Particles were made using plasma from volunteers immediately prior to cART 
initiation. The objectives of this study are based on a previous study that revealed ACT-VEC was 
a potent LRA in donors identified and treated during acute infection. ACT-VEC will now be 
evaluated in the context of donors diagnosed and treated during chronic infection. To evaluate 
this, we will evaluate the latency reversing potential of ACT-VEC relative to alternative latency 
reversing regimens, such as: PKC agonists, HDACis, and CD3/CD28 agoists. Moreover, we aim 
identify if we can decrease immunogenicity through highly-specific targeting of HIV-specific T 
cells.  
4.2.2 Production of Virus-Like Particle Formulation: 
HIV-positive serum from subtype D donors was collected immediately prior to cART initiation 
for the preparation of virus-like particle formulations. Samples were collected during the 
chronic stage of infection. Viral RNA was extracted from cells using a Qiagen viral RNA 
extraction kit (Qiagen, USA) and reverse transcribed into cDNA using a High-Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems, USA). Reverse transcription utilized specific 
primers to create two cDNA fragments which, when combined, fully encompass the full length 
of HIV-1 genome. cDNA Fragments were subjected to a nested PCR protocol to create 
overlapping 5’ and 3’ fragments. A list of primers can be found in Table S1. Primers contained 
an Integrase (IN) mutation which generate an AAH>RRK substitution, rendering the integrase 
non-functional.23 The 5’ primer also contained mutations within the ψ packaging region 
(698C>T, 718C>G, 719G>T, 720G>C, 721C>G, 722AT, 723A>T, 724G>C, and 731G>A, referred to 
as dS.1), thus rendering the particles incapable of encapsidating viral genomic material. The 
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resulting genomic fragments were transfected into Saccharomyces cerevisiae at an equivalent 
ratio and with 2µg of SacII linearized pREC∆gag-U3/URA3 plasmid. The transformation yields 
triple-recombinant yeast colonies that replace U3/URA3 with a donor-derived near-full-length 
viral genome (pREC∆gag-U3/URA3 →pREC_nfl_SubD.dS1.INAAH>RRK). Selection of 
pREC_nfl_SubD.dS1.INAAH>RRK occurs on complete media lacking leucine (C-Leu) plates 
containing fluoroorotic acid (FOA). This vector formulation is devoid of a 5’ LTR, cannot 
encapsidate gRNA (due to the dS.1 mutation), and does not contain a functional integrase gene. 
Yeast mini-prep was performed on colonies to isolate plasmids prior to transformation into 
bacteria. Plasmids were purified using a MaxiPrep (Qiagen, USA) and transfected into Human 
embryonic kidney (HEK) 293T cells using Fugene-6 (Promega, USA) by following the 
manufacturer-provided protocols. VLPs resulting from transfection were centrifuged at 300g for 
10 minutes to remove any potentially contaminating cells. Cell-free supernatant containing 
VLPs were then run through a 100 KDa MWCO centrifuge tube (Amicon, USA) before 
ultracentrifugation at 40,000g. Pelleted VLPs were re-suspended in sterile PBS containing 2% 
heat-inactivated FBS. Verification of viral particles included, i) size and polydispersity analysis 
(dynamic light scattering), ii) p24 production, iii) packaging knockdown, and iv) RT activity. After 
all of the aforementioned steps are performed, virus-like particles are referred to as ACT-VEC.  
4.2.3 Isolation and culture of donor CD4 T lymphocytes and monocyte-derived dendritic cells 
(MDDCs):  
Peripheral blood mononuclear cells (PBMCs) were isolated from HIV-infected donors via density 
gradient centrifugation. For T cell purification, PBMCs were treated with magnetically-labeled 
microbeads to negatively select for CD4 T lymphocytes (CD4 T cell isolation kit, Miltenyi, Biotec, 
USA) as-per manufacturer instructions. Isolated cells are immediately used after purification. 
Purity of CD4 T cell isolations has been described elsewhere (refer to chapter 3).  
Monocyte-derived dendritic cells (MDDCs) were purified from PBMCs via 2-hour plastic 
adherence in a T-75 culture flask (Sarstedt, Ca) at 37oC, 5% CO2. After two hours, all media 
(RPMI; 10% FCS, 2mM L-Glutamine) containing non-adherent cells was removed and added to a 
separate T-75 flask. The adherent monocyte population received IL-4 (500 U/mL) and GM-CSF 
(1000 U/mL) for the duration of the 6-day maturation process to produce MDDCs. Halfway 
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through the maturation process (day 3), ½ of media was removed and centrifuged at 300g for 
10 minutes. Media was discarded, ensuring the cell pellet it uninterrupted, prior to 
replenishment with fresh media containing IL-4 and GM-CSF.  
4.2.4 IFN-γ ELISpot Assay 
Human IFN-γ enzyme-linked immunosorbent spot (ELISpot) assays (Mabtech, USA) were 
performed on MDDC+T cell co-cultures. Performance of the ELISpot assay abided by 
manufacturer’s protocol. Briefly, ELISpot plates are washed 5x with sterile PBS prior to being 
blocked with RPMI (10% FBS, 2mM L-Glutamine) for 30 minutes. Plates were washed 3x with 
sterile PBS before the addition of cells at a concentration of 1x106 CD4 T cells/mL. Plates 
containing stimulation were incubated for 16 hours. After incubation, culture supernatants 
were gently aspirated and removed for additional experiments. Wells were washed 3x with 
sterile PBS prior to addition of biotinylated anti-IFN-γ antibody (1 µg/mL) for 2 hours. After this 
time, plates were washed and streptavidin-HRP was added for 1 hour. Plates were washed and 
subjected to 100 µl/well TMB peroxidase (Millipore Sigma, USA) for up to 15 minutes. Plates 
dried for 24 hours prior to imaging and counting of spots. 
4.2.5 Latency Reversing Co-Culture Assay 
Briefly, MDDCs were pulsed on day 6 post-plastic adherence with, i) media, ii) 5 µg/mL (p24) of 
RT-equivalent ACT-VEC (subtype A,B, or D), iii) CMV-tetanus-flu (CTF) recall antigen [250 
ng/peptide/mL Flu M2 protein (bei Resources, USA), 2 μg/mL Tetanus toxoid (Statens Serum 
Institut, DK), 5 µg/mL pp65 HCMV peptide pool (NIH AIDS Reagent Program, USA)], or iv) or 
pooled malarial antigen. Fresh, autologous CD4-purified T cells were co-cultured with antigen-
pulsed MDDCs on day 7 following plastic adherence. Cells were co-cultured at a ratio of 4 T cells 
to 1 DC at a concentration of 1x106 CD4 T cells/mL (ie., 2.5x105 MDDC/mL). For conditions that 
did not require MDDC-pulsing (PMA/Ionomycin, αCD3/αCD28, HDACi), stimuli were added on 
day 7 directly to unpulsed MDDC-T cell co-culture at concentrations described previously (refer 
to chapter 3). All latency reversing agents were used at concentrations previously outlined 
within the literature. Enfurvitide (T20; 10 µM) was added to all co-cultures to prevent infection 
of bystander cell populations upon reactivation. Co-cultures were prepared in dilution plates 
before transfer and 16h incubation on IFN-γ ELISpot plates, as described previously. Upon 
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completion of ELISpot, co-cultured cells are removed from the ELISpot plates and added to a 
round bottom 96-well plate for a total length of 72 hours.  
4.2.6 Quantification of cell-free supernatant HIV-1 mRNA 
After a 72-hour total culture, plates were spun at 300g for 10 minutes and 0.2mL of cell-free 
supernatant was collected/well, which represents 2x105 CD4 T cells. Viral RNA is extracted from 
cell supernatant using a viral RNA isolation kit (Qiagen, USA). cDNA was synthesized using a 
high capacity cDNA reverse transcription kit (Applied Biosystems, Ca). Quantitative reverse 
transcription PCR (qRT-PCR) was performed using TaqMan Fast Advanced Master Mix (Applied 
Biosystems, Ca) on QuantStudio5 (Applied Biosystems, Ca). Briefly, 1µL of cDNA was diluted in 
19 µL of sterile H2O and added to 30 µL of TaqMan Fast Advanced Master mix as per the 
manufacturer instructions. Primers and probes can be found in Table S2. The standard curve 
was derived from 1/3 dilutions of XbaI-digested pREC_5’LTR-SBF-1 plasmid with a known 
concentration. For each dilution, 20 µl of standard is mixed with 30 µl of TaqMan master mix. 
The cycling conditions were as follows: 60oC for 2 minutes (1x), 95oC for 20 seconds (1x), 95oC 
for 1 second (40 cycles), 60oC for 43 seconds (40 cycles). Results were analyzed using GraphPad 
Prism (GraphPad Software, USA). 
4.2.7 Statistical Analysis: 
Herein, P < 0.05 was used as a threshold for statistical significance. Mann-Whitney non-
parametric T test or Wilcoxon matched pairs signed rank tests were used to test for intra- and 
intersample significance, as indicated throughout. Correlative data was interpreted using a two-
tailed Spearman Rank Correlation. Only donors who exhibited sustained suppression of viral 
loads (>6 months before sample donation) were enrolled in this study. No blinding was 
performed in this study as all samples were treated identically throughout testing.  
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4.3 Results 
4.3.1 ACT-VEC potently induces latency reversal during chronic stage infection. 
As most individuals are diagnosed and cART-treated during the chronic stage of infection, there 
exists a need for novel therapeutics capable of potently inducing latency reversal at this stage 
of infection. During primary infection, activated cells may undergo death via caspase-1/3-
mediated events, die from viral cytopathic effects or, alternatively, transition to a memory 
phenotype that facilitates cell survival.7,24–26 The latent reservoir is primarily established in CD4 
T cells with HIV-specific TCRs, as these cells respond to infection and therefore make ideal, 
permissive targets.18,19 More recent studies have confirmed that antigen-specific clones 
contribute to the latent reservoir and further suggest that repeat exposure to recall antigens 
contribute to reservoir persistence.27 The timing of cART initiation also provides insight, as 
majority of the replication competent reservoir is established during this period.22 Such findings 
suggest that the creation of a heterogenous virus-like particle (VLP) formulation that 
encompasses the viral quasi-species immediately prior to cART initiation may optimally 
stimulate latency reversal of HIV-specific CD4 T cells.28 
The activator vector (ACT-VEC) formulations presented herein are based on previous findings 
that ACT-VEC can potently induce latency reversal at the acute stage of infection (Mann et al., 
2020; manuscript accepted). ACT-VEC contains all viral proteins, is morphologically identical to 
wildtype HIV-1, and lacks viral genomic material thus rendering it non-infectious.28 In this study, 
our VLP formulation was developed using HIV-positive sera from chronically-infected, subtype 
D donors (referred to as ACT-D). Plasma was collected from donors immediately prior to cART 
initiation, as VLPs derived during this period may optimally stimulate CD4 T cells harboring 
replication competent provirus.  
The ability of ACT-D to induce latency reversal was evaluated using PBMCs from cART-treated, 
chronically-infected, subtype D donors (ChrD-cART). Monocyte-derived dendritic cells (MDDC) 
from ChrD-cART individuals (n=4) were pulsed with ACT-D (5 µg/mL) and subsequently co-
cultured with autologous CD4 T cells (1x106 cells/mL). Culture supernatants were harvested 
after 3 days post-stimulation to detect viral 5’ LTR RNA via qRT-PCR. All stimulation conditions 
received the HIV-1 fusion inhibitor, enfurvitide (T20; 10 µM) to protect bystander cells from de 
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novo infection upon reactivation. Across the enrolled study participants, ACT-D induced an 
average 6.70- and 26.47-fold increase in detectable culture supernatant RNA relative to the 
global T cell activators, PMA/Ionomycin and αCD3/αCD28, respectively (Figure 4-1 a,b). 
Notably, latency reversal was achieved in all donors (4/4) treated with ACT-D-pulsed MDDC, 
compared to 50% (2/4) and 75% (3/4) of PBMCs treated with PMA/Ionomycin or αCD3/αCD28. 
Interestingly, latency reversal was comparable between ACT-D and ACT-B, despite the latter 
preparation being from a different subtype. This finding may suggest that there is a large 
degree of overlap in the TCR specificity of CD4 T cells responding to subtype D and B infections. 
Moreover, ACT-VEC therapies, on average, were better inducers of HIV RNA production relative 
to non-HIV-1 antigen cocktails, such as malarial pool antigen or CMV/tetanus/flu (CTF). 
Significance could not be ascertained due to the limited number of donors. 
To determine the antigenicity of the various latency reversing agents, MDDC-T cell co-cultures 
were performed in 96-well IFN-γ ELISpot plates. MDDC were cultured with T cells at a ratio of 
1:4, wherein T cells were seeded at a concentration of 1x106 cells/mL. Despite heightened viral 
RNA production, ACT-VEC formulations maintain low antigenicity relative to other T cell 
activators, including alternative peptide:MDDC formulations (malaria, CTF) (Figure 4-1 c,d). All 
non-ACT-VEC therapies were significantly more antigenic than the media control (p<0.05), 
whereas ACT-D (p=0.4857) and ACT-B (p=0.4286) did not differ significantly. The ratio of 
induced viral copies to IFN-γ SFUs indicates the relative amount of RNA release per activated 
cell (Figure 4-1e). If the reservoir has high specificity for a specific subset of memory cells (ie. 
HIV-specific memory CD4 T cells), the ratio should be highest for that condition. With this in 
mind, it is evident that ACT-VEC therapies exhibit higher ratios than alternative regimens.  
As mentioned in chapter 3, it is important to note that culture supernatant RNA was detected 
using primers specific for the 5’ LTR (R-U5) of HIV-1. As this region is absent within ACT-VEC 
formulations, qRT-PCR will only detect the presence of induced virus and not ACT-VEC. The 
inability to detect ACT-VEC VLPs using our qRT-PCR has been detailed elsewhere (refer to 
chapter 3). 
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Herein, we identify that latency reversal can be achieved in ChrD-cART donors using inter- and 
intra-subtype ACT-VEC formulations. Based on the assumption that a majority of latent provirus 
resides within the HIV-specific CD4 T cell population, it is possible to hypothesize that the 
similar latency-reversing potential of ACT-B and ACT-D is due to a high degree of similarity in 
TCR specificity across subtypes. However, it is important to note that latency reversal is also 
achieved with malarial antigens and CTF. This cohort has likely encountered malaria, CMV, flu, 
or tetanus at some point during their life as a result of natural exposure or vaccination. Based 
on this, it is possible that CD4 T cells with alternative TCR specificities were active during the 
period of untreated HIV infection, thus facilitating latency establishment in alternative CD4 T 
cell reservoirs. Despite this, a majority of viral reactivation is achieved in the ACT-treated 
conditions. Moreover, stimulation with global T cell activators were less efficient than any 
MDDC-pulsed antigen conditions. This finding is in line with other studies indicating that latency 
reversal is best achieved in the context of TCR stimulation.21,29,30 
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Figure 4-1: ACT-VEC potently induces latency reversal in chronically-infected, patient-derived 
samples. 
cART-treated donors (n=4) diagnosed and treated during chronic infection that exhibited viral 
suppression (<50 copies/mL) were enlisted in this study. All studies in this cohort are performed 
on subtype D individuals. ACT-B (5 µg/mL) and ACT-D (5 µg/mL) were inter- and intra-subtype 
specific stimuli used to pulse autologous MDDCs. Malaria (1 µg/mL) and CTF (CMV, Tetanus 
toxoid, Flu M1) were used as non-HIV-specific stimuli for MDDC pulsing. αCD3/αCD28 and 
PMA/Ionomycin served as assay positive controls and media served as a negative. (a) qRT-PCR 
of RNA collected from viral supernatant 3 days after co-culture. qRT-PCR values are background 
subtracted. (b) Grouped means were calculated for each of the co-culture conditions. (c) 
MDDCs were pulsed with any of ACT-B, ACT-D, malarial antigen, or CTF and subsequently co-
cultured with autologous CD4 T cells. PMA/Ionomycin and αCD3/αCD28 serve as assay controls. 
Antigenicity of stimuli on CD4 T cells was calculated by measuring IFN-γ spot forming units 
(SFUs). (d) Averages of IFN-γ SFUs for each stimulus were calculated. (e) The amount of 
detectable HIV-1 culture supernatant RNA was compared to the antigenicity of each stimuli as a 
ratio (copy number:SFU). Grouped samples were used to determine mean effect (+- SEM) of the 
stimulations. Statistical significance was determined using the Mann-Whitney unpaired T test.  
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4.3.2 ACT-VEC induces latency to a similar or greater degree than HDACi, TLR agonist, and PKC 
agonist monotherapies.  
Through evaluation of MDDC-pulsed latency reversal strategies, we have identified that ACT-
VEC formulations are potent reactivators of proviral transcription using ChrD-cART PBMCs. We 
now seek to compare the potency of our ACT-VEC-mediated latency reversing response to 
clinically relevant LRAs which have been the focus of many clinical and pre-clinical trials.13,31,32 
For each latency reversing agent, dosing was first performed in the latently infected Jurkat cell 
line, J-Lat 6.3, as described previously (refer to chapter 3). Unpulsed, ChrD-cART-derived MDDC 
(n=4) was co-cultured with autologous CD4 T cells (1x106 CD4 T cell/mL) in the presence of the 
various monotherapies. Culture supernatants were collected after 3 days of cell culture and 
analyzed for viral RNA via qRT-PCR. Through stimulation with histone deacetylase inhibitors, 
latency reversal was consistently detected in 2/4 individuals (Figure 4-2 a,b). Alternatively, TLR 
7&8 monotherapies, such as ssRNA, Imiquimod, or GS-9620 displayed a lesser ability to induce 
detectable RNA in culture supernatants. Although significance could not be obtained due to 
small sample size, it is important to note that, in contrast to the selected monotherapies, all 
ACT-pulsed MDDC co-cultures exhibited latency reversal. 
Despite their variable ability to induce transcriptional reactivation, most monotherapies except 
for Bryostatin (p<0.05) maintained similarly low levels of IFN-γ production (Figure 4-3c). This is 
in-line with previous findings indicating that these regimens are well-tolerated in vivo.33–36 
However, when considering each monotherapy in the context of latency reversal, we can 
conclude that ACT-VEC formulations are at least as potent, if not more. This may be due to 
potent induction of T cells stimulated through the TCR, as opposed to alternative mechanisms 
of reactivation.  
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Figure 4-2: ACT-VEC can potently induce latency reversal to a similar or greater degree than 
other latency reversing agents. 
ACT-VEC-pulsed MDDC were co-cultured with autologous CD4 T cells from HIV infected donors 
(n=4). Comparisons were made to clinically relevant latency reversing agents (LRA; HDACi, TLR 
agonist, PKC agonist) and T cell mitogens, including: SAHA, Panobinostat, Romidepsin, 
Bryostatin, ssRNA, Imiquimod, GS-9620, αCD3/αCD28, and PMA/Ionomycin. (a) Viral 
supernatants were collected and evaluated for the presence of viral RNA via qRT-PCR after 3 
days post-stimulation. (b) Group median of each stimulation condition from (a). (c) Antigenicity 
was determined using IFN-γ ELISpot after overnight stimulation with pulsed MDDC, LRA, or T 
cell mitogen. ELISpot conditions were performed in duplicate at 1x105 CD4 T cells/well. (d) 
Grouped mean antigenicity of each condition group, represented as spot forming units per 
million cells (+-SEM).  
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4.3.3 ACT-VEC induces comparably more latency reversal during chronic stage infection 
Previous studies conducted by our group evaluated HIV-1 latency reversal in the context of an 
acutely-infected donor cohort (refer to chapter 3). Transcriptional reactivation of individuals 
diagnosed and treated during the acute stage of infection represent the ‘ideal’ model for 
latency reversal. Specifically, during acute infection there are fewer opportunities for mutations 
within the viral genome and, as a direct consequence, fewer variants capable of escaping 
immune-mediated clearance upon reactivation. Mutations also contribute to viral diversity and, 
therefore, increase the number of CD4 T cells that can detect HIV-derived viral antigens. During 
acute infection, there are also fewer opportunities for co-infection with opportunistic 
pathogens. Co-infection facilitates the seeding of alternative reservoirs due to activation of T 
cell subsets with non-HIV-specific TCRs. The chronic cohort may also experience heightened 
levels of T cell anergy following cellular activation, further complicating cure at later stages of 
disease.37 Consequently, the requirements of a therapeutic vaccine candidate become 
increasingly vague as HIV-1 infection continues in the absence of cART. 
To evaluate the differential effect of ACT-VEC-induced transcriptional reactivation during acute 
and chronic infection, culture supernatant qRT-PCR was compared (Figure 4-3). At the chronic 
stage of infection, ACT-VEC had an ~4 log increase in mean detectable supernatant RNA 
(****p<0.0005). This observation may be attributed to several factors. Firstly, the proviral 
reservoir in chronically-infected donors is expected to be substantially larger than during acute 
infection due to the prolonged absence of cART. Despite this, the diversity present within ACT-
VEC formulations will ensure activation of many HIV-specific TCRs, including mutational 
variants.  
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Figure 4-3: Comparison of ACT-VEC mediated latency reversal during the acute and chronic 
stages of infection. 
Culture supernatants were collected 3 days after co-culture and evaluated for the presence of 
viral RNA using qRT-PCR. Donors from the acute (n=9) and chronic (n=10) stage of infection are 
represented as individual dots on the graph. A media control was used to determine the 
amount of background RNA detected in culture. Bars represent the median value within each 
population. Statistical analysis was performed using a Mann-Whitney unpaired T test 
(****p<0.005).  
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4.4 Discussion 
Addressing the HIV-1 latent reservoir remains of the utmost importance for potential curative 
strategies. Latency is well-maintained over time due to several factors, including i) integration 
in sites of low transcriptional activity, ii) downregulation of host transcription factors, iii) 
through epigenetic modifications, and iv) through homeostatic proliferation.29,38 Since the 
identification of the latent reservoir in the mid-90s, many different approaches have 
successfully induced transcriptional reactivation of the predominant CD4 T cell reservoir, albeit 
to varying degrees.34–36,39,40 However, most LRAs fail to induce an immune-mediated ‘kill’ upon 
transcriptional reactivation, thus leading to a non-significant reduction in reservoir size. 
Contrarily, many of these latency-reversing strategies (such as HDACi) induce the production of 
pro-survival proteins, such as Bcl-2, and therefore prevent death via NK- and CD8-mediated 
cytotoxic responses.41 In vitro studies of HDACi show that these drugs may directly inhibit 
proper functioning of cytotoxic cells.42,43 Other regimens, such as PKC agonists, have shown a 
poor ability to reduce the reservoir size, in vivo.35 Furthermore, these LRAs function through 
non-specific activation of T cells and may therefore heighten immune inflammation. The 
shortcomings of relevant LRA-based strategies suggest that there is a need for novel 
alternatives.  
The complications associated with latency reversal are exacerbated during chronic-stage 
infection. Specifically, the longer HIV infected individuals remain untreated, the larger and 
more genetically diverse their latent proviral reservoirs become. Compared to acute infection, 
individuals diagnosed during chronic infection experience more opportunities for antigenic 
exposure to non-HIV peptides. In the absence of ART, exposure to these alternative peptides 
can contribute to seeding within non-HIV-specific T cell subsets. Furthermore, CD4 T cells 
isolated from the chronic stage of infection have previously been shown to exhibit heightened 
levels of anergy or dysfunction as a result of chronic immune activation.37,44 As most individuals 
are diagnosed and cART-treated during chronic infection, this stage represents the primary 
focus of the curative vaccine research published to date.  
At the acute stage of infection, we have previously shown that ACT-VEC induces transcriptional 
reactivation to a greater extent than HDACi and PKC agonist monotherapies (refer to chapter 
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3). This model is idealized, as early cART initiation limits reservoir establishment and, 
additionally, reduces the degree of viral diversity in seeded reservoirs.45 Importantly, this study 
is in-line with our previous study and with existing literature which suggests that HIV provirus 
has a substantial reservoir in T cells with HIV-specific TCRs.18,19 Based on these findings, we 
evaluated our inter- (ACT-B) and intra- (ACT-D) subtype virus-like particle formulations in the 
context of individuals diagnosed and cART-treated during the chronic stage of  infection. This 
would expand on our data from the acute stage of HIV infection while also enabling us to 
determine whether a clade-specific or heterologous clade-based ACT-VEC would be more 
efficient at causing HIV latency reversal. We hypothesized that the optimal induction of latency 
reversal would require a highly matched, heterogenous, intra-subtype VLP formulation created 
using sera from HIV-infected individuals immediately prior to cART initiation. To that end, we 
stimulated clade D CD4 T cells with HIV-specific TCRs using clade B and D ACT-VEC pulsed 
MDDCs. We believed that ACT-D would outperform ACT-B a inducing latency reversal from 
ChrD-cART CD4 T cells due to the high amount of inter-subtype variability – approximately 25-
35%.46 Owing to this variability, ACT-B should lack many of the HIV-specific peptides required to 
induce transcriptional reactivation within ChrD-cART donors. Surprisingly, ACT-B and ACT-D 
induced comparable levels of latency reversal (Figure 4-1 a,b). This result was contrary to our 
hypothesis and may suggest that HIV-specific TCRs preferentially recognize immunodominant 
peptides that are present within both VLP formulations. Interestingly, similar responses cannot 
be achieved using pooled HIV-peptides (data not shown). Reasons for this could be, i) poor 
uptake or presentation of peptides, ii) poor peptide stability, or iii) a lack of diversity.  
Determining donor HLA type would help address this phenomenon, although this information is 
not available for the donors presented herein.  Additionally, this could be addressed by 
identifying which peptides are presented by the donors’ APCs simply by eluting them from MHC 
and detecting by Mass Spectrometry. These peptides could then be evaluated against known 
HIV immunodominant peptides. The matching immunodominant peptides could then be 
evaluated in latency reversal studies in clade B and D patient samples.    
In this chapter, ACT-VEC clade D formulations were compared to clinically relevant LRAs to 
determine the efficacy of each approach. Because the function of HDACi and PKC agonists are 
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targeted towards CD4 T cells, these stimulations received un-pulsed MDDCs during co-culture. 
Un-pulsed MDDC-T cell co-culture, alone, was unable to induce latency reversal, as we were 
unable to detect viral budding through analysis of viral RNA in culture supernatants.  
Alternatively, HDACi and PKC agonists were able to induce latency reversal, albeit in a smaller 
proportion of donors relative to ACT-VEC. Interestingly, viral RNA was readily detectable in 
culture supernatants from samples pulsed with CTF (CMV/Tetanus/Flu) and malarial antigens, 
respectively. This indicates that, within this chronic-stage cohort, alternative, non-HIV-specific 
CD4 T cell reservoirs may have become established in response to opportunistic infections in 
the absence of cART. To identify differences between these latency reversing strategies, deep 
gene sequencing will be performed on outgrowth virus collected from each condition. This data 
will be compared to proviral sequences information and quantitative viral outgrowth (qVOA) 
data. Moreover, next generation technologies, such as the FISH/Flow assay and the intact 
proviral DNA assay (IPDA), will provide additional insight into the efficacy of our ‘shock-and-kill’ 
approach.47,48 
In summation, we demonstrate that inter- and intra-subtype ACT-VEC formulations efficiently 
reactivate quiescent HIV-1 provirus in a ChrD-cART infected cohort. This information further 
suggests that TCR-mediated latency reversal is in response to immunodominant peptides or 
HLA molecules, although this finding requires additional investigation. Our study finds that a 
majority of latent provirus resides in the HIV-specific reservoir, although opportunistic 
infections prior to cART initiation may contribute to alternative reservoir seeding. Continuation 
of this study will aim to increase the number of ChrD-cART samples available for testing, 
followed by pre-clinical, in vivo modeling. The cumulative data suggests that ACT-VEC is a 
potent latency reversing agent that merits further investigation. 
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4.5 Tables 
Table 4-1S. List of primers for VLP construct development 
 Primer 
Name 
Directionality Sequence 
 INTR2 
A,B,C 
3’ CAATCATCACCTGCCATCTGTTTTCCATAATCCCTGAT
GATCTTTGCGTGTGCTGCTGGCACTACTTTTATGTC 
5’ Nested 
Set 
PRIMERF
A 
5’ GGCGGCGACTGGTGAGTACGCCAAAAATTTTGACTA
GCGGAGGCTAGAAGGAGAGAGATGG 
 PRIMER_
F.AB 
5’ AGCGGCGACTGGTGAGTACGCCTTTTTTGACTAGCGG
AGGCTAGAAGGAGAGAGATGG 
 0776FC 5’ CTAGAAGGAGAGAGAGATGGGTGCGAG 
 
3’ Nested 
Set 
 
INTF2.AD 
 
5’ 
ATACAGGATAATCAGGATATAAAGGTAGTGCCCGCA
GCACATGCAAAGATCATTAGGGATTATGGAAAACAG
ATG 
  
47MD 
 
3’ 
 
TCCCTAGTTAGCCAGAGAGCTCCC 
 
A-D Matching superscript indicates a specific primer set was used for the making of a VLP formulation in at least 
one donor sample. All preparations used the same 3’ nested set (denoted ‘D’).  
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Table 4-2S. List of probes and primers for qRT-PCR 
Primer Name Primer Type Sequence 
Sub AD Gag Probe 
 
Probe TCTGTTGTGTGACTCTGGTAACTAGAGATCCCTCAGACC 
Sub AD 5’ LTR PA Forward Primer CCCACTGCTTAAGCCTCAATAAAGC 
Sub AD GagR Reverse Primer AGCTCCCTGCTTGCCCATACTA 
*Concentrations are as follows: Probe = 100 nM, Primers Forward/Reverse = 600 nM. 
  
 
168 
 
4.6 References 
1. Spivak, A. M. & Planelles, V. Novel Latency Reversal Agents for HIV-1 Cure. Annu. Rev. 
Med. (2018). doi:10.1146/annurev-med-052716-031710 
2. Chomont, N. et al. HIV reservoir size and persistence are driven by T cell survival and 
homeostatic proliferation. Nat. Med. (2009). doi:10.1038/nm.1972 
3. Hosmane, N. N. et al. Proliferation of latently infected CD4+ T cells carrying replication-
competent HIV-1: Potential role in latent reservoir dynamics. J. Exp. Med. (2017). 
doi:10.1084/jem.20170193 
4. Whitney, J. B. et al. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus 
monkeys. Nature 512, 74–77 (2014). 
5. Strain, M. C. et al. Effect of Treatment, during Primary Infection, on Establishment and 
Clearance of Cellular Reservoirs of HIV-1. J. Infect. Dis. (2005). doi:10.1086/428777 
6. Eriksson, S. et al. Comparative Analysis of Measures of Viral Reservoirs in HIV-1 
Eradication Studies. PLoS Pathog. (2013). doi:10.1371/journal.ppat.1003174 
7. Sengupta, S. & Siliciano, R. F. Targeting the Latent Reservoir for HIV-1. Immunity (2018). 
doi:10.1016/j.immuni.2018.04.030 
8. Chun, T. W. et al. In vivo fate of HIV-1-infected T cells: Quantitative analysis of the 
transition to stable latency. Nat. Med. (1995). doi:10.1038/nm1295-1284 
9. Jiang, G., Espeseth, A., Hazuda, D. J. & Margolis, D. M. c-Myc and Sp1 Contribute to 
Proviral Latency by Recruiting Histone Deacetylase 1 to the Human Immunodeficiency 
Virus Type 1 Promoter. J. Virol. (2007). doi:10.1128/jvi.01208-07 
10. Verdin, E., Paras, P. & Van Lint, C. Chromatin disruption in the promoter of human 
immunodeficiency virus type 1 during transcriptional activation. EMBO J. (1993). 
doi:10.1002/j.1460-2075.1993.tb05994.x 
11. Sagot-Lerolle, N. et al. Prolonged valproic acid treatment does not reduce the size of 
latent HIV reservoir. AIDS (2008). doi:10.1097/QAD.0b013e3282fd6ddc 
12. Shirakawa, K., Chavez, L., Hakre, S., Calvanese, V. & Verdin, E. Reactivation of latent HIV 
by histone deacetylase inhibitors. Trends in Microbiology (2013). 
doi:10.1016/j.tim.2013.02.005 
13. Laird, G. M. et al. Ex vivo analysis identifies effective HIV-1 latency-reversing drug 
combinations. J. Clin. Invest. 125, 1901–1912 (2015). 
14. Alvarez-Carbonell, D. et al. Toll-like receptor 3 activation selectively reverses HIV latency 
in microglial cells. Retrovirology (2017). doi:10.1186/s12977-017-0335-8 
15. Thibault, S., Imbeault, M., Tardif, M. R. & Tremblay, M. J. TLR5 stimulation is sufficient to 
trigger reactivation of latent HIV-1 provirus in T lymphoid cells and activate virus gene 
expression in central memory CD4+ T cells. Virology (2009). 
 
169 
 
doi:10.1016/j.virol.2009.04.019 
16. Novis, C. L. et al. Reactivation of latent HIV-1 in central memory CD4+ T cells through 
TLR-1/2 stimulation. Retrovirology (2013). doi:10.1186/1742-4690-10-119 
17. Macedo, A. B. et al. Dual TLR2 and TLR7 agonists as HIV latency-reversing agents. JCI 
insight (2018). doi:10.1172/jci.insight.122673 
18. Douek, D. C. et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature 417, 95–98 
(2002). 
19. Demoustier, A. et al. In patients on prolonged HAART, a significant pool of HIV infected 
CD4 T cells are HIV-specific. AIDS 16, 1749–1754 (2002). 
20. Bruner, K. M. et al. Defective proviruses rapidly accumulate during acute HIV-1 infection. 
Nat. Med. (2016). doi:10.1038/nm.4156 
21. Kristoff, J., Rinaldo, C. R. & Mailliard, R. B. Role of dendritic cells in exposing latent HIV-1 
for the kill. Viruses (2019). doi:10.3390/v12010037 
22. Abrahams, M. R. et al. The replication-competent HIV-1 latent reservoir is primarily 
established near the time of therapy initiation. Sci. Transl. Med. (2019). 
doi:10.1126/scitranslmed.aaw5589 
23. Pankrac, J. et al. A heterogeneous human immunodeficiency virus-like particle (VLP) 
formulation produced by a novel vector system. npj Vaccines 3, 2 (2018). 
24. Chun, T. W. et al. In vivo fate of HIV-1-infected T cells: Quantitative analysis of the 
transition to stable latency. Nat. Med. 1, 1284–1290 (1995). 
25. Stewart, S. A., Poon, B., Song, J. Y. & Chen, I. S. Y. Human Immunodeficiency Virus Type 1 
Vpr Induces Apoptosis through Caspase Activation. J. Virol. (2000). 
doi:10.1128/jvi.74.7.3105-3111.2000 
26. Cicala, C. et al. HIV-1 envelope induces activation of caspase-3 and cleavage of focal 
adhesion kinase in primary human CD4+ T cells. Proc. Natl. Acad. Sci. U. S. A. (2000). 
doi:10.1073/pnas.97.3.1178 
27. Mendoza, P. et al. Antigen responsive CD4+ T cell clones contribute to the HIV-1 latent 
reservoir. bioRxiv 2020.01.10.902155 (2020). doi:10.1101/2020.01.10.902155 
28. Pankrac, J. et al. A heterogeneous human immunodeficiency virus-like particle (VLP) 
formulation produced by a novel vector system. npj Vaccines 3, (2018). 
29. Mohammadi, P. et al. Dynamics of HIV Latency and Reactivation in a Primary CD4+ T Cell 
Model. PLoS Pathog. 10, (2014). 
30. van Montfort, T. et al. Dendritic cells potently purge latent HIV-1 beyond TCR-
stimulation, activating the PI3K-Akt-mTOR pathway. EBioMedicine (2019). 
doi:10.1016/j.ebiom.2019.02.014 
 
170 
 
31. Bullen, C. K., Laird, G. M., Durand, C. M., Siliciano, J. D. & Siliciano, R. F. New ex vivo 
approaches distinguish effective and ineffective single agents for reversing HIV-1 latency 
in vivo. Nat. Med. 20, 425–429 (2014). 
32. Rasmussen, T. A. & Lewin, S. R. Shocking HIV out of hiding: Where are we with clinical 
trials of latency reversing agents? Current Opinion in HIV and AIDS (2016). 
doi:10.1097/COH.0000000000000279 
33. Søgaard, O. S. et al. The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo. PLoS 
Pathog. 11, (2015). 
34. Archin, N. M. et al. Administration of vorinostat disrupts HIV-1 latency in patients on 
antiretroviral therapy. Nature 487, 482–485 (2012). 
35. Gutiérrez, C. et al. Bryostatin-1 for latent virus reactivation in HIV-infected patients on 
antiretroviral therapy. AIDS 30, 1385–92 (2016). 
36. Archin, N. M. et al. Interval dosing with the HDAC inhibitor vorinostat effectively reverses 
HIV latency. J. Clin. Invest. (2017). doi:10.1172/JCI92684 
37. Meyaard, L., Schuitemaker, H. & Miedema, F. T-cell dysfunction in HIV infection: anergy 
due to defective antigen-presenting cell function? Immunol. Today (1993). 
doi:10.1016/0167-5699(93)90279-T 
38. Mbonye, U. & Karn, J. The Molecular Basis for Human Immunodeficiency Virus Latency. 
Annu. Rev. Virol. (2017). doi:10.1146/annurev-virology-101416-041646 
39. Elliott, J. H. et al. Short-term administration of disulfiram for reversal of latent HIV 
infection: a phase 2 dose-escalation study. Lancet HIV (2015). doi:10.1016/S2352-
3018(15)00226-X 
40. Rasmussen, T. A. et al. Comparison of HDAC inhibitors in clinical development: effect on 
HIV production in latently infected cells and T-cell activation. Hum. Vaccin. Immunother. 
9, 993–1001 (2013). 
41. Kim, Y., Anderson, J. L. & Lewin, S. R. Getting the “Kill” into “Shock and Kill”: Strategies to 
Eliminate Latent HIV. Cell Host and Microbe (2018). doi:10.1016/j.chom.2017.12.004 
42. Pace, M. et al. Histone Deacetylase Inhibitors Enhance CD4 T Cell Susceptibility to NK Cell 
Killing but Reduce NK Cell Function. PLoS Pathog. (2016). 
doi:10.1371/journal.ppat.1005782 
43. Jones, R. B. et al. A Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4 
+ T-Cells to Recognition by Cytotoxic T-Lymphocytes. PLoS Pathog. (2016). 
doi:10.1371/journal.ppat.1005545 
44. Sousa, A. E., Carneiro, J., Meier-Schellersheim, M., Grossman, Z. & Victorino, R. M. M. 
CD4 T Cell Depletion Is Linked Directly to Immune Activation in the Pathogenesis of HIV-1 
and HIV-2 but Only Indirectly to the Viral Load. J. Immunol. (2002). 
doi:10.4049/jimmunol.169.6.3400 
 
171 
 
45. Buzon, M. J. et al. Long-Term Antiretroviral Treatment Initiated at Primary HIV-1 
Infection Affects the Size, Composition, and Decay Kinetics of the Reservoir of HIV-1-
Infected CD4 T Cells. J. Virol. (2014). doi:10.1128/jvi.01046-14 
46. Taylor, B. S., Sobieszczyk, M. E., McCutchan, F. E. & Hammer, S. M. The challenge of HIV-
1 subtype diversity. New England Journal of Medicine (2008). 
doi:10.1056/NEJMra0706737 
47. Bruner, K. M. et al. A quantitative approach for measuring the reservoir of latent HIV-1 
proviruses. Nature (2019). doi:10.1038/s41586-019-0898-8 
48. Baxter, A. E. et al. Single-Cell Characterization of Viral Translation-Competent Reservoirs 
in HIV-Infected Individuals. Cell Host Microbe (2016). doi:10.1016/j.chom.2016.07.015 
 
 – General Discussion 
5.1 General Discussion 
Despite ongoing efforts, the development of an efficacious vaccine for HIV-1 cure remains 
elusive. Therefore, in the absence of a cure, HIV will remain a global health concern, especially 
since 37.9 million individuals are currently living with HIV.1 The advent of antiretroviral therapy 
has converted the HIV-related death sentence into a lifetime manageable chronic illness, and 
has been acknowledged by the World Health Organization as a cornerstone feature in efforts to 
stunt new infections and prolong life for affected individuals. The 90-90-90 initiative, which is 
based on the success of ART, aims for 90% of HIV-infected individuals to, i) know their HIV 
status, ii) receive ART, and iii) exhibit sustained viral suppression. While the original 2020 goal 
was not met, more people are aware of their seropositive status (~79%) and accessing 
treatment (~62%), worldwide.1 Furthermore, death from AIDS-related causes has decreased by 
33% between 2010-2019.1 Unfortunately, this is not enough. If we compare the rate of new 
infections (1.7 million) and morality (770 000) for 2018, it becomes clear that the number of 
people burdened by infection is, in fact, rising. This suggests that HIV-1 is becoming increasingly 
onerous on economic and social frontiers. The UNAIDS estimates that $26.2 billion USD will be 
required for AIDS-response and drug-access initiatives, representing an increase of 38% since 
2018, alone. Additionally, access and maintenance of antiretroviral therapy is not universally 
achievable. Specifically, low socioeconomic status is strongly associated with non-adherence to 
cART after initial diagnoses.2 In this UK-based study, factors such as, sexual orientation, ethnic 
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origin, age, and financial instability all contributed to a rate of 32% non-adherence within the 
population.2 In impoverished nations, including many in sub-Saharan Africa, this finding 
suggests a less-than-promising outcome to the HIV crisis. Truly, there remains a need for the 
development of novel therapeutics capable of preventing de novo infection or facilitating cure.  
To date, only two individuals, the Berlin and London Patient, are considered either cured or in 
long-term remission.3–5 In both instances, individuals received hematopoietic stem cell 
transplants from homozygous CCR5∆32/32 donors, which may have prevented entry of CCR5-
tropic virus into the transplanted CD4 T cells due to abrogation of co-receptor binding. Despite 
two undeniable successes in the field of cure research, this approach is not feasible at scale. 
The transplant procedure-associated risks (i.e. drug toxicity, opportunistic infections, graft 
rejection) greatly outweigh the necessity to take lifelong cART. Furthermore, in certain 
individuals receiving treatment, there are documented cases of post-treatment viral rebound or 
even death.6–8 Moreover, these regimens require advanced medical training and facilities that 
may not be available or are limited in many regions, such as in sub-Saharan Africa. Despite the 
drawbacks, such studies have provided tantalizing evidence that cure is, in fact, achievable, 
although its usefulness is limited on a global scale. 
A major hurdle to achieving HIV-1 cure is the prevalence of stably integrated provirus within 
host memory CD4 T cells. These reservoirs can exhibit high stability (t1/2=44 months), indicating 
that latent pools are unlikely to extinguish naturally during continuous antiretroviral 
treatment.9 As these cells are transcriptionally inactive, they do not produce viral RNA and 
proteins essential for recognition by the host immune system. Although many latent proviruses 
harbour large internal deletions and/or non-functional mutations, a small proportion (~2.4%) 
are replication competent and represent primary targets for curative strategies.10 Many latency 
reversing drugs, such as HDACi, aim to overcome key epigenetic barriers, including chromatin 
condensation or integration into sites of low transcriptional activity. Despite in vitro success, 
many of these regimens have failed to translate into an efficacious LRA, in vivo.11–13 
Alternatively, PKC regimens suffer from high toxicity and low therapeutic index, in vivo.14 More 
recent research has suggested that dendritic cell-based therapeutic regimens may be more 
efficacious and better tolerated.15 This supports the finding that latency reversal within the 
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memory CD4 T cell reservoir is best achieved through TCR stimulation with HIV-derived 
peptides.16,17 Importantly, the timing of ART initiation is crucial, as seeding of the replication 
competent reservoir occurs around this time.18 Based on these findings, we hypothesized that 
latency reversal be optimally achieved using a virus-like particle formulation encompassing the 
host quasi-species immediately prior to cART initiation.  
5.2 Development of a highly diverse virus-like particle formulation 
Killed/attenuated vaccines have shown success in the fight against many communicable 
diseases. However, concerns are still present for attenuated vaccines, which have the potential 
to revert back towards virulence.19 Additionally, inactivation with AT-2 or UV irradiation may 
alter the antigenicity and glycoprotein conformation of the vaccine formulation.20 Therein lies a 
need to develop safer, more antigenic formulations. To address this, we developed a highly 
heterogenous, sub-type B virus-like particle formulation (Het_B_ACT-VEC) for use in 
therapeutic vaccine regimens. ACT-VEC is designed to act as a transcriptional ‘shock’ as part of a 
‘shock-and-kill’ strategy for HIV-1 eradication.  
Our ACT-VEC formulation aims to overcome safety barriers that are commonly associated with 
particle-based vaccine formulations, while conveying the maximum number of unique peptides 
for MHC-mediated TCR engagement. Firstly, ACT-VEC lacks a functional 5’ LTR, including the 
Tat-transactivating response region. These particles were shown to be non-infectious and 
unable to complete reverse transcription.20,21 Secondly, viral RNA was removed from particles 
through mutation of stem loop 1 (dS.1) in the RNA packaging element, thus abrogating RNA 
encapsidation. Despite these alterations, ACT-VEC can still translate the full HIV-1 proteome 
and fully assemble into viral particles. In support of this, ACT-VEC formulations had readily 
detectable quantities of p24 and RT production.  
Importantly, ACT-VEC is developed using a yeast-based recombination system that can produce 
vectors representative of the entire host quasi-species. To increase heterogeneity within the 
formulation, ACT-VEC was created using the quasi-species formulation from five chronically 
infected individuals immediately prior to cART initiation. In the context of ‘shock-and-kill’, this 
provides more peptide antigens that can be recognized by HIV-specific TCRs. This is notably 
 
174 
 
different from pooled peptide ‘shock’ strategies, which are typically representative of a 
consensus subtype sequence but lack mutational variants. Moreover, VLPs maintain the viral 
proteins’ native conformations, as opposed to pooled peptides. These differences likely 
contribute to increased uptake, processing, and antigenicity of VLP-based regimens.  
This chapter identifies potential advantages of a heterogenous virus-like particle vaccine 
formulation over traditional whole-virus or peptide-based strategies. ACT-VEC was developed 
as a safe alternative to attenuated vaccines, lacking the functional machinery required for in 
vivo replication. Based on these findings, we now evaluate ACT-VEC’s ability to induce 
transcriptional reactivation as part of a therapeutic strategy for HIV-1 cure.  
5.3 ACT-VEC is a potent reactivator of transcriptionally quiescent provirus 
Latency is maintained by a series of epigenetic factors and, in developing an LRA, these factors 
must be adequately addressed. During the viral integration event, HIV-1 typically inserts into 
regions of heterochromatin exhibiting low transcriptional activity, or within ‘gene deserts’ 
devoid of translational products. TCR-mediated reactivation shows potential in latency-
reversing regimens, as downstream signalling leads to upregulation of transcription factors such 
as, NF-kB, NFAT, AP-1, and p-TEFb, which enhance mRNA transcription.16,22 The Het_B_ACT-VEC 
formulation, described previously, aims to induce maximal reactivation of memory CD4 T cells 
expressing HIV-specific TCRs.  
In this study, ACT-VEC- or LRA-mediated transcriptional reactivation was evaluated in CD4 T 
cells collected from individuals diagnosed and cART-treated during the acute stage of infection 
(AC-cART). Notably, this stage represents the ideal time to achieve latency reversal because of, 
i) less heterogeneity within the reservoir, ii) a lower occurrence of immunological escape 
mutants, and iii) a reduced risk of co-infection leading to the formation of alternative 
reservoirs. For these studies, ACT-VEC- or peptide-pulsed MDDCs were co-cultured with 
autologous CD4 T cells. For LRAs that act directly on the T cell, co-cultures included un-pulsed 
MDDCs. Notably, ACT-VEC+MDDC potently induced transcription of HIV-1 mRNA to a greater 
extent than observed with alternative latency reversing monotherapies, including HDACi and 
PKC agonists. Importantly, use of the latently infected J-Lat 6.3 cell line confirmed that all 
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therapeutics (HDACi, PKC agonist) were used at effective doses consistent with the literature. 
Moreover, these studies confirmed that ACT-VEC-based latency reversal is dependent on DC-T 
cell contact, as presentation of ACT-VEC to J-Lat cells alone was unable to induce transcriptional 
reactivation. Furthermore, to confirm that latency reversal was not a direct result of 
maturational differences within the MDDC population, we showed that all MDDC-pulsed 
conditions expressed similar levels of CD40, CD80, and CD83.   
To determine the frequency of latently infected cells within our AC-cART donors, we utilized 
deep gene sequencing on induced, propagating virus. This data suggests that approximately 14 
CD4 T cells/million are harbouring latent, potentially replication-competent, provirus. This falls 
within the estimated range, 1-60 cells/million, suggested by the literature.23–25 Interestingly, a 
highly sensitive, fluorescent in situ hybridization (FISH) assay using PMA/Ionomycin detected a 
frequency of 3.56 latently infected CD4 T cells/million.26 All-in-all, this may suggest that ACT-
VEC potently induces reactivation to a greater degree than ‘gold standard’ latency reversing 
strategies, although FISH/Flow analysis using ACT-VEC is required to verify this.  
It is important to acknowledge that, despite providing an efficacious ‘shock’, reduction of the 
latent reservoir also requires a mechanism for ‘kill’. Therefore, previous studies performed by 
our group have determined that ACT-VEC+MDDC was sufficient to induce Granzyme B 
production in a co-culture containing CD4 and CD8 T cells.20 This provides evidence that ACT-
VEC-mediated reactivation could be accompanied by MHC-I recognition, thus facilitating a 
cytotoxic ‘kill’ response. Importantly, several pre-clinical studies have implicated DC-mediated 
viral antigen presentation in the killing of latently infected cells.27–29 This evidence indicates that 
ACT-VEC may function as a ‘shock’ and ‘kill’, both of which are necessary for reservoir depletion 
and cure.  
This chapter describes our ability to potently induce latency reversal using Het_B_ACT-VEC in 
AC-cART donors. ACT-VEC-mediated latency reversal resulted in readily detectable mRNA in 
culture supernatants, and out-performed many clinically relevant mono- and dual-therapies. 
Importantly, our VLP formulation displayed low antigenicity, suggesting that the cellular subset 
being reactivated was limited to CD4 T cells with HIV-specific TCRs. As most individuals are 
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diagnosed and cART-treated during the chronic stage of infection, our next study aims to 
evaluate latency reversal during this time.  
5.4 Inter- and intra-subtype ACT-VEC induces latency reversal during chronic infection 
Because most HIV-infected individuals are diagnosed and treated during the chronic stage of 
infection, developing vaccines that can address latency during this stage are of primary 
importance. Due to the prolonged period of uncontrolled infection, chronically-infected 
individuals can exhibit a host of complications that exacerbate the difficulties associated with 
reservoir reactivation. As infection continues in the absence of cART-mediated viral 
suppression, the latent reservoir has an opportunity to expand indefinitely. Moreover, 
mutational variants contribute to increased heterogeneity of the viral quasi-species. Since the 
latent reservoir is thought to be primarily established in HIV-specific CD4 T cells, any variations 
present within the viral quasi-species may also reflect novel targets for recognition and 
infection. Additionally, prolonged periods of inflammation may contribute to an increased 
occurrence of cellular anergy and/or dysfunction.30,31 The combination of the aforementioned 
issues represents a barrier to curative research and, to date, have remained relatively 
unaddressed. 
Previous studies, both from our group and others, have provided evidence that the primary 
reservoir resides within CD4 T cells harboring HIV-specific TCRs.32,33 Following success in the 
acute stage of infection, we evaluated inter- (ACT-B) and intra-subtype (ACT-D) formulations for 
their ability to induce transcriptional reactivation in chronically-infected donors. Because 
diversity between subtypes can vary by as much as 35%, we hypothesized that optimal 
reactivation would occur in the context of a highly heterogenous, intra-subtype (ACT-D) 
formulation. Surprisingly, ACT-B- and ACT-D-pulsed MDDC resulted in similar levels of 
reactivation. This could prove significant, as it suggests that TCR-induced transcriptional 
reactivation may be mounted against immunodominant epitopes. Importantly, despite similar 
potency relative to other strategies (HDACi, PKC agonist), only ACT-VEC formulations could 
consistently induce latency reversal from all donor-derived samples. Pooled HIV peptides were 
also unable to compete with ACT-VEC formulations. This is likely due to several shortcoming 
associated with peptide-based strategies, including i) poorer uptake and presentation of 
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peptides, ii) poor peptide stability, and iii) a lack of genetic diversity. Overall, ACT-B/D were 
consistently among the most potent inducers of HIV latency while still maintaining low 
antigenicity. 
It is noteworthy that malarial antigens and CTF (CMV/tetanus/flu) were both able to induce 
latency reversal within ChrD_cART donors. As is expected with chronic infection, this almost 
surely suggests that alternative reservoirs have been established in CD4 T cells with non-HIV-
specific TCRs. In the future, deep gene sequencing of induced outgrowth virus will help us 
better characterize these reservoirs, in addition to HIV-specific reservoirs.  
Herein, we demonstrate that inter- and intra-subtype ACT-VEC formulations can effectively 
induce latency reversal within ChrD-cART donors. The data further suggests that stimulation 
through the TCR may be preferentially mounted against immunodominant epitopes present 
within both subtype formulations. Despite showing that the reservoir is primarily established in 
HIV-specific CD4 T cells, transcriptional reactivation was also achieved using malarial and CTF 
peptides, suggesting that alternative reservoirs are present. This study will continue with deep 
gene sequencing of outgrowth virus, and comparative analysis between conditions and donor 
cohorts. 
5.5 ACT-VEC as a therapeutic vaccine candidate 
In previous chapters, we describe the development and evaluation of inter- and intra-subtype 
ACT-VEC in the context of donor samples isolated during both the acute and chronic stages of 
infection. In these studies, we conclude that a single round of ACT-VEC+MDDC stimulation can 
induce transcriptional reactivation of CD4 T cells exhibiting HIV-specific TCRs, as detected via 
culture supernatant RNA. Additionally, ACT-VEC exhibits minimal antigenicity relative to other 
latency reversing agents. Because of its low toxicity and potent ability to induce cellular 
transcription, in vitro, our VLP formulation merits further investigation in vivo. In order to 
recapitulate our findings in vivo, we must first address several important details, including i) in 
situ targeting, ii) adjuvanting, and iii) determining the route of administration. 
ACT-VEC, in its current form, is a promising dendritic cell-based therapeutic vaccine candidate. 
Briefly, virus-like particles are phagocytosed and processed by dendritic cells before 
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presentation in the context of MHC-I/II, thus leading to activation of T cells with cognate 
antigen receptors. Interestingly, studies using heat-inactivated, autologous virus support that 
DC-mediated approaches are well-tolerated and contribute to a reduction in setpoint viral 
load.34,35 Unfortunately, the usefulness of DC-based vaccines is limited because of the 
requirement to culture and pulse autologous DCs. This intrinsic feature limits global rollout of 
DC-based therapeutics, as the current process is expensive and patient-specific. Furthermore, 
different APC subsets will possess different antigen-processing capabilities, thus altering the 
efficacy of a vaccine candidate. To overcome these pitfalls, a DC-based therapeutic candidate 
requires in situ targeting. In the context of ACT-VEC, our group has utilized antibody-
functionalized nanoparticles displaying anti-C type lectin receptor (DC-SIGN, Langerin) and/or 
anti-complement receptor (CD11b, CD11c)(data not shown). Interestingly, DC-SIGN, which is 
highly prevalent on immature DCs, has already been used for in vivo targeting of cancer 
therapeutics to DCs.36 Moreover, VLPs that interact with C-type lectin receptors are also 
delivered to T cells in trans, thus providing alternative avenues for latency reversal in the 
context of an ACT-VEC+adjuvant system.37 The ability to target our ACT-VEC particles to DCs will 
greatly increase the relevance of our therapeutic by overcoming key economic and logistical 
barriers.  
Utilization of a virus-like particle formulation confers numerous advantages in respect to 
antigen design, presentation, and immune responsiveness. For example, VLPs express HIV-1 
immunogens in their native conformation. In the case of the viral glycoprotein, gp120, the high 
resemblance between VLP and wildtype HIV-1 can beneficially induce a potent neutralizing 
antibody response. This is contrary to soluble gp120 monomeric/trimeric formulations, which 
have largely failed to elicit protection.38 Even attenuated/killed whole-virus strategies fail to 
present glycoproteins in their native conformation, largely due to the chemical- and heat-
inactivation processes.38 To increase protection using VLPs, our team has evaluated a series of 
point mutations to induce greater viral glycoprotein expression and thus facilitate B cell 
receptor (BCR) cross-linking. Additionally, as a therapeutic, the particulate nature of a VLP can 
facilitate optimal uptake and processing by APCs, thus leading to stronger humoral and cell-
mediated immune responses.39,40 In ACT-VEC, the adaptive immune response is further 
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strengthened due to heterogeneity of the viral immunogens, which can subsequently engage 
with a greater number of TCRs via MHC-I/II. Interestingly, the inter-subtype functionality of 
ACT-VEC (refer to Chapter 4) may further suggest that identification and incorporation of 
immunodominant peptides would beneficially impact the vaccine’s efficacy.  
Up until this point, ACT-VEC has been administered as a single-dose, however, most vaccines 
require multiple immunizations to convey efficacy. This is the foundational reason for prime-
boost regimens.  Despite this, the effect of ACT-VEC as part of a homologous/heterologous 
prime-boost regimen is currently unknown. Traditionally, a vaccine is delivered multiple times 
through a homologous prime-boost regimen. Still, more recent findings indicate that 
administration of the same antigen(s) using different delivery modalities can be more 
immunogenic.41 The rationale for a heterologous prime-boost strategy is that Env glycoproteins 
may induce a potent humoral response, but fail to induce cellular activation; alternatively, a 
recombinant vector expressing HIV-1 antigens may induce a cell-mediated immune response, 
but fail to produce neutralizing antibodies. Therefore, a heterologous prime-boost strategy can 
typically experience the benefit of both humoral and cell-mediated immunity.41,42 In the context 
of ACT-VEC, our research has identified potent cell-mediated immune responsiveness, however, 
the antibody-producing capacity of our VLP formulation remains unknown. Interestingly, 
increasing the amount of Env glycoprotein on the surface of ACT-VEC might be sufficient to 
induce BCR cross-linking and antibody production. As such, ACT-VEC may perform well as part 
of a homologous prime-boost strategy, as well as a heterologous regimen.  
Despite the promise of our initial ACT-VEC formulation, we remain interested in strategies to 
improve upon the vector’s antigenicity. Previously, we compared the antigenic differences 
between viral particles (VPs) and virus-like particles, including ACT-VEC. Unsurprisingly, the 
presence of viral RNA in our VP formulation contributed to an increase in antigenicity relative to 
VLPs. With this knowledge, our team developed a packaging-competent immunostimulatory 
DNA vector that can be transcribed in vivo through utilization of a CMV promoter. These 
adjuvants contain ‘GC’ and ‘AU’ rich motifs that bias the immune response towards IFN-α and 
TNF-α production, respectively. Based on preliminary studies looking at NF-kB- and interferon 
regulatory factor (IRF) expression, we found that VLP+adjuvant were more antigenic than either 
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VP and VLP, alone. Presumably, the presence of packaged RNA enhances recognition through 
innate immune-sensing molecules, such as toll-like receptor 7. Overall, incorporation of 
immune-stimulatory adjuvants may enhance the cell-mediated immune response and further 
improve ACT-VEC.  
5.6 Concluding Remarks 
The preceding work outlines the development and evaluation of ACT-VEC formulations derived 
from chronically-infected subtype B and D donors. In the future, work will initially focus on 
expanding the chronic study to incorporate more donors. Currently, we have samples available 
for nine ChrD-cART donors, with access to additional samples, if necessary. This work will be 
performed in collaboration with colleagues at Johns Hopkins University, where they will be 
performing quantitative viral outgrowth assays (qVOA). Additionally, outgrowth virus from 
ChrD-cART donors will be sent for Illumina deep gene sequencing and subsequently compared 
to autologous proviral samples. A collaboration with Dr Daniel Kaufmann will allow us to 
evaluate ACT-VEC in the context of their fluorescent in situ hybridization (FISH) flow cytometric 
assay. The FISH/Flow assay will provide us with single-cell analysis and more accurate 
information regarding the frequency of latently infected cells within our donor cohorts.  
Up until now, most investigations have focused on ACT-VEC in the context of a highly specific 
LRA. However, several studies have indicated that DC-based strategies are capable of inducing 
‘kill’ via immune cytotoxic mechanisms.15,27 Interestingly, a preliminary study has shown that 
ACT-VEC induces Granzyme B production in an MDDC+CD4+CD8 co-culture assay.20 To expand 
on this finding, a future investigation will aim to complete the Granzyme B ‘killing’ assay. 
Ultimately, the aim of these studies will be to associate ‘kill’ with an overall reduction in 
reservoir size.  
Upon summation of the in vitro studies, we will continue to evaluate ACT-VEC in vivo. To do 
this, we will utilize a non-human primate model of infection to test the in vivo efficacy of 
heterologous, SIV-derived ACT-VEC (ACT-VECSIV). Pre-clinical analysis will determine the efficacy 
of ACT-VECSIV to i) induce transcriptional reactivation of SIV-specific T cells, and ii) reduce the 
overall size of the reservoir. At this stage, toxicity and off-target effects, if any, will also be 
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noted. At the current time, it is unknown whether ACT-VECSIV will be administered as part of a 
homologous or heterologous prime-boost protocol, nor has the route of administration been 
confirmed. Assuming that these initial in vivo studies are well-tolerated and at least modestly 
efficacious, we will continue testing ACT-VEC in the context of human clinical trials.   
Herein, we describe ACT-VEC as a highly specific, albeit potent inducer of transcriptional 
reactivation. In both cohorts of infection, ACT-VEC induces latency reversal to a similar or 
greater extent than clinically relevant LRAs, including HDACi, PKC agonists, and TLR agonists. 
ACT-VEC exhibits low antigenicity, suggesting that it will be well tolerated in vivo. Moreover, 
successful reactivation using inter- and intra-subtype ACT-VEC formulations may suggests that 
TCR-mediated reactivation is preferentially mounted against immunodominant epitopes 
present within both subtypes. Overall, ACT-VEC represents a novel strategy for latency reversal 
that merits further investigation in the context of therapeutic vaccination.  
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Graduate Teaching Assistant (GTA)         2018 
Microbiology and Immunology 2500B 
 
Graduate Teaching Assistant (GTA)         2019 
Microbiology and Immunology 3620G 
 
Laboratory-Based Training 
• Rahul Pawa (M.Sc. Candidate)               2016-Present 
• Renata Ceccacci (4th Year Undergraduate)            2019-Present 
• Chanuka Wijewardhana (M.Sc.)              2016-2019 
• Seth Kibel (4th Year Undergraduate)              2018-2019 
 
Publications 
 
Joshua Pankrac, Katja Klein, Jamie F.S. Mann (2017). Eradication of HIV-1 latent reservoirs through therapeutic 
vaccination. AIDS Research and Therapy; 14:45.  
 
Joshua Pankrac, Katja Klein, Paul F. McKay, Deborah F. L. King, Katie Bain, Jason Knapp, Tsigereda Biru, 
Chanuka N. Wijewardhana, Rahul Pawa, David H. Canaday, Yong Gao, Sarah Fidler, Robin J. Shattock, Eric J. Arts 
& Jamie F. S. Mann (2018). A heterogeneous human immunodeficiency virus-like particle (VLP) formulation 
produced by a novel vector system. npj Vaccines; 3:2. doi:10.1038/s41541-017-0040-6. 
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Jamie F.S. Mann, Joshua Pankrac, Katja Klein, Paul F. McKay, Deborah F.L. King, Richard Gibson, Chanuka N. 
Wijewardhana, Rahul Pawa, Jodi Meyerowitz, Yong Gao, David H. Canaday, Mariano Avino, Art F.Y. Poon, 
Caroline Foster, Sarah Fidler, Robin J. Shattock and Eric J. Arts. A targeted reactivation of latent HIV-1 using an 
activator vector. Manuscript Accepted. 
 
Joshua Pankrac, Jamie F.S. Mann, Emmanuel Ndashimye, Rahul Pawa, Renata Ceccacci, Eric Arts. Potent 
reactivation of latent provirus using a heterogenous virus-like particle formulation. Manuscript in preparation. 
 
Joshua Pankrac, Chanuka Wijewardhana, Rahul Pawa, Katja Klein, Eric Arts, Jamie F.S. Mann. Virally packaged 
RNA in virus-like particle vaccines enhance antigenicity and augment latency reversal of HIV-1. Manuscript in 
preparation. 
 
Conferences and Presentations 
 
      Infection and Immunity Research Forum (IIRF)                        2019 
      Oral Presentation 
      Canadian Association for HIV Research (CAHR)         2018 
      Poster Presentation 
      Canadian Association for HIV Research (CAHR)         2017 
      Poster Presentation 
      Infection and Immunity Research Forum (IIRF)         2017 
      Poster Presentation 
      Infection and Immunity Research Forum (IIRF)         2016 
      Poster Presentation 
      Western HIV Investigator Group (WHIG)              2015-2019 
      Oral Presentation(s) 
      Canadian Association for HIV Research (CAHR)         2015 
      Poster Presentation 
      American Society for Virology (ASV)         2015 
Awards 
 
• Ontario Graduate Scholarship ($15 000)              2019-2020 
Schulich School of Medicine and Dentistry, Western University 
• FW Luney Travel Award ($1 000)         2018 
Schulich School of Medicine and Dentistry, Western University 
• Dean’s List                               2016 
Western University 
• Leadership Education Letter of Accomplishment                               2014  
Leadership Education Program, Western University 
• Western Scholarship of Excellence ($2 000)                               2012 
Western University 
• OPG Bursary for Outstanding Achievement in Science ($500)                        2012 
Ontario Power Generation, Canada 
• Honourable Delegate Award (Top 1%)                               2011 
International Model United Nations, United Nations 
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Certifications 
 
• Radiation Safety Training, University of Western Ontario                     2019-2022  
• Comprehensive WHMIS Training, University of Western Ontario                     2019-2022 
• Biosafety Training, University of Western Ontario              2018 
• Hazardous Waste Management, University of Western Ontario                                                           2018 
 
Community Involvement 
 
• Scientific Educator, Regional HIV/AIDS Connection              2020 
• Leadership Education Program (LEP) Facilitator, University of Western Ontario                     2015-2016  
• Physiotherapy Volunteer, St Joseph’s Health Care London                     2013-2015 
• Conference Volunteer, American Society for Virology                                               2015 
 
